var title_f30_3_30768="Midurethral transobturator sling";
var content_f30_3_30768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1044px;\">",
"  <div class=\"videoplayer\" h264=\"./images/OBGYN/65049/Midureth_transob_sling_conv.mp4?title=Midurethral+transobturator+sling\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Midurethral transobturator sling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30768=[""].join("\n");
var outline_f30_3_30768=null;
var title_f30_3_30769="Calculator: Mid-parental target height prediction";
var content_f30_3_30769=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"HeightPotential_form\" name=\"HeightPotential_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"HeightPotential_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Mid-parental target height prediction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"HeightPotential_fx();\" type=\"radio\" value=\"Female\"/>",
"              Female",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"HeightPotential_fx();\" type=\"radio\" value=\"Male\"/>",
"              Male",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height Mother",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_Mother_param\" onblur=\"HeightPotential_fx(); minMaxCheck();\" onchange=\"HeightPotential_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_Mother_unit\" onchange=\"HeightPotential_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height Father",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_Father_param\" onblur=\"HeightPotential_fx(); minMaxCheck();\" onchange=\"HeightPotential_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_Father_unit\" onchange=\"HeightPotential_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height Potential",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Height_Potential_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Height_Potential_unit\" onchange=\"HeightPotential_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|cm\">",
"                cm",
"               </option>",
"               <option value=\"2.54|0|in\">",
"                in",
"               </option>",
"               <option value=\"100|0|m\">",
"                m",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      This height prediction is based on the sex adjusted mid-parental height, using the following formulae:",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Girls: subtract 13 cm from the father's height and average with the mother's height.",
"      </li>",
"      <li>",
"       Boys: add 13 cm to the mother's height and average with the father's height.",
"      </li>",
"      <li>",
"       13 cm is the average difference in height of women and men.",
"      </li>",
"      <li>",
"       For both girls and boys, 8.5 cm on either side of this calculated value (target height) represents the 3rd to 97th percentiles for anticipated adult height.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents.",
"        <i>",
"         Arch Dis Child",
"        </i>",
"        . 1970 Dec;45(244):755-62.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30769=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function HeightPotential_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.HeightPotential_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"param_value = parseFloat(Height_Mother_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_Mother_unit.options[Height_Mother_unit.selectedIndex].value.split('|');",
"Height_Mother = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Height_Father_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_Father_unit.options[Height_Father_unit.selectedIndex].value.split('|');",
"Height_Father = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"if (Sex == 1){",
"HP_Sex = ((Height_Father - 13) + Height_Mother) / 2",
"}",
"if (Sex == 2){",
"HP_Sex = ((Height_Mother + 13) + Height_Father) / 2",
"}",
"Height_Potential =  HP_Sex;",
"",
"unit_parts = Height_Potential_unit.options[Height_Potential_unit.selectedIndex].value.split('|');",
"if (doCalc) Height_Potential_param.value = fixDP((Height_Potential - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.HeightPotential_form){",
"",
"if (Height_Mother_param.value && isNaN(Height_Mother_param.value)){ Height_Mother_param.value = ''; alertNaN(); }",
"if (Height_Mother_param.value && Height_Mother < 0) {",
"Height_Mother = 0;",
"Height_Mother_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height Mother is 0 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_Mother_param.value && Height_Mother > 300) {",
"Height_Mother_param.value = \"\";",
"clrResults();",
"Height_Mother = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height Mother is 300 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_Father_param.value && isNaN(Height_Father_param.value)){ Height_Father_param.value = ''; alertNaN(); }",
"if (Height_Father_param.value && Height_Father < 0) {",
"Height_Father = 0;",
"Height_Father_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height Father is 0 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_Father_param.value && Height_Father > 300) {",
"Height_Father_param.value = \"\";",
"clrResults();",
"Height_Father = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height Father is 300 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.HeightPotential_form){",
"",
"Height_Potential_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f30_3_30769=null;
var title_f30_3_30770="Subungual fibroma";
var content_f30_3_30770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Subungual fibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6kxkd81Tkcxkj9atlsZ9PaqV5ggcGtImTGTMHQEEE4rJuDtdux9avxt8rD0rM1LOzjvWiRJmXtwcms9pxIMZ+lJeOQxzmqSkBjirYxZsLk+9Y1xOfMIB71qXb5jODmufuX+bj8aQy9FLlRuGapXsu1jz2pEnAAAz9aSSIO++QcelS5JDjBt6FOIPOcqDgd+1ThkjPJ3N3GKazbsKnyoP0qLADnPIHf1rCVXsd0MKupIbjn19McVBNO7N8uB9KXBYkAcepqFwBnBrFzbOuFFIQOxb52/AGo3kVT2P1pjugyB971qtNvf8A1Y/Gs3M2VJDvPTzMjDnOQD0/Gllee9wly0YUdOOn0pI41jXc/AHUYzU6OuPlUVPMDguhDOiw26mNF3ewxWY88oblevYVsTZZQDj39qrMOxAPvScn0KUF1Rnlyw5TH1quYozk5A+hq3dHG7g89KqGNSACRkdRS5+5fsU1cgkiG47JdpHvURjuXLfMHA7EZBqWW3J6kH0xVKYPETslcH2NNVEZuhfYbJaQvyUMEg6+hqvIfJwGHynoR3qWO8mUYmIkX/aFREhyREQN3VG6fUVfOuhzzpNDTKp7cU5ZlFZz+ZFMY5BjbTDcBSctTuZNGmZlbjBAoJ4Jx7Cs2G6QZPUmrAuA+CtLmKLQBYcnnOfpUiHPTmqfmZPpQsxQk80rjSuaR6ADvS8kZzmqqycDB61OpYsOooGoj1yAPapo3Kr0pv4Uu4DAxRexLiyYSjuOaA65qtI4pNxxxRcSgy00gHTrURJZutQ5yeTUhPTFJyY+UkMeRzSFMDjI+lTI4ZaQjcxINLm0JcSAjaOCfrSefKoyDU7R7jmq7r82O9NVWhezTJor+decnNXItckTHI4rL2Z9qaVx0wSKtV5IiVGLOi/t13jxxntzWDq1wbkE7efTNRbe/emt6Vp9YZl7BLYySj5HytT03dOavsgJqIoB701VQnRY6ByMVdWXjrWeDz7VKjDNbRqJmUqbRfD5I9KlWQ45rOWXB5NSLN71akjPlZoiXoO1OWTJrOWU4p6y5Oe9UpCsaiPn0p4kKnqfzrOWXnNSiZfXAp3QjSST1PB9KlDjt0rOSXI4NO8z0Jp37EWLzP0APFMLkdKgV8igt70ATh8CioN59aKaA+tmJx17VTujkYHOBVxyPzrPuSQaxiaMotJt3E9KzLu4D9c1Z1F1Ax2rDuGJLZPFaEla925OB171lPJ5bE5rSuJAV9qwdRk2k+pouMbeXW5cHvWbOck4PPaq0s53HmrNmN48yTlQOKUpJFxg3ohbeMoN78n0plxI0ucnA9qluHyNqkZPPHpUEuCBjpXJObZ6lCkokOeMfw9896QOZDjotI43EhiemOKVV2phRgVi5Haqeg6TC9M4HeomBJ+Xp6mpUGUJJ4HrTTKrdMAdqhstRIXt0A+dscUsaQbtu8IO7elSOjyLggfWq7x4BOevGKm6K5L6DJpYIw0aAsgb73rS25RjnOAe1RNFvTJHy+tTWwwMDHHQ1LepbppISZMZGT9KidPl6HNXFjO75vvUCPJZSBjHFK5D0Me6GQOOfpWaUCykMevSuhuYT0wMe1Ztxb7MsBwKlm0GmrFBl4PAIqpPHy3y+1aQ2sM4wPWkEXnsYxhR3du1JEzVtTDWFN2GIBHIBHU+lVpo1EjEEgdd3p9a3ZbZI5HRZFkC4+b/AAqldw+ZJtzgsODj+daGEo31RnG1F1IkUwBYqdkg/i44/GufNq7lvnxg4Oe1eieD7rTLG7jkvUM0qkrJE4/1eRw6f1rJ0izWe41S2Z1KxSs4KjO4E8Vo7WR51TmjJ2OR8iWM4jG8etWI/ORcvHjHbFd5d+HLRYVkhdgZFBDE4we9YN7by6fMqzhXhYfe/wAah2M1WexiC6KnLIRUsc6yuAMCr0q2znaAuTWdcWqw4ZMg9altmsaiZoJEcjaeKtowXg9aybe5aNBk5PcVcT9/hgdpqoz0K5tdTQ3AgUmQT1pbC0kc4cgj2p99bC2yysc1adxqor2GtHwKjZDnA4psNwHJBBGKspyDjmlc0KpVlHXikDHPWrLJz0NMMeOtZuRSQ+EgLgGp48kDH0qmpIORVqCT5h/KlzA4kwUj1xTHjOeRVlRnGKVlDA9c0mybFPyyTjHFAt+vYVcjj6E9fSrCxjA9qaZL0Ms23y9CKheE+lbYjXHIyaYYVYelO5FzAaIg4x1phj68cVszQjt1FVHiwSKdxpXMxoiBwOKaQR0Bq+UAPSmtHxximpCdMzmJB4o3NVlogAc00p+NV7Rkunch3nNSLI2RzSNH+dKic8irjWaM5UETLIetSeYRgVGF9PyoIOPQ1qsRYxdBEyPuwQSPbNTxSFM73Lc55qkuV5NP3HHNaxxCM5UGX1lFP8zjrnNZwc84FKJMEZrRVomboyNNZRnbmis5Zu460U/aIn2TPsuVsHk8HnrWZeygKcNWhcsCpAFYWoy/IRjmnEkyr6bcWG7kViTTkEg96tXM3ztxzWVdyFc/nVAR3d1iPHSsK9uNzH5s0t9OzNgHms+RiAd3WplKxpTg5OyIokMkuMn5j0NarIERY14UDk1U0lTJPvJ+UDNXPMzIB71zSlfU9CnTUXYiVfLyzcs3QVHNxhQOTU7kLJknNQfeYyNnFYN3O6nEjK/TnvUMrnOc/KKkdlV9zAlc8CopmCqduOW/Gs5M6YoYpkJxng805FUc56dBjpSHKKm3GRToHR3xIeeST2qLmyiWEZiQFBznvUVxBLv4IAbg1YknRU/dnn25qrPcF1A3MR7daTYlFvUaHWMGAEHBzn1pxVAjAZ3DkcU3cC6qUJbqCaFwJPmBGTgqTSuNx6E0bZ2bjnI9KWQYzszg+go8ho5BuTax5AqReA5b5m7DtRcycepE0e7njHas/UNin5QGA9eMGrpmI3DbjHX3rPuoRNdYkUBSOB602wjGz1M3KklY9uO4HammJsfu+WHBBq79jd5BHECNzbjt61YNktqxW6RnJ4IHHP1osy3NLRbmRJGGcJJ8uBnf3U0lxbxQjz9zpG44AG4AjrV4tCwOyN1kU8gnIx9arwwtPc/Y4sFpQdq5/i/xqk9TCUHuYMyJcyySGLaCSAU44NI0jW2p20u3GUEb7TgOBxn61JeLNZNLC4dSSA4Ixgg1T8z7QHUyYkjIZRjIPPOKL3VjCtT69DrofOlDS2rRiEDDCQ9MdQRVfUoI51IkT5Su5WQ5H4+1MmmEensjB/PlPUcZx7U3Sb1NPkMdwzsikNtbgj1FU0tzync5U2aO+J38sqMow6EUQJHnZK4kUHGRXa+ItHt7pVurAHymXzN3oPcVwNxEbScmbOzdjb057fhWfNrYqOpJqEUCKrRHHPIpLRggBJzg9az7icgsnOeuKn0+Rd4VyMGovZmp1mnyGNFlDZ9qmvHjvozgbWFYsUjJlUb5TzV1LldoBAU/WrUxEKwDnHDClh3RvgVLdNhA69utQCddoPGaaZtGRdwSOlI6fKcjFQwXGeGFWSuSCRxSZ0RZTKkdqdDkuDzip3U5wenrUaqcjBNZS0NTShGV96VRzSRcL74py8sMVVzO2pKicjtU4XHbntUcfGBViM7iBjFNESQzZx6kGkKdwBVkJtPNKyDHFMzehQkQA5IqpNF1IrSmTA5P5VUcYz6UXHFGc6AnAHFRyRkcirxA64NMdQwouaWM50J5NR4wcYrQMY6VE0RznsKLj5Sv5eR0xSeWRyelWhHnHTNOEGTnB4HTtVXIaKoj3HH8qcYcdBVkRAE1KqA+lK5FjPaM5GRzU6w/LyKsmL8KVF2tgmqjKxLiVWgyPeoWtznpWuQAcHFN2KcjFVzMzsY/kkHBorUMAHI7UUuZi5T6uu5AgxXNancAqwB5FbOpSrtBBrmb5gVYkV6yPLM+dgzA9qxb9xsbmr0zkA4PSsO/mIYjPFEnbUqMWzLuGO/r71UuJRnb3qW4YkmqEh/eDPeuOpO56lGkoo3rBNlqfUjrTum4k96liQJAuGyoUHPvUTYZCpzznpUyNqauMK/KS3XtTGOyMjjOOtN2kMBkgrj8qWc4ABH3qybO2CsV8l5PYetKsYXLbdxPrVlIQw56dDQFTDIQQ36Vm2bryKDoFhd34YcgetPtlR0G5l24GCalcYZXA3R/dIPb3pk8TRndBgI/3lxWcn2OiKuPMaxnCKCOu3096qmDedwJVv7p71YtEnKtmPC5zuxwastC5iIZTg8jNJCbs7FaMMX3GRFI4A/pSiAvIZN42jGQRyTVuLBJZmG48dOKdMqoFBXcCMcdRTMnLUoTB0dSwwCcZP8AOpyCkIAO8nIBp8kPnNIWfJU8gdqiRfLIZjuB6LnhRQS/eWgwx+ZjAyo4J7U67gWII0jLu7KDkgVIY3ZwYBtxzgDgVC1pKHd2Z2GMkHqfpTSJe421uJIriMxARoGG9tvJFaXiQx3jqM5DLu8wDv6Vhwy7dwkLFc8n0qzHMxtzG2WB/wBWSOqmrTsrMmpS95TRmXEcedyKg+ULlTxmqLRBFWWYEruzuzg5HvWo6qpIYKD2x3NVZHLWzwMMpIxYH+6RSRU72JNeigns9P1GMCQuTHKrdyOhNc1qenJYTQ3Wn5lhc7nUDIi56Z9K7HQI0m0+4ikywRwyAjjcf6Vz+p262OqeV57SbiJPKB4GeoPtW0lpdnn8z5nBPYoLHPIrKzEFWDjByPUVlSXjLd5kAOQVdmOep61vrYS2U4imbyoroFopc9umCO2Ky0s7hrS5gSRfIYgPIUGMj3qXFs45JJnTQ3fnaGscDEqemPT61zfiO0DRrOgPyj5uea0vD3m6eDald7Nzlj8uT0FWdQsJxbs1zGAsoIBBBGKyknuiE7Ox5/FCZw8T/wCsTke9UHZ0baBhhzWw6fZrslwQ3Sqd/GnmB04L/pSsapl6wuDJENxww71cjc+ZntWTZHbE2eoNa1vG7pleahxBmnAm7ljlfSsy7ws/41es2YEqc9KW5td8TMB8wOauzaHB2ZXiy5yK07RgyYP3hTbKNJbMYADr+dIgMUg+tPQ3jPWxYkXIBHTuKr42ng1bIyvHSq7cH61jM6YllASO5FSwglgcHNR25BHX8hVqFDnJpXGyZF3HpkntU6RfNTIRjnnr2q7EvOcVomYSYwL69aCOORTyCGOaUrkdKZBVkQkcDIqq8Xb171oEbRzUDAM3oPSguJnPFjPPHrUSqSx9K0XUHOKi2fMOKBtsoNEe1NRM8VekQAdDioUiJPBFA76Ffy8scVIqEDnNTpHhuR2xUuwYwBTJuVhGNpNL5JAOM5NTlcE09SM89aCWVgh9ulNCfvAc4FW9mcnOKYUww4yPWgSEKZGeDSMnAIHPSrKqGGQPakKEdAaq5NioqkDn8KKsEcHPX0opBY+gb2YMhwRXO3Tk8dzWrenAOCK569kK9K9o8XqZ1/KQX7Dp9awLuXL5HQmtHUZwQAprIZTyxya5as9bHoYanpzMr3DgA+gPeq8BV5wWPepro5XpnFQRKoGQPnrA7raHS24xaZyCM46VHg7yx/Ki0O6xBJxk8fWnquDk857U5CpEFwuOe5NV5WyUYEkDg5H8qtzjaeoLGqUgbzFXHTnFYt2O+FrXZPG5AUtjOeAKdJHuvDgnCjP40LEzuFVcsOT2wKaiu0zFer84PpUM2hYTcxQKxOOh4pqrKsbK2Cqrwe5q1FGTE2SpOOlLAEiD+YQSmMZ71BpeyshttIUtVYnrzjFKpZ2Y9BjkGmYJDnp/FzSE7iqF9x9MdKBNX1ERijgAjbngdxVmNA2MuEz0YDOT6VVMZLkoNoXke9bmlSWcMRN9vyPu7OeaFqzOo7K5neW85MccTDnk4x+P0oe1jgVldt7/AN1T0rVv7icL5jRvBbScoMBS319az5H2pkL83VjnNXZIzi5NaFe6LxROVYkbelVreYtJGW5lyMY5qe6MnlheCx6jHX3qCFRbtGdmcHIAouUo2TbG6lar5yujq7begGPwPrVKQGOfDFiAAE+la2qXXmTgphY2AOAMc9wKpuIyu4fwjI+lFiYybWpn3QjbLMQDjcPcVmwo3kzPlQBwoJ61p3W3Khht2fMzE8FT6CqyRIiwyCBTGCTkZDYz1we5o6l81kO0C6uYFlcEogXCs3TOenuKy7/y0vRNPEkhZjlgMDHYita6BmZ3V1jhiOUBHQdQMetZryul2kphjMuTKTjcjKe2K0vZWORwvNy7mdrc8Pm2rpMJMZ3eoFWdeu4BoVvbWWI1kkV5G6EfT3rJu1R2ZY0wmc4PNaXkSXmhMIIgXTGTxxzkUoyu2cmJoqCQ+CP/AIk62qu/mSv5yBjwcdz9a0QWuLdY5N80qr8oXkD0+tc+ouEt0KANKyjzTjOzB7egre0kRxTK/mssjqsgUnAC9gPeiS0scT7nNa3Y+ZKXh68HHc+ornrqFZ4Q8QwwbbjsDXoWt2aW0YeZjgsBx1AJ61yOpWKW91KsDYiyGBz1NZLszSLMuwX/AEgo3TofetGAtBcmNidvWstWl+1b0UkkZJ9aviZZSrjh161LLNZMk7gOlWfOCkIT97tVe0nDx4zzU09uoiSZTlwefpTd1sJDbAmO+KE4Vq07202Rbl5HrVKUCSNJ0GHXjitBZTNbLySDVqzQ76plS3JZT3wKY4y3SnxK0NyUJ+lOkXLnFYyWh3wlqFqxR+TitSH7tYxOyTI/OtG3m3RjmszRplxDjAOBVyLkZqkgJxuAx71ftxkYBq4sxmShATmgpgCpQOKcNpBDVZiUpkJXpVYJzk1qOhIOOABVRoyT0plp2KpXnJpGUdjVsqMdKjaPpgZzQJspSK23kHFRouBmrjbSSrU3yxnAoL3RAoJPSptgHan7FHanKozz0oJIGjpjRYq4UBp2wYwaYr2KYBCdOaVowcAcA81b8n060wrzjIzRYNyGIKnAyRUhIbPtTQhzx0zTiMev4UCIXQZz60U8c5wevWikFj2S9kDHNc1qLgRsT6VvXrBRx6VyeqzEsVHevZm7I8elHmkZEx3vzz6VBI5+lT5x97vUTZ7dK4G7nsU46FCQnIU56806UiBg6DJ6YpSoyfbmmXADKuD+FJM0kaenvutgD68CtIMpxnvxWTYKFt4mGcseR1rSUjPTheabdyYbkdyABnv2FJHHt+YUSylk2kEEHOafH86DrzWTOyPQdcRqIYmLnL89OgqOKaLYjA7cg4IFTA7IVZgcq3Ge1UoyhchUAwc5FS2jaEdC+IRJliWyR2459aY0KbVWTluTnufrUbTSM6IuB7Z7VNk7TsiYuODg1LK1WrGKIZUbBHzN0/u06CCGJizOu7r83tUskSoBIEX6Hg+9K8KyRZ2EFVLFurUBfQzPs88sxMcg2sMHPQA+9dVYWosriGQywHAAQMM5btWbBDGYEcgrbr1Zsnf7Cqs9zNM5NsQig7VzwRSi1FhOLqKxr6tdareTGO+gikgjPybQMVUNrcTO4h2/ZY+vHUdzVOHT5xAJbgusbnABOSx7/wD661LeC5jRCBiEfNsbt6Zq15mLjyaRsZ4tsOzyPGvdQW5IFQXCqspKkBMdcV1NrYWusWro04WeL7x2fdrMvLJ7BTbtEJh2kPQii2hKqa2ZzEoZmAHKjuf6Uy5VQuFyM88dhWvdr+6MkSny/vMg/gNYU7OVwUYAkYJo2NY+8SRbdQv4kfy41YfM+M7RUeo6ZLDI4Ro/LbkMXBOB3NORAr4JblcE1owyx2cDgWq3FrIdrMx+ZT6Z7VSV9zOV4tWOZ3YUr8zdhkcHFQyKYk8x3G5+Me3vWzd7OILC3HmM2cYJP0qgLQXltMyRjzIP9YG460Na2E5K17GLcwqzh4TgN1PvV7w/brOLm3dmR1UyDuCQfSoLtRHIrRxjyyMFQ3Q96gF5JpkyTQsZSp3FCMFgeozUrQwxEXODSJnglbWWgJdVu/lDHABA68Vp2METaucxuLWFdrSE/KCo4J/Wo/EKwSWMd3GsixNH5tqyrghm65NWfD0Kar4aubUXBs7sRFXjfjeAM7sVsmnoeRJdTTlitdasgqKwbJK88jjr9K4g2VwLm9s5BCIlkARpDjn1ro/CUuyFYvuNbHPqSvr9K6ZtOs7uCRzCkplbJbHPsc1jPuKL5WeLazbyWF+yMRlcEYHBB7iq7xsuJU+ZHGT7V0vjbS3tpihBZoujY6of8K5+3kCwmMjOBn61mdEXdEumynb9a31DPbBQeSK5ZJdkmSNqN0rqNLlWW2wD83vQmJkunoZLeSFlAbB4NXNI2eU0UnysDkVBHMtrKC33j3ps+77QsiDjqSKuLsrjWpoX9vCsodj8wH51SlTBHNLdTede28fUEVcuYQuAaGr7HRSk1a5kz8fWrFnllBPNJdR/KMjj1pLEkDb71zyVmd8XeJqQE8cZz61qWxwApFZkI5AYEfStO3VemWppamE0W0Yc+lLgAZzmotgBz3qROASOtaIwsHrgYzVaQfMcdanGDnjkU1kHrzQBCFwcAc0hBU4/SpH+U4HX1NRMSGOec96Y0iJky3NN2bam4B96eygjqKQEQAIpRGNtBHHGKeoIXI5HpTFYiHy8YBHrVea8WHrgkVIymbK5CD9abHpURYln3H3NBat1KJ1CV2O3ge1RmSRmyX/Wtg6bGB97ArNvYPKk4QkUa9Rqz2HJPIoHOR71Ks5fG4ZqIJH5e5jjjpULyHpCu4+/FBLVjTiCyNwcn09KKzVlnjCOEGe/rRTsK567fSMISa5C7lMkhOa6LVrjbEVBXnviuYOcnK4NeliH0POwkOpGc4yO1QSsRnFWHwFz3NV1XdIQSPWuVs9WJCyFk+bv6VbjttlvvlUEHpUZHzcDip5Jme08oAZH8qasTO70KlpO8coRQNuSQR2zWqMBvlzx1zWLE2JVPocGtmI7o2I6n3pJ3CPuyIX4LY+YHv6Vctl27d4wSoIqMIAORxn9ak3EOWPNRJHUnfQS4hLfKuSD1GeKoBWiZmjj46EHtWkJwdwUAketVmkkJOMc9eKzaOqm2RAEKWDkMASM/wAqvxwSxWEcsjKGlqplWKhuMEdOav6jdM7RRFQFgTZkHqe/44pBLmbVispkmVUkYHHqKtyArEFD49+x+tVEK4yrlR0yepq1DiUgyfMG5KnnNIGtRt0xWDcWYRN90KePwFS2wihaCaeItGOQqnJY1TlQlWWMAB2wq+g+ldLo2mSJf3M53SRWwVV3cjOORinFXdyaklGOpdt7V5Nk6QtuOdsZGSF+lSS6eZ2GAyyOMBm+6COxFa1te3CyOsiKgUZTb/cPU+5qKXUJY980rxpCD8rY+ZvQ10cqsedzyuY8Dvp8kVvGhRJAwnLLyfce1WNV8yOEIcMzjKN1wAOtBuvtKSbIvMdyNshbGD6ZqLXJ4Xt4o3ULcqMDDcL659aTQ1dvzOPupWsp2k8sTRNxIuMB6jFrZ6qxaG6e3u26QTjCn2BroooBPbEELsiG7pyTXPX1l9ouGKjcuN3HGT61NtDqhZu97MjWxmtnK3CHep5X0HqDVK4Sddzg7Eb7205BrYtWuE0xgZjvUlR5gyQP8KzWk8o7woVsdOoPFKWmwJuTdyike5HGT5xxtKnnHUmqScMzsW38DHZgTzmtu7gCWcV7BsLL94DoM1UFqt1dGIOEXYX3HjIxn86WpLmtTDuIlDPFt2gMTz3rK1GPneMHI6jua19QdHuDtDAdc9cn2qrcW6PLDk4Hy7lbvUvXQmWiRFo+pF430mWZJcIZosoSwXuv4Hp9av6WJDeh5W8ydvmUqcFhjBQ+tO8W20OgeJNA1GwmDxZEUoMYBAf27ij7Dd3EuoSRxSFrXLgL0GeuP51cLxfKeVVs/eXUs6gogvoLuwdnQNzhcHpyMfp+Fb9iWZ4HiGAfXp171zmjyOkYu8edbHBKMMPlfY966DSpFWWZWwIS29ADkjPbHtVON3c5m+hla9CJr+VbyJtsgKxHPbr+Oa8+v9PktZ5FC5AO4c9v8a9j1S2jvrdnVAJrc7kwenrgVy3ii1jnktiIW5UZboM+tYyi0XTn2PN7uMPHvAIxVvSZ8SAE9O1S6rZSWF2IpP8AVyAsrA5BFZ6gxTBh0qLWOjc6C/YuokGcj0pLa6aOQK3KuMc9qjjkD24AySR3qUSRCCNgo3r1pve5cdrEiHy7uPeT1ytbBcvK27pjisC6n86WBgMENgkV00iRpAhJBLAVUOpezRUlQOeORUVtHiZgPrV1IweF6YqO2UfaW6elZTWp105aMtoh3DHX35q/bnHWq8agOMVcRTkA9Kolu5MV44oBwMYFKD8v0poy2DjAzQzOwYI9OaMDFS7BgVGRtPsaZJDKvQ1Ewz2watMu4c9qYwzjjmnYLlV84xkA1IMdMVI0YPTrUZBXr0+lAXGbNp470E4UjuKnXa/HcU2dMxnApDILWElix5NXEiG7kYNOtFAQdatNGDkj8KpEtlcoMYHArGvm8ybyolyehPpWpfOVTYv3jUVpbrGQ2MseTSvccUY9nYGObbctnJ6CtyOyiVPlUD680y+iVlDKfmX070+yukdRvb5hwRRfUHd7EsNtEM71/GippHVhwcUVV0TZly/n3sQCcdaonJPFPlYFzSGuuq25GOHjaJHIePlA4GaiiUl93GcdKlkYAmnrxGDkFumKyZ2x2InDZIwCD6U2A7ZOFOMfNUgwOvY5xTArHcRJgY6UIb1VivcwlbsgrhW5Uip7V2CPC3Y9c0y43SqN2Q3QE1WS5+zTAEZzw+e9MnldtDciVgHV8bl9+KicMy4P5in2r70BY84/OnLg4x+INJmlOWo6K3JwQegzj1pWQbc4qxGFWJtj/OOPqKjiGdwk4wayaOiMmV8GPA2fNu4Oe1CnEuGG7f19c1ZePk5OR/DUKqTMDxweR61NjZSRLCPImUyAY6DHOM06JYWlWNUOGb759qczo2FYYzxxUc1vLgr98r2HTFNE6lidGhkVwrKCeN3TH1rpdDuTb2yKGJDZwx559feuN8y7mWKE5ZVfoxxtFbNtBPG23c8bLyCTx+FNabGNSzVmdTHdwGFQjssuePl4BrJ1SUyzmAyBolXLhk+Un0BqpHc3SyFIyPMPJJ6H86lQHY39pSiM8AOccmtE7mHLyq5a0GNbbT7n7Qyi3H3U6DPr7VDNab7AXDElAdqqw++2eufSmXdrPONnnpH5R2nHIkz0z+FLplyySSwuThQEORwSewH9aq9tzNRbfMtxWjmsoWLRMcDGTzWDe+ZMxZkVB2I6kV017KrQMN7Z7HJyDXOSjcsscqhmBJDqcE1L8jog+rGW12WiMVxteM9cAbgPWsuaJTO4U4Cqck8/jV67ube0sbW0tNxMgMksjAbs56VUsraSbcUgZhg/MTx+NQ9dCkkk5bBEYYrRdzM0UvysCOhz/Ks8r5epzbcEFSE46fSrV1JBFmF1LAnJOc8/T0pLZVS4aYx7iEyAeBmq32Mm+VNnLzwvLcuVXa27aAvrVfVQ0LRbl+YJhsHgkV0N/OiwSyqFEpccAc9Oa5q+O0vFNIoiYglgMn2IrN6OyLvzLUq/FCYXcNobdAUSNXTJO4cDn8639D8QXE1tDeWiyBtqiWALxkjoCa5PxXbsul/ckViqqWbrt6jFdL4ZvH1vwgGZYRcRHYTGAvQcMQO9Ep2lc86rBciOjWWMmFrvybd342hgxDdgfwqlLGbJ8KxKlyY26YYD1/pRp1t/aemAiNmuoz85I6KOhz61cuYVjiMVz+8hYblcdfzrpvzI8+3Kx/2yEWcdw7qHkAIYN3Haq8Vo11vFyFZWO9RnI69K5fUrSRD/AB4zkLjpn+laUWpyW9vsUsvlgKABlmHrWD11ZVrbDfHWmAabFLFCoMJAcqOgP9K4Nl3xDP3l4r1aG7TV9LktmHMq8Z65FeY6jDJaXTxOMFWrJ7m9J6WZNp5Ijxmn7CXdD9ar20hSfaVwp5FXJjiRGz14NNbGsXZkNsvUH+E5roxseGH5t3FYZIWOYJ19as6TI7RAnt3qYvl0OmKvqaxynSm2rMJl+UYJpZAWQcACmKCrKwwRmonubw0RuKuSMVYD9u/vVWJ/3YPenq27B707ktFxCW68U8R9x+VQwHJyTzVxMMPSqjqZtWGhTjoaawHep8dMGmFeuRzVEbkO32prqTntU2eOeKjb5jyOB+tMCCLJ+Ujmkf5eG4NOdWydox6c00gunPLCpLSTIiG3AqTmpicxENwaTaOMdfSpNny8jBpXKaQ6zyU9SKubRt5GKqWPyuynuatzZ+6Bz3xVIxfYy533XbYw3pUsULucscZHSpxbmKTdjJJzU8KDn1pGi0RClmuPm5781n3lkIXEkZKg9RW6V4wBnPpUE8WVww4PrQ1clPUxhbl1yj4+p60VaKGF/wDZPcUVFmbXLEgAc0o5pshzMxxmnKSD93iu+b1OWlskQTZDmp4seWOOc+tMK7pBTjE/GF696zOpbDJFVFJ5L59aiyFBYj71TmMlBlHB9aSWPYGIBPbmmikRuSfmHCqw7VnalFmRiADkZFaGW+z9cjPIqO6i3y9MYXmh7Djoxuh3ZMogkGARwT61qyBo95Azt6/SuajDRu0o/g6CtyK7MkKSoQSRz3zSXmKUWpXRbhchd2cE06KfDYJBPqR1qtEy9duMjGM8VLGAy7PTmpZtG3UsKyyZHoe1AUByQ5BPAFMhGNu7AJqdthIbG0jqamxV+wMFAUhcc5IHr61ZgIclVVUA6MTVXzk4VSCB1qSOT94Bu+UnAHrSuDuWUs8puibOMkjrVnT3ujKFBUovUt0//XTrdY4AxDgMB/ePX0xViy1LyYpJiMgnK/KDzVK25hOcmmkhdZeZYeApKjkEZxVa1hMhQXbhXVQVyoyme5q7FMrxtNcbFA+ZY84Ck9CfWspzJFDL5zo0zPlmU5yOwqlZMzgm1Zly5lEdpKN48zzANy9WA71FY+RL9oN2ZQoA27Dgj3zWdPPmNkIVScEbe9RiUoJYyS2VwR70ubU6FTtGxaur0RTspiJEfysp43H1qre3luy7ghj/ANkjOadmaeB0LK3lDJLLyVqrcWv2eJJs4BONp5BX+lDbGmlozNuGDNHIBgqdp/E1uRT/AGfR5lGI3c4TGRn1P0qrJpkh8tiFSBwZdx6gD1q1JNay8BVkaNQoaQk5+goirO5lWnF2SMaKzeVgzNz79zVfUI3WJQm/ecnDN39QK2HuvLjceW7qTt46A1T1SMmZRIgX5Bsx/jQ49iOdt6nOx27SxSFywC/M30PGPzrHvg802xY9zD5NoPeui1KRwGjgDgsAGCDqKveFdH+06ti4UIiqWkc8cDsB6mp5buyKnU5E5M4TxneNlIZ4uYEUFSvOQP5VL8HbgOlzCJlHnEqYcZLj+97Yre+PZtobLTLiIQ/aJQwHQsqYwoNcB8MJWi1aJoDJ5nKH0GRxiorLlZypqpT0PedItjZyzyRqQgXAI756j3BrHlurWcz2W025zlJeoHrWxpk4vJxBcyGJNv7ts8Bu+RVG9tbZrtE8sb1yNxbgj2Fa0qjcTzZRs2Yc26S42ozbFXKSDkjHYfX3qhPm5uHIgdDGAHBPAGfWtu5hmWFo4sIpPIHX2IFY9vaXNlJJczyR7MgYkBw5JxxVtXsrCT6mnbWyoomiUIqMCVHTB7iue+INjEqw3cOQ5GJOPyNdNA6rqn9mi4SSSTliOi+34VR8X2TvpEys26WM8jttFZVEjSm3zI81jcvLESSMDbwa0JM5RQDk/nVC0GXjBHfvXUJp589JGHAHaoiro6ZPlZQitpZd+UIUD0q3YQ7IsDoB61urCRYFlIyQRWTZIwVkfsaTVmbUpXTJN7H3A4zTUPfBBz09ateXlcDjPWo2AXHJzWcl1OmLvoXICWRcDHtVtRjH61Qt5CzADoKvINzcjFERyVi3FkE9KtR4B/8Ar1UTgA46+lWUdRgMBn2q0zOSuTggAc1HJwxx1NTQ9fall4H0qjJFV8Z5GR3FNLAZHOOtPbJIyCS3f0oBHXGc9aZfKVwwZsUiph+D9anJ4yVGaiA8wbhxUlIcV2nIxzTzywXGAe9CdiRyOhqZcHrzRuDGLEVmyD0qwAC5IOD6inIgK59ajSMo5OflNMy6j8EkHOfrTxFuHX2oRAzDuPWrZRRjbQhsqbWVvWnSdAMD8qnCA/X0qa50/wAi6jgnnjQuBvPXy89jRYm9jKaFH4PT2FFaWoxXC3ji6ZTKFA3L0K44I/Cipehd7nOwPuYZPIqypy2D09ap2zfMwHqasqTuIPQV2PdkUxQxV+nHapA3y5HHUkCo2H8XWlydvAOTUG61JIpCQQ2T2APanADzSpAznqaiYkupIxwKV19cZzSehRH9nZT5mDsDY68UqOXcl8EY29OlSOx8sjPTqKYocRlYxu39KTY0VDGq2lw2eG4AxVJGFrbh9reV3xWscg7WBQSKQR3zWe9v5sT7j045oNVruPiuAygqQy54q/C+QGH3v51hlRaRZK9R0qxZ3XmDAb6Z71I7GzDIsmdxw2eAamJPAIO096pWzK4CnIb1xVp42Ubd31zQVfURSqSFuAv61MLlVIYjcAeKsWkVpLbbZW8uVTySM5HpVJrcxONpBHUD1qbDjOMnqbek+XPHkKSA+WJ5BFTXSryY4wqKOo7/AFrEN1NCd0aMiDk4Oa0Ib/dbbHkVvMGcY5FWnpYxlBp3RWmeSWYL1UDC89TT43Rt0cgIOMZNMi8os4cMI0w2c8nmlu4VileWP50Y8OWyR9KS2uU2r8ti1JYytAk1tCJCgwf6k1j3TlLkjdgjuOhro7XUXj014YGCuo+cEcgGuZuh5pMgGQvb2qpW0sKjJ8z5izYO3+kFmPzIVx7ZFTmJbh1jlZgq4NZsMjRM5UDL9VHYVoWM+LO5mVSJVAUZGRQhVdNUaGr36XEQtrdhtBAdyPujsPpWPJp0S2QnM7BE5bC/L1xwaqXFy6yyLnBIwcD8aVHkjhjjZmkDHJjJ+XnoapSvuYuk4r3WblrLbJEUjwYh2C/MW7GsPxCJYYY3B3pjII7H3qK41F0mxAsY8sHkD7p9frVO91C3bT5cljcSYBU9M+tDaa1M40pRlcp2l00EstxOrOQAojBzg+tW/tSvpUzrcS287ypGm0jI3df0rmGuTGrKrFc8k55LVmXd3NK7yrwsA8zBPp3rmc7M2nSu7s5bxvcm71+7G9jHCfKXPPC8c1D4Uu5IdRhjMjrCW6L296zrh5JJJHlOWkO5j6k1d8OxhtUhUkLnJBIzzjpSexC0R7t4Uv4v3sbMLqUn5GJ4I7Y9627qJLiYPN1ZeCpztrynTru5sTDc2R+YfKD1z65rrNIv5rhFtJ2JXljIBhufesaVdRfKzlrUH8SOr0jyvMaCTEt5GMAd8e/pSaratZyxXGoKrHnywwyq9+azrC6TR2M8E3EhCszru3c8AmtTxVqNxOkbywxCMJnaeQe1erTkpRPOktTi3uGHiC3lkUJyziRR9/PWtPU5/OtLqacMC8TKq+p+lY925F7ACpAIxHjgEfTtW09rEbbMjgfKSSx9ulcs9LnRbY8rVtlzHxjHeux0i5a7vI4z8oIrlbmMLOAvUNgg9q6vwsPMv0EifdHapp9japtc17uF7S1mC/NtHFY9g3mqWxg55rb1aRreUbBvEny4PaqMcYRW2gDPpRJe8aUdIixLyc1DOoIJHUdKl2tvUYOPWm3GBKQrZ47VE2dVPe5HZnDc+taiA4wR9KzYEIkHofWtZRwoI/GpgazZJGrZwegqaNMvnmmKcA561ZiG48dfSrsZOQ9QVwTT2JYdOKcB8ox1zSEHZjvVIzIm+UDNREfN8p5A5FOkDHqCPekz1xjNBaGudxGOlMbJGCcnFAJA54p2Plz2oGySIA9RUypg4AqNMZHWriqNvHNCIY1OFH60hx17UvQEU3OD14pPQW4YbjBx9KuRZ2DNQQ5dwPTmrbLsximhyfQj/i6475rXkitr4/aJra+WRxlxEmVY+oPbNZmMt1B6cdjW5fw38l0z292ixHBVROF2DHTFXFGUjIv5XkvHZ4TF8oRY26qoHFFJdxTJcMLiQSS4GSH3fTmiodr6lq1ji7eQiZlPY1eT7+RWRJ5kF84kUqCa0oHB9Qa6pu0ncdNXRb/iOaXJ2/L1xUS5LYJqTPIUdz1qGapWGsn3efyqRSTL1BPU800KxmZB6GnKSucLnIqWyiaRA7HcQPcVHCWUxHgLnFAZsjHTHFSqYzA+5SW6jHapKJbwrOhXYPNj6EdxWbNAGmLL/GpwvYGtCPcrJIqZBHUVBKsgy4ABU7jTCL1sZt/AGtI3xux1z2NVbjbawr8nDfwjsa2LhhtG0bo35Xnofei6gic2rnawwQSP601qaKVrJmbazYA3HA9cdKvm6KqFJz7561n3ttuugq5CD+73pTIiKEkO1gM9OGpBJWfMjYgdeR/CTuz3qdsYJJPsaxEu9o2gg47E1esphM/lmRQD03HFInzL1tIA5wykMMEEZBFJM8SPtiXaD09qqyFYJmj3KSP7pzViCB5snPA7n+lFug+aK95iNIEYqysVYZ3D0qHepBVG3Ed89K0lt1DRLgthSpHqKypoVt7iRScKp4JHt0oasEKsXuWncxTCSN9wI+fdn9amWRXkYyIkcBHzBfT1rIacBu+wnr70tySkMRjyA4OcnmmpBJdDSuH03ymEeS2ME981Tmu2niSJQsYQcgHG761SSJigwGZumOw75qWRDHbRSvkhxwwGB70O+4kox0buNiQSzKzuEiHDE026uAdzRnIXp6Yqjc3iq20n5M9KqT3VzOGS2xtIwQF7Ur20KcW3cjvboFGKscnjjjNQNIjwws5AcMRt9qjlQxYMmCVHTsKrQ5luQXGUJ5YfyrNsqVmtCpdjbM+FIycr3FU9dk+xaWLdlAnufmbPUJ2/OrV/qESTFpVLFWG2MdNvuaxNfvrrxDqjSxwDftCKkY4VQKxk7amNSTlaJzkoJfCitXw3DJHq1tcLwqNvJJ4IHUGtXTPDDbVe9coG7AVtwaWltYXHkRZcAZbqNueRWftbuxDtYRIYY/mjYhJm+THTk9K6LT7aZY1c5OW2tt9KU2KPY28tkBJCQMlhjHHatkFrSJYVSQpgbseprBQlKd0YTqpQsO8hZLR5EtRKUYFI2PB+ta9vqkeo2PlKsSTKNrRuOh9MVzGqanPZxSLCrwjI+boTUsl3BNYx3GxFnugXadRggjjFe1SdopM8yUShfpJc6r5kwiWSEgFYz0b0NXGud1kYMMNo2swHGe4Bpk5P2hi5BJPUDjnvV6IodGKRgs24sMdzWFTc1WljzO4GNRmQE4Dd67fwdaSyTrMPupw1cReuP7VmOejYP1r0Pwhex2ullnxuY81FJ6m1X4dBNaukm1Qxoo+QfrUaxjbgHJPWsmeYS6xNNu+TPatSEg4IFXe7NYx5Yojl3o3qPeq55cep5q7dKCcdz2qGSPaoYcVlNXOmGwm0Bxg8+laMQ/dqSee1UoE3EFvwq7BGDnJOBREbLu1SMg80sOVk+XgE85psfyqcj2p7Nhsg5FaEtaFvblSQPx6UBWAxjIPemLITHwcH1p+SADnNFzOxE467hx0qu4APFW5DkdBUDpjBIzQVEjMe5OaZz071KMke1L5eCG9KC7hHkAVajJKgdKhC+1WFjyn0oIkJGN/PUg4pCoJOeaWL5XIqUL71LEkS2icZFWimQDjNNtVwgJNTquRx0qkrES3EtmihZvPgE4PT5iu2pzc2X8WnLn/roarMuR6801lDDjt3quYXLcdI0byM0MQijOMIDnH40UrxCIDbLHKeCQmeM0VDuNWOF8SSS/blQnC+oFLbuAR3HpUvjKIw3akdB1qlayggEV1VtJFYf4EjWj5OR0qUgEccc1VifhepNTBueT+VQ2bJEsIdZ2c+vFEe5SCcn5sYHpVdXJOCSas7QW9BgGpLQ5hg4GR6ZpSpIRlPX5TSsQQMnk8YpRnaFPfvSAlZGWEqr5K4NKX3mNiSwxg+1MiDu4wMnpgVMkpVWjdQjg8ZoFqtitNHjMQAC9QaiIZrdlJww9KtOVcGQ7SfQdqiYFH3ADY3Bwady4sS2nV7dY4kVphkbjWcse26fzVyxOAV7Vo2u0boux5TtzUkYWCYxOFLgZGDn86Lj2ehhXNrcR3TRkqsWcgEZqAuyPt2sG6hutdAf387mdlR1X5OKqJCGBDj5uhb0oauO99zFW4eRnDEbj36ZrSt9Xu40CsysB03L/Wq32H9+6nD84Haqoge1eZlztU8qTkVOqKcU9DobrVoZNNKQlhPJw4/uj0z71lrcSuQM5XsMVGr2syJ+7lVupMfIP8AhVaS6ihOcSSc9yRj8Kbu3dmUY20SL88gVOSCx7Dr+NNt79VXbKFbvtI+9+NZJvmCEBhtbqCKheQI+VYEHkc9Km9jVRurM6iHVoNptJY/s5BAypyGBHT1qprF1M+1S+IzwuOmBWZBqcavulRS56tjmrVxPazHd5hjRuCFPFXe6sc3JySukYU1y0NwC2yUDs2eams5JvMbACxsdwXFIzRJLJH5eYycBsckeuarMZ2crACq9iep96zS11OmU+ZWsWb6N1nkEmAq4y3QAe9c9fargPDZDC9Gk9fpUuvXF29m8DsBEWDlEXAJrIs1E0fAww6is6mhz8zsWtK0uXU7kRqCIwcySYrvdF0KK1cR28fzkAEnqRVfwBA00LRqgwG+9XaxIIbwTFvvZHNclRu1zCUvesjFv7SNXYIoY7cAkcD3p2i2WYZYW2PlioVR2ra1EkxDG0IQQwx1qv4euo7ecqi4RGJwepNZq09ES5NIZeWs+naSkSpGAWAw3UH2qvczTSRpD5fmSEglh6mtXxBfrP5cn3ieFXGMH1rn5JAWBXeAzBSB7dTmuuLs9Dlk+ZFi7RnuHhnQFVAXDdqqm2iillsEj8wbg8IK5HzVo2uJCd2HIPyjrj3NUb6W6e7lEe/yIIsAjrnqa700Y7lO9Ej3flnaWHHyngYqQyCxsHDEo6A9KpadcT3ErukQMaAb5D1FLrsi3FmTET5jj9BXNUkm9DaMb6HCKhnvWZ+STkmurswkGnMQ24hcDmuT09tsp3Hk1reZ5cOQTtPbNZppbHQ1fQtaYxmkw3JzmuqiwEAI5rB0GEPulJ47Vv4IHHAq6SsrmlTewsqkLkj6GolBfjGcjpVqQ71A6qOc00rsZSp5qty4MbFHjBPUVYg43Fc9e9PEfy7sDk5xSxrgN0BzSWhVydD94HtSpjaQaFGVGRUiLgNkjNG4riRcNgZxU5GXx0FRI3FSq+ccHHemkIaeo/KmOSoIFSEZzxjNNkwBz1PWqEiAdRxmnMSG/pTQwznnmjPI9KBk4bHQc1NG2RjFV1BJJGKs2+AMcUiZAFwwPQ+tTRqTIAT3puQetWkU5B4xSBOxYCn+GkLlW4HPc5qSI5JycVG+AWOBVXIEKsxGT1rTktre1N1I0DOkAVFVyf3jnvWazblHvxitOffFb/vbyR3tnTKgAqmfT1IqokyKV/CkE7rHlVZVbaf4cjOKKh1OOVLmVWcyZxJ5vdwRn+VFS1qUtjlfiIh+ZkzjGa5fSpyygEcj1r1aWwsruKR9RddgHyivL7wwRX0yW+PLDHGK6q8ftCwsr+6acUvAqbfnms6GTcR9Kuq3ygY6cmudM7bMtRkA4IyDU5LjaoUZ6/hVSLNTh33deF/lTCxPjKduaQO27kcCn2uCCj45HemEbXxIpAHH/wBekSt7F2zkUOHK/UKOcUt0qMhCfOfvD1qK2zFOhXOCOtOlH+kNs6exoH9orfcyQdqtwdpoaKMhWVmCseCCcClkXbuMeCe+e9MiVZI1Rm5JyQD0oNF3ZMQsbFZBuQ9GPY+tNlXFuoZQVB3eYo5P1oOHco5+Xop9qWHcism0Mvv2oHYW6RcJKZFIUDBAqGaSBZRkExMuT7mpFgCrIGYlB/Bmm2sCzuEDEoeOe1MHYaNkuqxNIirA4+X0FVCPLu5knVfKckKa1tQtI7e32rL5mRgr3U1mybGWEKAXT7zE9aXkEbPVFRrRrWbMQ3I45we/tVKW2Cg8lkySR71sTHzWLwqY5F/hz1qm53kyIvzL1TNBoroyjaoVyjEZpkti20MUyPar0vlsP7jn9Kntxm3dc7mOMACpQ22tTEayG7OB7Cp57IeUrKu04xirVxA8TDcvNWpFDWuAoVhyM96FElu5leQpj5PReRTEtyrRyH7nc1v2y+fb5MS7sYxWebeUNIjZCg88cVTWxnfdGXqtgPs5bhtwrl7KCOK6lSRtm4YX616EF3wbRg4HIPeufu9MVr1HT5jkZAHSsqqujKNndM7Tw5ZW+l6YFclnfGSvbNaTSGaVAu0iPoQKytGvRJI9hKPljUMXPUn0rSFxErl4mUMDgKa5KkbqxxbSNSeFJoWdFDccfWuQvWCTKYiHmB+YdM+1a8eoizuJASDGy9jzn1rnnPmyTTpGxkjbdmuVx6o1iu5bnufOQcbCq8DHek0bFzb7zjIYgr/Dn1NZlxJ+5+0RsU5KuOoIPenaJKh8x3lYsuOB90+5ropSfMrmdWHu3R0FgyWplVOdxJAbrj1NQpq9mmjzAEm5cupAFZ39olZTEkAb5WOehP41hKwjhlJJ3M2FB4xXo87SONU77nReFZIiZIJNqoVJbHXJqj4xRI1SW3K+WqksFPFN0UlS8YKneMNxnNV9bmt7bQblRgPjYUzzmuZu5qo+8cTp64LMcfMeM1tNEskMaAAAdTWfp1nvQZYgAZzVyzDSXWzIIHp3oaOuCuzq9Bt8Wg+Uf4VqSqNuFqDTgEjVfUVcfAYA10RXukO7lcidQAgyOnao+MjJ5FTx4289RTGj3sNtQzWOhNCd4+bnFSonJwAD9ajtxt464qVgd2QTzQtUVYcMqMH9KlUbgoH41GgyeeoqaM7Tg/lTSAQJ83NLgBgc4ApzNgkGmkjAp7AiVyM96R14BYdqarFsg80uWKgHb6c0xPQrzDYcjp7VDyWq2RuPzD8qZtCsCOaQ0xEJK9OamiUE9s1CzjdxU0I2jnr3pCtdkqDcwBrSXHbis+BSz98etaK9cUIlkgbPH6UMozyKYM554p7PwKLk2I3zxg4ORitdt80Ui3GnXTPKVZzH8qsR39qxzJtfBBYZHsa2bmK5nnaa2uk8k42nzduwehHtWkGTIzrxbqScyXEAhDYCqykAAdhRWlcyq8V6xmDxvsVBnq46sB2FFTNa6Di9DGuwJLWUMPyrynW0+z6oT91W9K9kntH8mXIHSvKvFtmUkMncV3VYXjYww0+WVxltJlVz1Iq6pOAQeOmaxbCQ7VBNasLYbHrXCj1kX4pPlwOSKmjbkFjyBgiqsH3TgcjrUkfEpweccVYmi+DxgHII4I7VZaUzQDAUMnBPrWdGduR0JqeMYkyTzSJcerJYHGQcnipvMJkLjhh1A7ioXCB1ZF/dt0JPenMcPuHB6EUD3JH2gBgAVY4YdxUXljGIzyD1pwkEbkYwGHPvSshjJCHcrHPFBS0GIUOUYHdnOalBYZIBBPr3qKXbtUMuxiOHz1pgbbjO4gd+1A9WTM7ORwAO/FImFyYgCAetVnm3NkMQBx9afFclQVxhT14oHbQdIhA3BgEHUCqpOVeRNoYnpirrzBwqbQNoySO9UZ2iMe8BlbPXtQOKHO2wIpOO4aqrfcbIxJnIb1q18sqR5YsR1FVrwh2IXcqg8KaTLRC3KhpF3AnFOiQEFhuTnHHpSGJ9qkEAk+tS7fLQgyfJ6A0kDeg64WOSVSoYgnGT3pkcTudnXsM+tSFjwckoORx0pB5soAUhRu5zTZntoSrbPCSsmAQOADUi2Ms0DTAsq9DxT7Ewpua6JZgcVLLqD28RhjT5H601sYTcnsjJaMR3BG9VU/dGM1DcK6OHVVwuc/U9KdcEy3AYDA9PSlG7eFYnaORxSWw5QehzF7cXttdpPbsyMuTuHf2NW7DXBezeVLiOVmGSOhrSvrRJY3C9VNcw1iQ/mRLtfPymsJ07g4pq56IbFLsJsnyV6nFZtwZLdZYA6je2S3qK89n1DVLGdys7qx+9g8GtyDxDa3NoA6OtwigEPzuPtXPOmraIw9nKLs9UbSXNs1vKrqfM5+UDhvSodPJnxN5ixxkfcIGDWb9ocsqbfs+RksfmFU0uDbkRRvui5+madOk3YyqdTavJ/td6EMrIoT5VXjIA61landMbEwI6Fd33gPTtT7CVbxHkQAGIFVOeWPpWIRNIw3skagn5HPUj+dddlYxS1Om8NyeTEjSkMCMEZ6Z9aqeJFDxSrtG7dnjpjtVrQ7RnhgaRVRZDnI/rWPr8jQ31xErZjDZyawva7ZpGN5EdmdsY57YxWp4UsnklZ8gDOayIG+0AFCMgV22g27Q2iP8ALnqcVVNXdzomuRWNSOIRMv0qVkIXeep6Zpsbb8sew4pzcqPYV0dDFIhTkEn1pIXKkgDr3xTwedvanRptyccVDRtHYkhX1FTRL1A4zTYyBipQxBAGBmhId7ChMEGn4A5AzTCvIOakUcnHamDYMoPNMXAzntT2PaonGQSTigELGcEqOhp7ALwMHPQ1FGo5z6ZzToyGQjkYoBoBjjIpHUH1pGfBGDwOtIQ7KW7e9IBB8pGzipVPy5OC3vUYx+VOjyRj1pWGX7OZmOGxgcVeILcACqFqArAd+9aQ4UgdKpESI+vFMxsZsZGeTz1qRsFeOCKjDZJBHXvSZIxQxlLMSASK35BaQi7VbGN/s+3O7OWB6msRTuYKB1ra4guB5t+fPRRGw8rcMeh9aqDImVdQiUXZ8tVRCqsoUYwCP50Utyxe5kPmmXd/EVx+lFD3EpWRLO7Ogj5yOpzXB+K7AyQycciu1USCUFjjisjWI/Mjl/iNemzki7M8os0aGUqa2IJOmap38EiXjEDvUlueRnrmuCrHlkevRmpRsbEfXKmlOSdwIyPSoUfKdDSqMNkAg96zuaLzLo+6fQ8mpFbCEZJqvE/fPGKkj6/0qxtFmNwMrglW6j0+lSuckeWcpxlT1qsrAMAePepwQ2Qx2v2b1pMXoL8u/cuWH909RTgWVD8xKHv3FMVo5DhwUkHRhUcjzZySRjjI6H60hi4Z85OQPWmFiMBT8vp2pzMCozw3qOmaYQSwDY47r3pFoYSWPGEx2qYSptIdDn1FRFN2QRwOeKCdgGCDn1oKbuODAnOCUHBxxVaYuw2r93PFDkk/Lz7UwE5IGQT3FFxxHRFkJ4ITrkUjSMxbapwe9KBhMMX47+tRfKZMF3APrQgLCskajYu5j61HIMooLKDn0oYFY8+WSD3JpFuJJIyqwgbeDQFhflLEmQ4HYdKhRss3zNjnA9amAYx52KMdadCXjidggOeRigW242CQvtUrn3p0vJ2h8kd/Si2cwjlR60hCklj97270/IlvUrgDzCoOHHP1p8rFCpJGw0jRE8x9/wA6QI27ZLwBTY9HqyxBD5jlAwBIJyf5VRubP902TwPSrj28bpuglJbpg9qJrU28CM8gkz1FK1zGVk9GczqOlb4g2CRXLy2LicKAeuQfQ16SsatG24Z9Ae1Z19piSxkrgHrUunoZOVjlrpptPtssgmyCQwbp61DpupQyXVuZo9kaklu/atxLFIYHjlQscE5PQ1zbRgSsY0Kj0rKUGtURyqV0dhbWMclv5tqm4NJnIIxzTNQ06GNQZIxI0bcFT/OsbS9T+ylA5by1/hB6VsR3BvoGMDqzNyykYIFKUrRMPZtO5Z0U3VwsjxLtjTPXt9K4/wART5vpVVy75wx9/Sutur0aRpkgL7rmRdqRL29zXK6bpxurjdLnexyeKySclY3pQSfOy34fsneSNmBK9xXe2yMsAAbCrxis/T7dYYfkUADjOK0FPynk7fWuuEFFDm+ZkplC5UdKkV8YVumKqoRng9qTzD3HtTEoFoMNxx+dT5+UZHNVrUA5OcHpirirkY9OlIdrDRjOWIUDualDA+9QSMp+UqD3qSIYPOPwpXCxKPvHPOBUqHnAzzUQXAJPSk3ncGAyOnFOwrWJSQGBNMkYH2pr8ICfrTSCW6/KaZSAqX+XtSsxAAHTpSNycHoKAQSOaQxUGOT+Ap7EFf60hBCk9jUTPjjJo2EK2M+9WIU6BRn+lVo13uMjA9a0l2Rg44NMLktqgD88kVcY/h9Kgtwqx5H3vepl6k4BpXMmNYsAB60xhtIBqXvz17U0rnOaQ07CIfmHUZ/Sty7eFLghrPzSAB5rMcvx14rLtbZZSw86OLGDmQ4z9K2Ea44zqcPAxjP/ANatIrQzqSVylNtZyyoIxj7uScfnRSXrOs7GSUTMQMuvINFSyNyGRSGw5OV4NU7gbd25eDV6QsJwWGcnrS6sgVkIx81enY40zhNZsd5Zo+O9c4B5cpRvvetej31soRSBkH1riNdsnt7lZQPlrOtT5o3OjD1eWVgtmYrxzU4zu5P1qlat90jvV0N82R06VwHqJ3HKTnAHepVLA8dajUDghualU8cjimUySJTITwM+9OVGYHHIHXPUUkaNt3Kc+gqRFDZ3fK1AkxqjaM8nP50+ISDcVIwP4SetO4I5GOetK0ZOW4b6GgfMRuVXk/Kf7vao3Lc7Rgeo6Urj5QCPzoAK9BtHfBpFIidmA+U4PQ+9RswVhuB/CpnBIBY8+9Qspx6CgtCMc5PBqNVbd91ippCjDrhh6CnxYxwWVvQ0i9h3Q/MHAxTWKPwuTjualfepHO7600lVX5kG49TTENlAMa7Zee+ajwqlQznnrUm9WIVVU4Heo5HOMmNePSkNIlkKH5U3bf504grwASMdKhEkqx7wgx0yKka4ZlVWHJpi3JFB2geWAPWljCGRTIMDocUqTnBDDtikMmccfjQZu42RMy4jZtucYpQJU525B45FKGIkDJxih7phw4JApiuxFxsAKHI7iidrY264d946g01JcKTGfzqvlXVs4XB61alZEuNxvnAjLcbeuOtRFzKx/eYz+VRyw5kHzjn1qNR95WwSO4ovcHTTNCPyntzBMMsejEVj3vh45aSMgrjIxUjSOv3zgdjViG4O0qZOvv0o0e5hKi1sczc6Xsbhio9xVT7MIWLiWTd2KnFdgzLzuAb61CYYXzhFDeuKhwiwXMtGYOnWTXMimXcwznLdTXT2tpEirGoC4/i9KhjYIflQDHGKtxMWJbOAaErBytstxsETao6VBI5GeaGmQHAPJ6VGf7xJNJjUbE24E8HHHangDGFPJ/SoouevSp4VZmPHsKRWxbtFCgAmrYBPA61BCmGHXirsWN+7+dOxg5akXk8jcKbtGeM1acBjxyTTVjxnjJpW1BSYhwF6k1C2AAF4AqQHGf5VHgYOeKqxVw2ZGAxNOWNgMZI56ihSA3FP35wO1IY1+BkL+NQ5cAEDj60+XkfXtTwgKgseRSGQ73ftTvLAGXY/SnvwuAB/hTN/Iz19TQwJQNq9MZ5qaLMjqOvvVYvu9S1W7UbQDg1IGlGBwNvSgAlwM8CkjbaMk804NTZkMZiXzg05fv8AJ5xSEcZFPi47ZqUBNb28k2TGjvjrtGcVOLK5/wCeEuB221HGzqfkdlyR0OK1zHFGJN95ckxEByOgzWkYpmMpNGRLCyOUkBXHUEc0VYvhsvXUF2AA+Zzknjr9KKTVnYaZTmysrYO4ZwKnuGFyI1kB4HWoHy7k4wpPFWZYCqKenGRXqnDHcqXUB8rAPSsTVLIT2zBhyO1dFFl0JfoKWKwFxDI2eT0FNCbs7o8mT9zcGJu1aKHcnFO8Q2Jt71mUd6gtpM8NXn1oOMj1qNRSiWYyPxqZOQKgQDI61MDjA5x2rI3LkMnkyEg/gae2Wcue/aqyE8ZqcNjkHj0ouIN+CcfIO/vTghxkEY746018MPl/GoS+HJHSgpK46RsnAOcUgyeVDfWo3cY4PWmgsM5PHsaDVEkpONuARUarjPJ47ZpWDEg9R3po4bqc0AREfMeoqVARnBBHvQQzE85oIZRgrkdeKQ07jtucMyt7EVHKqjoT+NHmFR1ZR6Go3k3HlgRQVqMMYDcHr0AoKkYDPgCh3JHCfjUZxgFeGPY0DVx3UFFOeaciuCCcH600IEHOST6dqdnAyc+lAXJNzKRnGKcJW7gVBIxLDDZH0oHP3mGKBNXLC7iSO3tUZckjcpIFRNI+cA/LRls9fwpXDlJlmTdyopp8vcxPeo2yeAo4phJH31wPWqvoKwsrN1I3LVaZAV8yNgG6FfSppNpUbHPPY0yVPlHygn2p3FYrxKshwWAI7HvSeQCNy4z/AHad5YByQAPSkdcYChhTuS2IUwflyDUWSrcj8atRR5bnn60NF37UWJ5iupOCalXewHPHoKUJkkdamt0KhgB1FTcTkiONHJGVwPerkSZ4zTEHy45yKniBAGM5NBDY6NMVZjXrg/Wmqrb1wBjvVpIiwyuOKdjJyJUwCOamj5OOMVEihPrUg65I60zNskJOST6Um/EZz+dITx9Kgkc46/hSGlcfnIz0qNjuPUCoxnHNGDnjPFM0SJI/lz83NKTjBNRHg5Az7UhJYdMYqWOxYJ3npxTC3XGQBTY1bjNPbbtx3FAAznPA4FIGGeQabkk46CkGCfmzxSYyeEAckY9K0YExGGx165NZkeHkVRnHcVqKCUwBQTJ20JGdgoPapIyW5aoVRivJI9qnjVgOaTM20OI4qSNQCKSMEdfWpAefalYVxzAqcjn+laZebz1E8Ee64UB0L4z6NnsazdwPTqOlX52tbpzM1x5W77yMhJH0q4aGUiK8dnuH8xPLdcKF/ugDiior2cT3BaLOzAVd3UgDGTRSe4JOwyRCHRWyRmr16MSRrghMY4qg7Mbrk5Ga07kDyoyxyPSvVOBMiWGNoWKHn3ptiTE+1j970pIY2WUFSdh7VJPhJVI6+vtTG0YHizSPNV5FHJ6YrzwI0MzK/GK9uurb7RanB3E1wGu6GRKzhevPAqKsOdGlCryOxzaSelWYpBzmqgBicxv1FSxj0715zjZ2PXjJNF1N24EHGKkVg74I59ahj6Zz2qRcEccH+dIoGPJGc0wCQAnapz708LzyePWkUkMTjcuaC0RhAwIPy5o24IGMD1qRueR+VRsSoweR6UFITZtJILHNOxtXrTVIxnkVKrE/MelBQxSByw780jsqtlGwKa+0k+pqCYMWwSMUmNK4TSMQMkMM01VJ52jH1prFR/Dk+1NO8KDsbk0kXYkDdR834U1d3zYYZzxmozIVYBgcDsaVn75wKYkPEbEbjKoIprSsARvB59Ki3ce1OQJgnIx2pDZKjTOMHHp0p6QucnANM3kL0BFLHK3TOKZL8hzREYyvNQsoD9watB2xzmmN74pWFzMhClujEfWjZIeuCPpUpPy9aAuWzzn60w5iFlPAK0mEwAcirONhyKYV35xigjmISM4yRntTGQ54IqcgjHyjim7echvwoFcRFIXLL1pjL6jAqwAT1NJt5wOvrRcjqQoAGwMj61OmApJBqRUGBuFTcbcAcUyJMgRC33RVmELx1LdPpTV+UfL+dSQllQ5HWhEtk8aovXJzUoHXYdoqAHK+lL5mB0NUZFhSN3I/ChpCCcdqrNMQRzS7stTC1ycygHjrUTN83bHrTOcmnLjB3cUikrDkJP0qU4xgcUxQAPlprqSvWgGxkxODg+1QqxNOkB6ZphIXFSzWOxMZWwARim7z603zOMA0iBWbBJFAyXcenU09U8wjJAH8qQlRgKcmlUBmC5wSeaRJdslRDlQMe9XklYZAxg1SiCjoORU/mrt4HNMiWpP5hP8AWp4WbqaqLIHA7VYh3dsUjKRaOTjGOaG6Y71GJM4GcH6Uu7pz0pk2LEcpSN0yAr43DHpWuz3CsqNqFsrkAgFP/rVgAsSNuMg5rW8qG8LXLRXYLcuETcpPsaqL7ESQy/tpg0kss0cpXAfZwV9MiiklvY2W5OxleXbGEPRUHr70VM99Co36lRN2QWHJPetC6XMC5PAqouZCoTlhV+9+VIxxu6EV6x5yILeRyyr0x0ovIJvOyWGzsRVy0jSR1B4NWmjXeUYbvekN7jLBsW4ySCo/OsnUfnkcEDB6V0Ftbqp2dD2rP1G1UTFSOtNMVjynXofKviVHGagj5AxXX+I9MDNkLXKSwtbuN3Arlr038SO/DVdOUcu7Oc9KnjIxyeahBB5Bz7VInIyVz7CuW1jvWqHnvjpQqsSAxyKUdD7etREsTxwKLXNIkzfKR0I9RTWUZyeuKjBbPUCnOjdTyMdaLFIMgDJoyNvHAppUY4NCjjp0qbDuKwwvQYFQOm4g7eKlLH04phY8DpQFyIAI2QD6UyU7jkMQBUkvBG3PvVfJyQBSLWorp0O8n2prjaOCDmpHJQDpn1ppORjOKCgEScZfkjpSBR1UDA6UYOeop7NkgcYoFqNKd+F9KFRif4alIGMADNNwT6igVx6fKOck/pQxCjJ6mhVPQZNMYfU+1ArIcCpOO9O4x1NChRg4ofax5GPpRYgCAE5JpAB+BpG9QaAW2c8UEsQqC/U0hGw07Of4sH0pGCk8HgUhD1XPTrSgZPXOKhA52uOKm5UZFBLQ5TycHNOJ4znr6UzkjJ4GKcFIUYHFMljs9KcshAxnj0pvPFD8H69qaZI/fkZHApPNywFQsQOlIDk80XDlLYwRzSqQOSRUIf5eOlRs/pTuTYtF6DLgD3qm020dvzpvm5pXHZGgsvvTjKAMH86zvO6E8VIZl25Oadw5UWHk44quz4z3HpTTOvsPrULyru4pNlRROHAGad5mfaqJuBnABzQJz6GouacpqKwyKsQkYznnsayI5cjnrVhJ8H5elNMlxNdJMHk5p6uMnBrOWbIGelTq/HBouRY0FcgdOKsxS5xms1ZCwAz0qdX+Xg/pTSsZuNzQMgxSqSenU1UjJI5qYFl5AzQTYuI+0fMM+tbFxFdz3Hm2rFoOPLZHwqjHT2rnvMYdjz1FIshzwTn0qk7Gbj1NnUmie9dlYM2AGZehbHJoqtqZSG6VERVXy0OAO5UUU29RJaFyxdI2DvwTVqXLoCQM9apKgZE5AYVfWFmtgxzuB6GvUPPHxRttEig8VNGxY/Ny3XmkMixxoo9KljUbfMzikMI0l88OAcetXJIllwWA3CqzTurcdDVyOLzIAwPJ5p7COc8QQIqgqTg/zrktUsPNt2YLnFdzq8DFARkjrWXHAJYGVhk099xxdmeaRsVcqwxjirUZ46/r1qfxHaG0nbapxn0rKt5wRycGvPqU3Fnq0avOjU+Ujg//AF6iYHFNR+OKUuCcMOM1mdURp45PSpFk4FNyuQRyPekJyemB70GlyRXGeQKa2M5U4pChprA4oAhfJb5WpUGM55peN2DQFA5B5qS9LBkMOnFRMRuFOJ+9mojgDkUmNIRiM+uKWWRpMFhjtxTMrnPNND7jjOcUFEmz5QdwBp0Y3HnH1qFXAbBwamjOBu7UrCexYWPIyMAUbVzjPHemh8jgHFAIyc0GepJnGdp+pNRtweOtJkEcDFIGHJIIpgtR2QV6c1GO+Rik3ZPU0hAToTu9aQ7D1yxOO3eg5Ckbv0qPdt5FKJMDPX1oE4ghJyCDj1oHBpDPxwOKaXG3nrSFZk5II60w5PAbio0bsOlOTrntQS0TKQAPmp+/j2qGkJ6Ci5nykzP6CkaYAe9RPn14qHzD0xmncOUkMmTmlV896ij5HzDFPGM4oEyTcSaaz849OtIR71HJjoTQSOZgajaULkA1DIwzVaSRh0/GkyopFszZAxnIpd+4deKoiQ7Tmm+bjJzRcrlL7Sqo9frULXA7mqrS+lMLZNJlxii2ZuaerluSeKpj3NPXJI9qRoXUcetTLLg+grPXqKtJyOTUXYmi+kueDUyznH0qinUYqZc47iquRyouJMxH3uKuRM3cn2rMjbPbHtV6NsIKtESSRdSSRQBn8atRzueMis7zs/yqxGx4xTtcxkbFnfXFuzGBlXd1yoOatJrF60hDSgDGc7FxWfp0UTxzz3TP5EABKp95iTgD2qW5hiks3utPZ2RP9bE/34/f3HvVrmS0MHa5Lc3fnzNJOd7kAZAoqnqax2d75cRbZ5aNycnJXJoqW9dRqLa0NqDLgOhPB+bjFbpcPaqMEMR/d61joSq+V/CvINbQAuNO3A4ccCvWPLuVrfayPvyHHSrcS7oRyKrpb8KJGIYj1q5DbiElWYhTyCOaB3Ar5wCqPxqzZsqMYnOOOKjRBF829sDscVHIwafcR2qhFi5hUqQcEHgVki38qYZ4Ga2o2SaAqW+YdBVS5jIUccnnNJjOX8TaUtwjbQOmc15nqlo1oxZQa9cmlw5R+R71ia1o0d3AxXkkEiplHmRrTqcjPNLS9ViQW596viQHuPWsXULZ9OvWDg/lVy3udyr0rz5x5XY9WnPmV0aKuOoHFPRwT2NVkk3DA/WpBz6VBvcsBvekJBOM81EDSjr65plXHFOc8E/WomPJ56daUvknue1REcHFIaFLZ4XA/wAajdiR24p5VTyAOKNgJqS0yAjgnGKjI6AVM2BxTQORjFBVxqqOealU8BTUZznIp3Xk9aBNj2Y4600ZP8VAHGSRinAgAnFAMerYWmE4BJNAJzg00jLc9qBIaXIIOacXyuaRiMA8ZppJ7UhgWx9aQt8vPHtUT5+tBLE4AzSZQ5T6dPWpEXdzjk96bHGT96rakqnC0ESlYSNMDAH1qUMM47UwDJVjuB9O1IzAH3+lBje4dSxBpjEdBjNIZMc9qiLLnPrQCAGkz3xTTIij5iOelIGz3z9aBsmVhigOOOOaiL470B8UzKRIZMZNQvKSxzzSSvmqsj4zgCmSPkkXqc5qu8nOBx61HPKQRu5qsZOxNKxUUWHfBx+tRk5PFRbgTgn3qRB1OaLGiJMjFOXBqNcZBqb5cc9aRSkOxyB1p6/Lx2pF64HSl3EDHWkx3JR0GOKmDDoTyarIcnnoKft3HOeKdguXIH6bulWVcBvX61nocDk81Jv6Y6UEtl9ZFUc1MsoYYzWYH3d6mRhihMh2NFHIIweDVgXGD1x9KyxPwPTFH2gHAJpmbVzestUktHkKxpcJIu2SNwSGH9KbbalPaTiaEMCOCNhII9CO4qlo2tvpN2JY2JibiVAcbl/x9KmufE+oiRzFqF15OTsLgA47Zqr6bkOGuxNqWqte3bTmMQkqq7RnAAGO9FYd7qct3OZrmRpZWABc9TjpRUt3ZrGFkeopGWiXYSWHXitnTlSSzcBsP2BrJtwyp8pzkc57VpaTCHcg9RzjNewj58kuIXLqp5+napi6xxKjD7o6VIJD84Ckn1qJod6CXBPPIplDnJkj3BSoNEcDyIcdB3qWJkaPavOOad5wTC8gngmgCvZqVnKHk9qmvlwuMH/D6U11EEscinIzWmrJc/Jt6Dr60ML2OdkgSbcMZIqpGAk3luM+tbJgMczKvr+NUntsykkYNIo43xpoUVzGZVA3Y64rzCaOSyl2kHaK941OPzLYqRzivNfEGmZdyFGayqU1JHRRqOJzdvdBxnjg1dSbLDgGsK4t5LeU4Bxmnw3WMc81xSi47npxkp7G+JRSlgTWWlxkAk1OkoYZzUWNEXcg47GkLds5Heq8co/vHFPLg9TQUmSE8cc1HnH1pN30PvSZpWLTHH1PWg4x/gKj3knBoYk9CaQ7kmPl6cU0tjoKbvOOopC/J9cUALnsKTf9fagnt0FNJycn8qAbHsxOABmoiTnqc/ypSRg0wnBBJFAJjm+91oJ+tMY7z8vQUgPv9aRRL24qSNec5AquHxyTU8ci9RyPegiTZcQADJpXHYHiohMB6VHNOMDFBjdtkjPjimM/Ynmq8km6mFwqnPQ0FWJy+e3NML981A0oHTp71E8xNAFlmqu0mG4/WmNPgYyKiEmTuJpAT+Zk805ZAxxmqrSLjPYenSo/PC5ORzxTJepbdiO9QO42VA1xgdc1SmuASeQaZFiaaQFvaoDN81VnnwDjOartPuPXH1oLNAOGbrzU4mHRTmsdZyMnNL55yMHikM2RMO5OPen+f6EVjrPnODS+fxkGgEbInx160vnDisU3PHWlFz7jNIpaG4k3zdOmKlWXPFYS3eP4hmn/AGv35oE2bpmIpwuQRWF9t461G1+MZz0pNiOgN0oAI4NM+3dOcVzj3/OM1DJf46GlzWGonSm/5yTzSfbec5rlTqHPXNN/tEcncPap5i+RHpvhC4aX+0ntIorjVYoVa1icBs/N8xUHqwHarKaz4vefYlteSvnHlyWgKn6jbjFefeHBa3iX1/qN5Na2Onoskj24zKzM2FVPQk960NcvbqTQX1bQdd1K+0mMhLmGeQrNasem8A8qezCtFJ2MnFc3+Zr+MJ7e2164jthEmEQypEcqkpUF1X2Borj/ABgIdE1s2Vs8jR/Z4ZsucnLxhj+porOTd2bwS5UfS0ZKgDGe2a09HUtcMpft1qpaYdnhk6oODipLYtGx38cYBr37HyxqTI8MqpF8wbrUzAxwdsMcH2qQKzwQyxEFlHPNRzuSQMEqep96QytHG9vMSvzKac6qELSA7qfLM0MQDqT6GoFcyMfMPynp70AOHIVixx6VYtpWWZQeRUMMRlz5fRe9PmlOVC9uppjLVyuZd/Ttms66lAkVx61rrH9otxjG6qF1asdyuBnt7UgTK13GstvuAwcVxWpWjPKc8V2kZKqYyMge9Zl1AJZSMY5/OjoWnY861HTEL8jNcvqmjyxOXiXK16VrNo0bbgOB3qj5Uc8RVgCe9Q4KejNY1ZU3dHmEbujAMCPar0U4xgjANb+oaIrk7E5zWFc6ZLatwOK46lBx1R308TGehIkikkDtxUoY9+lUIyc9MVOkvHJrFpo6FO5a3Dil8z24qDePahpMdKC1Im3UM2MVWD8EHrTfMGKlotE7Hpz1pcgDrg1XEmPr2oabjJpDLAbjjGOhpN2Rx2qsz5PH40CXBJ9aB2LJkAqPuc1EJFPGaRnwTg/rQBOhJ9AKa/XioRIMcmmNOoBOScUATM+OuPrTRLjvVNrgE9cVE1xg4BzSHuafnE9+aQzgdTx3rJN2d2M8UxrgY5NBLiav2gY6mo5LkdM1jvc4IxUb3OT97ApXDlNaS4OOTxUbXQA4JrJe49fX1qJ7nJp3E4o1WuupzUX2rHQ8VkGf2przHHXFIk13u8jhuKha6AJ5rIM+AeTUTXJxgtTuQa0t2TzVV7jqazXuhk881F9qGCKncDRafvmozOCay3u+eoqCW8yOtMm5teeOc0guFArB+1ZHWo2uvc0WE2dCLoDoaX7WAOtc19rb1pftJxkZp2C6OhN4D3oF3jvXOi5PqaX7SfWlysOdHQm9GcGkF9g8kfnXOm6Pc9Kja7560+Vh7RHSPqAz1qGS/wAdziueN2T3qJrjPc0vZh7WPc3JtQOc7jUBvm9TzWR5rEUKSe9NUxe2fQ0/trdDTDcvu4JxVRB6nNSotPkBVZM3fDniJtIkuo7izi1DT72MRXVrKxUSKDkEMOVYHkGotB8QXeiam13ZBCsitHLbyjdHNE3WNx3GKm8L6LDqU0896JzZWwTdHb482eR22xwoT0LHv2AJrcitbC41LUdMn8NadGtgjPMbG9c3Kqv3jGzMVlZRkkY7GqUCXU1d0Yni3Xl8Qa8+ox2otEaGKIQB9wXYgXg+nFFVNb0w6TqktoJlniAWSGdRgSxOoZHA7ZBFFJ26mkZWWh9hpMZbuUjqxzmtMEOqJIuNo61hv8rELwAa6CDmBCeTtr2D59bmlp6xmIShuF4IojIEjqPmRuRTvD6gwTAgEZ71HeKEmbYMfSkCJBG0qeTN3+6apzx+RKsbg7Oma0U+a3jLckUmpAGMZHagpFFsQkpCxw36VAkxXKEAtmpVALKSMnFVLni5XHHNAGtEzxRI2MYqzfKJ4UkTINQSc2qk9alt/wDj2HXp60CSM4xZyGHzVn3cTqxx17GtK9OGyODmoJiTHzTL3Me7t/OgYMPmx1FcrLC1rIc9M13Mf3HrmdaA8w8DqaljXYq2kIuMEDBpmoaUHQhlH1xTtKY+bjNdBcAeUvFW+xnez0ODk8NLMCygg96ybvw1cwAlASBz616LAPmNWpEVoDuUHj0qJ0oy6G0K80zxeaCaE4eMjFQeZgnJr0XXLWEFj5a9K8/vEVZmAAFclWkobHo0qrktSLfnnP400ygjkAVGeBio3JrnaOhSZN5ncUnmnHtVRicjmmknHU0i0y6ZQBxUTTj1qoScnk1ExPrUGiLguMHFMe4OSM/jWfKxHeoixPc0h3NA3W04zmoWufQ1RcnPWosnJ5oC5ee55PIqM3XuB/WqEhIbA6Uxic1IF1rjng8Uxp/cmqLk+tAJx1qUwuWzKT0pryVVJPPNNcnHWnci7J5JuBzUBn7E/Qiq7k4qBvv47ZpgW2n4HI5qF7j0p0MKPHIWXJB45q3bWVu4BaME57k0CaMp7o+vX9aaJmbhVY/QV1SWVskmVgjB/wB2tOG2h+web5SeYTy2KE7i5TgvKunI228h98Ui6ffuTttnOP0rvVRQy4A5HNORRkjHFLmHyI4NdE1FxnygAf8Aap6+Gr9wD+7B9M9K9BCL12jNIoGelHMw9mjhV8K3hQlpYxjtjNPXwjN8u65TB9BzXdBQWUEcUTIoQYAo5mJwj2OH/wCESf8A5+jn/doHhFzz9qH0ArtCBg8U5UUAEKAT1pqT7idOPY40+ElyAbhvqAKl/wCEPj2gmeU59hzXXqoLHIHFTn78Z71Sk+5DUV0OI/4Q+FiVWWbp14qRPBVps/eySk+ucV3TgCWPAHIHakKKJRwOetF33ItHscSvgiy7ecB67qmXwhp6MMI7H/aau5RQzhWAK4xj2phRVfAUYxRdgrdjkY/C2nZGLdfxNS/8I7pyHi0QnPHWumkRfKc45HSiCNSdxHIHWi7KOcXQLPjFumfYcVOmi24GRAgAHXaK6aE7mAbBH0phUFkBHB7UWI5mReFreGFpbdRDbyvLFc28kgwgmiJKhj2BBIz2rRi8KW1rfy31ro1zZ3JDhZLuVPs1vvBDPuHLgAnA71CsaMACoIyeKjnUCOMDOM9M1SZLuzB8S6ZZ3eoKbaNTbQQx20LHhmRFxkjtnk/jRVqYAsx75orNvU0i2kf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30770=[""].join("\n");
var outline_f30_3_30770=null;
var title_f30_3_30771="Chapter 1B: Units of solute measurement";
var content_f30_3_30771=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 1B: Units of solute measurement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30771/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/3/30771/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of regulation of solute and water balance is estimated clinically by measurement of the plasma concentrations of the appropriate substances. It is therefore important to be aware of the different ways in which solute concentration can be measured &mdash; in milligrams per deciliter",
"    <span class=\"nowrap\">",
"     (mg/dL),",
"    </span>",
"    millimoles per liter",
"    <span class=\"nowrap\">",
"     (mmol/L),",
"    </span>",
"    milliequivalents per liter",
"    <span class=\"nowrap\">",
"     (meq/L),",
"    </span>",
"    or milliosmoles per liter or per kg",
"    <span class=\"nowrap\">",
"     (mosmol/kg).",
"    </span>",
"    For sodium ion (Na+), 2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (or 23",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    1",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    1",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and 1",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    all refer to the same concentration of Na+.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATOMIC WEIGHT AND MOLARITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Table 1 lists the atomic weights of the most important elements in the body (",
"    <a class=\"graphic graphic_table graphicRef50668 \" href=\"UTD.htm?32/24/33164\">",
"     table 1",
"    </a>",
"    ). The atomic weight is an assigned number that allows comparison of the relative weights of the different elements. By definition, one atom of oxygen is assigned a weight of 16, and the atomic weights of the other elements are determined in relation to that of oxygen. In a molecule, i.e., a substance containing two or more atoms, the molecular weight is equal to the sum of the atomic weights of the individual atoms. As an example, the molecular weight of water (H2O) is 18 since ([2 &nbsp;x 1] &nbsp;+ &nbsp;16) = 18.",
"   </p>",
"   <p>",
"    One mole (mol) of any substance is defined as the molecular (or atomic) weight of that substance in grams. Similarly, one millimole (mmol) is equal to one-thousandth of a mole or the molecular (or atomic) weight in milligrams. Since the atomic weight of Na+ is 23, 23 mg is 1 mmol and 23 mg of Na+ in 1 liter of water represents a Na+ concentration (written as [Na+]) of 1",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    The concept of molarity is important because, from Avogadro's law, 1 mol of any nondissociable substance contains the same number of particles (approximately 6.02 x 1023). Thus, 1 mmol of Na+ contains the same number of atoms as 1 mmol of Cl- even though the former weighs 23 mg and the latter weighs 35.5 mg. However, 1 mmol of NaCl (58.5 mg) largely dissociates into Na+ and Cl- ions and therefore contains almost twice as many particles. As will be seen, these relationships are important in understanding electrochemical equivalence and in the measurement of osmotic pressure.",
"   </p>",
"   <p>",
"    Although the concentration of uncharged molecules, eg, glucose and urea, also can be measured in millimoles per liter, they are more commonly measured in the clinical laboratory as milligrams per deciliter. As an example, the molecular weight (mol wt) of glucose is 180. Consequently, a glucose concentration of 180",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (or 18",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is equal to 1",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    To convert from milligrams per deciliter to millimoles per liter, the following formula can be used:",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp; = &nbsp;",
"    <span class=\"nowrap\">",
"     (mg/dL",
"    </span>",
"    &nbsp;x &nbsp; 10) &nbsp; &divide; &nbsp; (mol wt)",
"   </p>",
"   <p>",
"    (The multiple of 10 is used to convert milligrams per deciliter into milligrams per liter.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELECTROCHEMICAL EQUIVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positively charged particles are called cations, and negatively charged particles are called anions. When cations and anions combine, they do so according to their ionic charge (or valence), not according to their weight. Electrochemical equivalence refers to the combining power of an ion. One equivalent is defined as the weight in grams of an element that combines with or replaces 1 g of hydrogen ion (H+). Since 1 g of H+ is equal to 1 mol of H+ (containing approximately 6.02 x 1023 particles), 1 mol of any univalent anion (charge equals 1-) &nbsp;will combine with this H+ and is equal to one equivalent (eq). Thus:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;1 mol H+ &nbsp; + &nbsp; &nbsp; 1 mol Cl- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;1 mol HCl",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;(1 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (35.5 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(36.5 g)",
"   </p>",
"   <p>",
"    By similar reasoning, 1 mol of a univalent cation (charge equals 1+) also is equal to 1 eq, since it can replace H+ and combine with 1 eq of Cl-. As an example:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;1 mol Na+ &nbsp; + &nbsp; &nbsp; 1 mol Cl- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;1 mol NaCl",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;(23 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (35.5 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(58.5 g)",
"   </p>",
"   <p>",
"    In contrast, ionized calcium (Ca2+) is a divalent cation (charge equals 2+). Consequently, 1 mol of Ca2+ will combine with 2 mol of Cl- and is equal to 2 eq:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;1 mol Ca2+ &nbsp; + &nbsp; &nbsp; 2 mol Cl- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;1 mol CaCl2",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;(40 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(71 g) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (111 g)",
"   </p>",
"   <p>",
"    The body fluids are relatively dilute, and most ions are present in milliequivalent quantities (one-thousandth of 1 eq equals 1 meq). To convert from units of millimoles per liter to milliequivalents per liter, the following formulas can be used:",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    &nbsp; = &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp;x &nbsp;valence",
"   </p>",
"   <p>",
"    or from Eq. (1),",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    &nbsp; = &nbsp;",
"    <span class=\"nowrap\">",
"     (mg/dL",
"    </span>",
"    &nbsp;x &nbsp; 10 &nbsp; x &nbsp; valence) &nbsp; &divide; &nbsp; mol wt",
"   </p>",
"   <p>",
"    There are two advantages to measuring ionic concentrations in milliequivalents per liter. First, it emphasizes the principle that ions combine milliequivalent for milliequivalent, not millimole for millimole or milligram for milligram. Second, to maintain electroneutrality, there is an equal number of milliequivalents of cations and anions in the body fluids. As will be described in later chapters, the need to preserve electroneutrality is an important determinant of ion transport in the kidney and in ion movement between the cells and the extracellular fluid. This obligatory relationship could not be appreciated if the ionic concentrations were measured in millimoles per liter or in milligrams per deciliter (",
"    <a class=\"graphic graphic_figure graphicRef53607 \" href=\"UTD.htm?41/8/42126\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite these advantages, not all ions can be easily measured in milliequivalents per liter. The total calcium (Ca2+) concentration in the blood is approximately 10",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    From Eq. (3),",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of Ca2+ &nbsp; &nbsp;= &nbsp; &nbsp; &nbsp;(10 &nbsp; x &nbsp; 10 &nbsp;x &nbsp;2) &nbsp; &divide; &nbsp; 40 &nbsp; = &nbsp; 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    However, roughly 50 to 55 percent of plasma Ca2+ is bound by albumin and, to a much lesser degree, citrate so that the physiologically important ionized (or unbound) Ca2+ concentration is only 2.0 to 2.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    There is a different problem with phosphate since it can exist in different ionic forms, as H2PO4-, HPO4(2-), or PO4(3-), and an exact valence cannot be given. We can estimate an approximate valence of minus 1.8 because roughly 80 percent of extracellular phosphate exists as HPO4(2-) and 20 percent as H2PO4-. If the normal serum phosphorus concentration is 3.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (phosphate in the blood is measured as inorganic phosphorus), then,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of phosphate &nbsp; &nbsp;= &nbsp; &nbsp;(3.5 &nbsp; x &nbsp; 10 &nbsp;x &nbsp;1.8) &nbsp; &divide; &nbsp; 31 &nbsp; &nbsp;= &nbsp; &nbsp;2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    Similarly, only an average valence can be given for the polyvalent protein anions. If the plasma protein concentration is 0.9",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and the average valence is minus 15, then from Eq. (2),",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of protein &nbsp; = &nbsp; 0.9 &nbsp;x &nbsp;15 &nbsp; = &nbsp; 14",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OSMOTIC PRESSURE AND OSMOLALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another unit of measurement is osmotic pressure, which determines the distribution of water among the different fluid compartments, particularly between the extracellular and intracellular fluids (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=see_link\">",
"     \"Chapter 7A: Exchange of water between the cells and ECF\"",
"    </a>",
"    ). The osmotic pressure generated by a solution is proportional to the number of particles per unit volume of solvent, not to the type, valence, or weight of the particles.",
"   </p>",
"   <p>",
"    The unit of measurement of osmotic pressure is the osmole. One osmole (osmol) is defined as one gram molecular weight (1 mol) of any nondissociable substance (such as glucose) and contains 6.02 x 1023 particles. In the relatively dilute fluids in the body, the osmotic pressure is measured in milliosmoles (one-thousandth of an osmole) per kilogram of water",
"    <span class=\"nowrap\">",
"     (mosmol/kg).",
"    </span>",
"    Since most solutes are measured in the laboratory in units of millimoles per liter, milligrams per deciliter, or milliequivalents per liter, the following formulas must be used to convert into",
"    <span class=\"nowrap\">",
"     mosmol/kg:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp; = &nbsp; &nbsp; n &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p>",
"    or, from Eqs. (1) and (2),",
"   </p>",
"   <p>",
"    (Eq. 4) &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp; &nbsp;= &nbsp; &nbsp;(n &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    &nbsp;x &nbsp;10) &nbsp; &divide; &nbsp; mol wt",
"   </p>",
"   <p>",
"    (Eq. 5) &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp; &nbsp;= &nbsp; &nbsp;(n &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    &nbsp; &divide; &nbsp; valence",
"   </p>",
"   <p>",
"    where n is the number of dissociable particles per molecule. When n = 1, as for Na+, Cl-, Ca2+, urea, and glucose, 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    will generate a potential osmotic pressure of 1",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    If, however, a compound dissociates into two or more particles, 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    will generate an osmotic pressure greater than 1",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    At the concentrations present in the body, for example, ionic interactions reduce the random movement of NaCl so that it acts is if it were only 75 percent, rather than 100 percent, dissociated. Thus, for each 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of NaCl, there will be 0.75",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    each of Na+ and Cl- and 0.25",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of NaCl or 1.75",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef77422 \" href=\"UTD.htm?26/54/27502\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30771/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the laboratory, the osmotic concentration of a solution is measured not as an osmotic pressure but according to other properties of solutes, such as their ability to depress the freezing point or the vapor pressure of water. Solute-free water freezes at 0&ordm; C. If 1 osmol of any solute (or combination of solutes) is added to 1 kg of water, the freezing point of this water will be depressed by 1.86&ordm; C. This observation can be used to calculate the osmotic concentration of a solution. As an example, the freezing point of the plasma water is normally about -0.521&ordm; C. This represents an osmolality of 0.280",
"    <span class=\"nowrap\">",
"     osmol/kg",
"    </span>",
"    <span class=\"nowrap\">",
"     (0.521/1.86)",
"    </span>",
"    or 280",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"   </p>",
"   <p>",
"    Only solutes that cannot cross the membrane separating two compartments generate an effective osmotic pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40133?source=see_link\">",
"     \"Chapter 7B: Exchange of water between plasma and interstitial fluid\"",
"    </a>",
"    .) Thus, a lipid-soluble solute such as urea, which can cross the lipid bilayer of cell membranes, does not contribute to osmotic pressure but will be measured as part of the plasma osmolality by freezing point or vapor pressure depression. There is therefore a difference between the total osmolality and the effective osmolality of a solution, with the latter being determined only by osmotically active solutes (such as Na+ and K+ across the cell membrane) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40133?source=see_link\">",
"     \"Chapter 7B: Exchange of water between plasma and interstitial fluid\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14518?source=see_link\">",
"     \"Chapter 2A: Glomerular anatomy and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30771/abstract/1\">",
"      EDELMAN IS, LEIBMAN J, O'MEARA MP, BIRKENFELD LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37:1236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7275 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30771=[""].join("\n");
var outline_f30_3_30771=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATOMIC WEIGHT AND MOLARITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELECTROCHEMICAL EQUIVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OSMOTIC PRESSURE AND OSMOLALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7275|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/8/42126\" title=\"figure 1\">",
"      Electrolyte concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/54/27502\" title=\"figure 2\">",
"      Units solute measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/24/33164\" title=\"table 1\">",
"      Atomic and molecular weights",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14518?source=related_link\">",
"      Chapter 2A: Glomerular anatomy and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=related_link\">",
"      Chapter 7A: Exchange of water between the cells and ECF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40133?source=related_link\">",
"      Chapter 7B: Exchange of water between plasma and interstitial fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30772="Fenofibric acid: Patient drug information";
var content_f30_3_30772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fenofibric acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20742?source=see_link\">",
"     see \"Fenofibric acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6838326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fibricor&reg;;",
"     </li>",
"     <li>",
"      TriLipix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fenofibric acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Gallbladder disease, very bad kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12174 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.139.118.95-7D9FC8501B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30772=[""].join("\n");
var outline_f30_3_30772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838326\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027560\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027562\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027561\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027566\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027567\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027569\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027564\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027565\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027570\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027571\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20742?source=related_link\">",
"      Fenofibric acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30773="Fluticasone (nasal): Drug information";
var content_f30_3_30773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=see_link\">",
"    see \"Fluticasone (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=see_link\">",
"    see \"Fluticasone (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flonase&reg;;",
"     </li>",
"     <li>",
"      Veramyst&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fluticasone&reg;;",
"     </li>",
"     <li>",
"      Avamys&reg;;",
"     </li>",
"     <li>",
"      Flonase&reg;;",
"     </li>",
"     <li>",
"      ratio-Fluticasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9349484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9349533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Rhinitis:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flonase&reg; (fluticasone propionate): Initial: 2 sprays (50 mcg/spray) per nostril once daily (200 mcg/day); alternatively, the same total daily dosage may be divided and given as 1 spray per nostril twice daily (200 mcg/day). After the first few days, dosage may be reduced to 1 spray per nostril once daily for maintenance therapy (100 mcg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Veramyst&reg; (fluticasone furoate): Initial: 2 sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day); once symptoms are controlled, may reduce dosage to 1 spray per nostril once daily (55 mcg/day) for maintenance therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avamys&reg; [CAN] (fluticasone furoate): 2 sprays (27.5 mcg/spray) in each nostril once daily (110 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg)/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9349532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=see_link\">",
"      see \"Fluticasone (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Rhinitis:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flonase&reg; (fluticasone propionate): Children &ge;4 years and Adolescents: Initial: 1 spray (50 mcg/spray) per nostril once daily (100 mcg/day); patients not adequately responding or patients with more severe symptoms may use 2 sprays per nostril once daily (200 mcg/day); once symptoms are controlled, dosage should be reduced to 1 spray per nostril once daily (100 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (200 mcg)/day. Dosing should be at regular intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Veramyst&reg; (fluticasone furoate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: Initial: 1 spray (27.5 mcg/spray) per nostril once daily (55 mcg/day); patients not adequately responding may use 2 sprays per nostril once daily (110 mcg/day); once symptoms are controlled, dosage may be reduced to 1 spray per nostril once daily (55 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg)/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avamys&reg; [CAN] (fluticasone furoate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: Initial: 1 spray (27.5 mcg/spray) per nostril once daily (55 mcg/day); patients not adequately responding may use 2 sprays per nostril once daily (110 mcg/day); once symptoms are controlled, dosage should be reduced to 1 spray per nostril once daily (55 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg)/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9349534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as furoate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veramyst&reg;: 27.5 mcg/inhalation (10 g) [contains benzalkonium chloride; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as propionate [spray]: 50 mcg/inhalation (16 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flonase&reg;: 50 mcg/inhalation (16 g) [contains benzalkonium chloride; 120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9349542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as furoate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avamys&reg;: 27.5 mcg/inhalation (4.5 g) [30 metered actuations; contains benzalkonium chloride]; (10 g) [120 metered actuations; contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9349463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Propionate spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F242541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Nasal spray: Administer at regular intervals. Shake bottle gently before using. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Discard after labeled number of doses has been used, even if bottle is not completely empty.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flonase&reg;: Prime pump (press 6 times until fine spray appears) prior to first use or if spray unused for &ge;7 days. Once weekly, nasal applicator may be removed and rinsed with warm water to clean.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Veramyst&reg;, Avamys&reg; [CAN]: Prime pump (press 6 times until fine spray appears) prior to first use, if spray unused for &ge;30 days, or if cap left off bottle for &ge;5 days. After each use, nozzle should be wiped with a clean, dry tissue. Once weekly, inside of cap should be cleaned with a clean, dry tissue.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flonase&reg;: Management of seasonal and perennial allergic rhinitis and nonallergic rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Veramyst&reg;, Avamys&reg; [CAN]: Management of seasonal and perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14225198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis (ABRS) (Chow, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9349456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flonase&reg; may be confused with Flovent&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9349491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (7% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 3%), fever (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (3% to 5%), abdominal pain (1% to 3%), diarrhea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (6% to 8%), epistaxis (4% to 7%), asthma symptoms (3% to 7%), cough (3% to 4%), pharyngolaryngeal pain (2% to 4%), blood in nasal mucous (1% to 3%), bronchitis (1% to 3%), runny nose (1% to 3%), nasal ulcer (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Aches and pains (1% to 3%), flu-like syndrome (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alteration or loss of sense of taste and/or smell, anaphylaxis/anaphylactoid reactions, angioedema, AST increased, AV block (second degree), cataracts, conjunctivitis, glaucoma, hypersensitivity reactions, increased intraocular pressure, nasal candidiasis, nasal septal perforation (rare), psychomotor hyperactivity, skin rash, tremor, vaginal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F242544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluticasone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F242529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9349495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F242533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Nasal). Management: Consider using an alternative nasal corticosteroid when possible, partiularly for longer-term concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Fluticasone (Nasal). Management: Concurrent use of telaprevir with inhaled fluticasone is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F242546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     St John's wort: In theory, St John's wort may decrease serum levels of fluticasone by inducing CYP3A3/4 isoenzymes",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F242534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9349487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with systemic corticosteroids in animal reproduction studies; teratogenic effects were not observed following administration of fluticasone furoate via inhalation to pregnant rats or rabbits. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9349489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9771508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluticasone are absorbed following inhalation to produce detectable amounts in breast milk. The use of inhaled corticosteroids is not considered a contraindication to breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9349541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Flonase Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/ACT (16 g): $102.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Fluticasone Propionate Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/ACT (16 g): $84.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Veramyst Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     27.5 mcg/spray (10 g): $133.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F242537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including Churg-Strauss syndrome)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alenys (AR);",
"     </li>",
"     <li>",
"      Alisade (EE);",
"     </li>",
"     <li>",
"      Allegro (IL);",
"     </li>",
"     <li>",
"      Avamys (AU, BE, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, SE, SG, SV, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Clefan (MY);",
"     </li>",
"     <li>",
"      Dalmam AQ (HK);",
"     </li>",
"     <li>",
"      Flixonas (PK);",
"     </li>",
"     <li>",
"      Flixonase (AR, AT, AU, BE, BG, BR, CL, CN, CZ, DK, DO, EC, EE, FI, FR, GB, HK, HN, IE, IL, IT, JM, KP, NL, NZ, PA, PE, PH, PL, PY, RU, SG, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Flixonase Nasule (IL);",
"     </li>",
"     <li>",
"      Flomist (MY);",
"     </li>",
"     <li>",
"      Flutaide (PT);",
"     </li>",
"     <li>",
"      Flutica (DE);",
"     </li>",
"     <li>",
"      Flutide (NO, SE);",
"     </li>",
"     <li>",
"      Flutinasal (GR);",
"     </li>",
"     <li>",
"      Flutinase (CH);",
"     </li>",
"     <li>",
"      Flutitrim (SG);",
"     </li>",
"     <li>",
"      Fluzone (GT);",
"     </li>",
"     <li>",
"      Lutisone (HK);",
"     </li>",
"     <li>",
"      Nasofan (HK);",
"     </li>",
"     <li>",
"      Nasoflo (PH);",
"     </li>",
"     <li>",
"      Novex (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F242527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F242543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Maximal benefit may take several days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &le;2%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/3/30773/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9135 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30773=[""].join("\n");
var outline_f30_3_30773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349460\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349461\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349484\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349533\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349532\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349534\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242539\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349542\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349463\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242541\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242540\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225198\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349456\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349491\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242544\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242529\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349495\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242533\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242546\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242534\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349487\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349489\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771508\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349541\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242537\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961908\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242527\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242543\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9135|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30774="Ultrasound traumatic neuroma";
var content_f30_3_30774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/51601/US_traumatic_neuroma_conv.mp4?title=Ultrasound+traumatic+neuroma\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound traumatic neuroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a real-time image of the median nerve at the wrist in a woman who had old self-inflected slash wounds on the wrist. Months after this, a small palpable cyst like structure developed that was sensitive to touch causing median nerve distribution paresthesias. Ultrasound shows a normal median nerve (N) distal and proximal to this enlarged cystic traumatic neuroma (TN), with demonstrable continuity both in the axial (first segment) and sagittal (second segment) plane as the probe is moved from the wrist proximally over the cystic structure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30774=[""].join("\n");
var outline_f30_3_30774=null;
var title_f30_3_30775="Hematopoietic cell transplantation in sickle cell disease";
var content_f30_3_30775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Shakila Khan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Griffin P Rodgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30775/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/3/30775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is an accepted form of treatment for various hematologic disorders in children, such as aplastic anemia and beta thalassemia major. However, its use in other hematologic disorders is not as well established. This topic review discusses the use of HCT in sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Its use in children with Diamond-Blackfan anemia and the myelodysplastic disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"     \"Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS AND BARRIERS TO HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT is a potentially curative treatment for all of the hemoglobinopathies. The most extensive experience showing the durable nature of cure has been established in patients with beta thalassemia major for more than a decade. In beta thalassemia major, the course of diminished life expectancy is fairly uniform; criteria for patient selection have, therefore, centered on the availability of a HLA-matched family donor and transplanting the patient early, before severe organ damage has occurred, in order to achieve a better outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of sickle cell disease, data concerning the efficacy of HCT are not as extensive, due in part to the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical course of the disease is quite variable, and prognostic factors that might indicate which patients are most likely to develop advanced stage disease, and thus be candidates for HCT, are lacking.",
"     </li>",
"     <li>",
"      Patient eligibility is limited because of the presence of advanced stage symptomatic disease, often involving severe pulmonary and neurologic vasculopathy.",
"     </li>",
"     <li>",
"      Serious concerns about transplantation-related mortality, as well as the potential for treatment-induced malignancy, exist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Siblings as donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT is currently performed in sickle cell disease only if an HLA-matched sibling donor exists, limiting this procedure to less than 25 percent of eligible patients because, on average, one quarter of the subject's HLA-matched siblings will also have sickle cell disease and thus be ineligible as donors. Siblings with sickle cell trait are, however, acceptable as donors; the safety and feasibility of peripheral blood stem cell mobilization with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ) in individuals with sickle cell trait has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the management of sickle cell disease\", section on 'Granulocyte colony-stimulating factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL EXPERIENCE WITH TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31285832\">",
"    <span class=\"h2\">",
"     Survival and engraftment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first patient with sickle cell disease to be treated with HCT was an eight-year-old girl who had both AML and recurrent vaso-occlusive crises. After HCT, in addition to having a normal bone marrow with no evidence of AML, her hemoglobin S level decreased to the level of the donor, who had sickle cell trait, and she had no further vaso-occlusive crises [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional studies with larger numbers of patients were reported from Belgium, with overall and disease-free survivals of 96 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar results were reported in a French study involving 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The first multicenter trial from the US, published in 1996, reported results in 22 patients younger than 16 years of age who received a HLA-matched sibling HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/6\">",
"     6",
"    </a>",
"    ]. Patient selection was based on strict criteria, including patients with severe debilitating clinical events such as stroke, recurrent acute chest syndrome, and recurrent painful vaso-occlusive crises. The conditioning regimen avoided total body irradiation and included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and T cell depletion using either antithymocyte globulin or Campath antibodies. A combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and cyclosporin or cyclosporin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was used for prophylaxis against graft-versus-host disease (GVHD). An increased incidence of neurologic complications, with seizures in some patients, occurred; these complications were mostly resolved after prophylaxis with anticonvulsant medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the 22 patients reported, 20 survived; 16 had stable engraftment of donor hematopoietic cells, and one had stable mixed chimerism. Four patients (18 percent) had graft rejection, similar to the 13 percent rejection rate reported among children with beta thalassemia major who received HLA-matched sibling HCT. Two patients died of central nervous system hemorrhage or GVHD. Kaplan-Meier estimates of overall survival and event-free survival at four years were 91 and 73 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=see_link\">",
"     \"Specific issues related to hematopoietic cell transplantation in beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A year 2000 US multicenter study reported on the progress of 50 children who received HCT from HLA-identical siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/7\">",
"     7",
"    </a>",
"    ]. At a median follow-up of 39 months, the six-year Kaplan-Meier probabilities of overall and event-free survival were 94 and 84 percent, respectively. Of the 47 surviving children, 38 had full donor chimerism, four had stable mixed chimerism, and five developed recurrent sickle cell disease. The cumulative incidence of graft rejection or recurrence of sickle cell disease was approximately 10 percent. Similar results were obtained in a series of 100 patients undergoing stem cell transplantation in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/8\">",
"     8",
"    </a>",
"    ]. Kaplan-Meier estimates of overall survival, event-free survival, and disease-free survival for this latter group were 90, 79, and 81 percent, respectively.",
"   </p>",
"   <p>",
"    The US multicenter study noted above also evaluated the long-term effects of transplantation in 26 children who had at least two years of follow-up after HCT. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 22 patients with stable donor engraftment, complications related to sickle cell disease resolved; none had further episodes of stroke, pain, or acute chest syndrome. This is an important issue because chronic transfusion therapy, a therapeutic alternative to HCT, offers marked protection against first or recurrent strokes but does not prevent them. In one series, for example, 13 percent of patients had a recurrent stroke at a mean follow-up of about three years [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among the 10 engrafted patients with a prior history of stroke, all showed stable or improved findings on repeat magnetic resonance imaging of the brain.",
"     </li>",
"     <li>",
"      Linear growth improved. Among individuals with engraftment of donor cells, all but one had a Lansky (",
"      <a class=\"graphic graphic_table graphicRef61298 \" href=\"UTD.htm?38/27/39355\">",
"       table 1",
"      </a>",
"      ) or Karnofsky (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ) score of 100 percent, demonstrating good to excellent quality of life.",
"     </li>",
"     <li>",
"      Five of seven evaluable females had impaired ovarian function, presumably reflecting an adverse effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      conditioning.",
"     </li>",
"     <li>",
"      Three of 26 patients in the late-effects cohort developed grade I to III acute GVHD after transplant, and two had chronic GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Center for International Blood and Marrow Transplant Research (CIBMTR) reported results of myeloablative HCT from HLA-matched sibling donors in 67 patients with sickle cell disease transplanted between 1989 and 2002. The following information was presented [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Average age at transplant was 10 years (range: 2 to 27 years). Two-thirds had received more than 10 transfusions pre-transplant and the serum ferritin level was &gt;1000",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      in 36 percent. Stroke, acute chest syndrome, and &ge;3 recurrent vasoocclusive crises per year were present in 42, 35, and 36 percent, respectively.",
"     </li>",
"     <li>",
"      The source of stem cells was bone marrow in 81 percent. Neutrophil and platelet recoveries at day 100 post-HCT were 100 and 96 percent, respectively.",
"     </li>",
"     <li>",
"      Grade II-IV and grade III-IV acute GVHD were present in eight and two patients, respectively; 13 patients (19 percent) developed chronic GVHD.",
"     </li>",
"     <li>",
"      Five-year probabilities of overall and disease-free survival were 97 and 85 percent, respectively. At a median follow-up of five years post-HCT, 55 subjects (82 percent) remained free of sickle cell symptoms (ie, recurrent stroke, vasoocclusive crises, acute chest syndrome) with hemoglobin S levels &lt;50 percent.",
"     </li>",
"     <li>",
"      Nine patients (13 percent) experienced return of disease (hemoglobin S &gt;50 percent) within the first year post-HCT. Numbers were too few to explore risk factors for disease recurrence, although approximately one-half had received &gt;10 transfusions prior to HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest published experience with HCT consists of 87 patients with sickle cell disease who received matched sibling donor myeloablative transplants between 1988 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/11\">",
"     11",
"    </a>",
"    ]. Cerebral vasculopathy was the principal indication for transplant in 55 of the patients. After a median follow-up of six years, the following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall and event-free survivals were 93 and 86 percent, respectively, for the entire reporting period. For the 44 subjects transplanted after 2000, EFS was 95 percent.",
"     </li>",
"     <li>",
"      The five-year cumulative incidence of graft rejection was 2.9 percent in those who received antithymocyte globulin (ATG) as part of their conditioning regimen and 23 percent in those who did not.",
"     </li>",
"     <li>",
"      Estimated five-year transplant-related mortality (TRM) was 6.9 percent, with no deaths after the first 12 months following HCT. There were no deaths after the 40th transplant procedure and none when cord blood was used as the stem cell source. On multivariate analysis, risk factors for TRM were transplantation before January 2000, presence of acute GVHD, and non-use of ATG.",
"     </li>",
"     <li>",
"      Acute graft-versus-host disease (GVHD) of grades II-IV was present in 17 (20 percent); risk factors for included age &gt;15 years and the use of HLA-mismatched grafts. Chronic GVHD was present in 13 percent of assessable patients. None of the recipients of cord blood developed either severe acute GVHD or chronic GVHD.",
"     </li>",
"     <li>",
"      No strokes or silent ischemic lesions occurred in patients with successful engraftment, including those with progressive cerebrovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31285824\">",
"    <span class=\"h2\">",
"     Other outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes of HCT on pulmonary, gonadal, and central nervous system function were reported from a multicenter trial of children who had successful engraftment after a HLA-matched sibling during the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/12\">",
"     12",
"    </a>",
"    ]. Two or more years after successful engraftment, the following outcomes were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function &ndash; Pulmonary function was usually stable or improved at a median follow up of 3.2 years after HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/12\">",
"       12",
"      </a>",
"      ]. Among the 11 patients who had restrictive lung changes at baseline, five were improved and six had persistent restrictive disease after HCT. Of the two patients who had obstructive changes at baseline, one improved and one had worsened obstructive disease after HCT.",
"     </li>",
"     <li>",
"      Stroke &ndash; Among 25 patients who had experienced a stroke prior to HCT and had stable engraftment, there were no subsequent stroke events after BMT, and brain magnetic resonance imaging (MRI) exams demonstrated stable or improved appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gonadal function &ndash; Most of the males had hypogonadotropic hypogonadism (low testosterone levels, usually with normal gonadotropin levels), and most of the females had ovarian failure (increased gonadotropin levels and subnormal estradiol levels) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/12\">",
"       12",
"      </a>",
"      ]. These effects are presumed to be caused by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      treatment that is used for myeloablation during HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21142822\">",
"    <span class=\"h2\">",
"     Indications for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend HCT for patients with severe symptoms of SCD that are unresponsive to treatment with transfusions and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    if an HLA-matched sibling is available as a donor. This recommendation recognizes the SCD-free survival of 80 to 90 percent after HCT, and the 7 to 10 percent mortality associated with HCT for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4643940\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches have been explored to address the limitations of HCT in patients with SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Early&rdquo; HCT in young children with SCD has been explored as a possible means of reducing SCD morbidity and HCT-associated morbidity and mortality. Outcomes for this approach were reported in a study from Belgium, representing a subset of the European experience in which two groups of patients were included: 36 who met the standard inclusion criteria with evidence of a morbid course (late transplantation group) and 14 who were transplanted early in the course of their disease and had not received more than three blood transfusions (early transplantation group) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/15\">",
"     15",
"    </a>",
"    ]. For the entire group, gonadal dysfunction was present in all 14 patients transplanted close to or after the onset of puberty; one patient developed AML. Grade III acute GVHD was present in only one patient and extensive chronic GVHD in three.",
"   </p>",
"   <p>",
"    Early transplantation (as compared with late transplantation) was associated with the following benefits after a follow-up period of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of overall survival (100 versus 88 percent) and disease-free survival (93 versus 80 percent)",
"     </li>",
"     <li>",
"      A lower rate of adverse effects such as death, absence of engraftment, mixed chimerism, and relapse (7 versus 25 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because accurate predictors that can prospectively define the severity of sickle cell disease in infants and children have not been identified, enthusiasm for HCT in young presymptomatic patients has been limited, especially in the United States. Accordingly, the role of early transplant in presymptomatic young children with sickle cell disease has yet to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alternative donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of alternative donors (eg, umbilical cord blood, mismatched related donors, and matched unrelated donors) used in patients with beta thalassemia major remains uncertain in patients with sickle cell disease. The use of alternative donors in patients with other hemoglobinopathies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link&amp;anchor=H801617#H801617\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\", section on 'Alternative donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal reports of successful engraftment using cord blood transplant from matched sibling donors in patients with sickle cell disease exist [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/19\">",
"     19",
"    </a>",
"    ]. Eleven such patients were reported to the Eurocord Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/20\">",
"     20",
"    </a>",
"    ]. There were no transplant-related deaths and one graft failure; estimated two-year event-free survival was 90 percent.",
"   </p>",
"   <p>",
"    The role of unrelated cord blood transplants in patients with SCD remains uncertain. In one report, seven patients who had experienced a stroke underwent eight transplant procedures of unrelated, incompletely matched umbilical cord blood [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/21\">",
"     21",
"    </a>",
"    ]. Three patients have sustained donor engraftment without detectable levels of hemoglobin S or symptoms of sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/21\">",
"     21",
"    </a>",
"    ]. One patient died and the remaining three patients failed to engraft.",
"   </p>",
"   <p>",
"    The use of stem cell donors who only match half of the recipient HLA loci (ie, haploidentical donors) has been proposed as a means of increasing the size of the HCT donor pool for patients with SCD, but remains experimental. In an observational study, 17 patients with severe SCD underwent non-myeloablative conditioning followed by haploidentical transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/22\">",
"     22",
"    </a>",
"    ]. This therapy was well tolerated and was associated with long term engraftment in 11 of 17 patients (65 percent). Further studies are needed to determine the risk-benefit ratio of this approach outside of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H8#H8\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Haploidentical donors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22619530\">",
"    <span class=\"h2\">",
"     Experience in young adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with myeloablative HCT in young adults with SCD is limited. French investigators reported results in 15 patients older than 16 years of age (range: 16 to 27.5) who received HLA-identical HCT after full-dose conditioning with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and ATG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/23\">",
"     23",
"    </a>",
"    ]. Death from massive cerebral hemorrhage was observed at day 32 post-HCT in one patient with severe cerebral vasculopathy and Moya-Moya. Acute GVHD of grades II to III was present in eight patients and was easily controlled with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . At a median follow-up of 3.4 years, overall disease-free survival was 93 percent, with a normal quality of life without the need for immunosuppression.",
"   </p>",
"   <p>",
"    These results indicate that myeloablative HCT can be successfully performed in selected young adults, although further studies are required to define optimum candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonmyeloablative conditioning regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable interest exists in using non-myeloablative conditioning regimens to reduce regimen-related toxicity. The application of these less toxic approaches to hematopoietic cell transplantation (HCT) for patients with hemoglobinopathies is being awaited with interest [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, two reports have indicated that stable donor engraftment after nonmyeloablative HCT has been difficult to achieve among immunocompetent patients with sickle cell disease or thalassemia, leading to graft rejection when immunosuppression was reduced or discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations led to a phase I-II feasibility trial of nonmyeloablative allogeneic HCT in 10 adults (age range: 16 to 45 years) with severe complications of sickle cell disease who had not had a response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and who also had an HLA-identical family donor. Nonmyeloablative conditioning included 300 cGy of total-body irradiation plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    and was followed by prolonged administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    post-transplant to prevent graft rejection and graft-versus-disease. Results of this trial included [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All 10 patients were alive at a median follow-up of 30 months post-HCT.",
"     </li>",
"     <li>",
"      Nine of the 10 patients achieved long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle cell disease phenotype. Mean donor-recipient chimerism for T cells and myeloid cells were 53 and 83 percent, respectively, in these nine patients.",
"     </li>",
"     <li>",
"      Neither acute nor chronic GVHD occurred in any patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This regimen remains experimental and not all transplant centers are prepared to do this type of transplant. In addition, long-term follow-up of these patients will be required to determine the risks of immunosuppression as well as whether or not immunosuppressive therapy can be safely withdrawn, reduced, or otherwise modified [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Donor lymphocyte infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single report of a four-year-old male child with sickle cell disease who underwent HCT from a HLA-matched sister, with mixed chimerism results at eight months post-HCT suggesting imminent disease recurrence, exists [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30775/abstract/30\">",
"     30",
"    </a>",
"    ]. He received two donor lymphocyte infusions (DLI), resulting in easily treated acute graft-versus-host disease followed by complete donor chimerism. Two years after the second DLI, the patient has a normal hemoglobin concentration and excellent growth and development. This intriguing report indicates that DLI can displace residual host hematopoietic precursor cells, and suggests that this procedure might be successfully employed in other patients with recurrence of sickle cell disease following allogeneic HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4643849\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic cell transplantation (HCT) is a potentially curative option in patients with sickle cell disease (SCD). Unlike the situation concerning HCT for beta thalassemia major, in which the major issue is availability of a suitable donor, the current dilemma concerning HCT for SCD revolves around patient selection and criteria for transplant.",
"     </li>",
"     <li>",
"      Limitations to the use of HCT in patients with SCD include the variability of the clinical course, which preclude predictions of which patients might benefit from HCT, transplant-related risks because of pulmonary and neurologic disease in patients with advanced SCD, and the need for a HLA-matched sibling donor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Limitations and barriers to HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In several series of patients who have undergone HCT for SCD, five-year survival rates were 90 to 97 percent, and transplant-related mortality was 7 to 10 percent. SCD recurred in some patients, resulting in a SCD-free survival of 80 to 90 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical experience with transplantation'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      We recommend HCT for patients with severe symptoms of SCD that are unresponsive to treatment with transfusions and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      if an HLA-matched sibling is available as a donor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recommendation recognizes the SCD-free survival of 80 to 90 percent after HCT, and the 7 to 10 percent mortality associated with HCT for such patients.",
"     </li>",
"     <li>",
"      Early HCT in young children with SCD has been explored as a possible means of reducing SCD morbidity and HCT-associated morbidity and mortality. However, because accurate predictors that can prospectively define the severity of sickle cell disease in infants and children have not been identified, the role of this approach has yet to be defined. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early transplantation'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The use of alternative donors (eg, umbilical cord blood, mismatched related donors, or matched unrelated donors) remains uncertain in patients with sickle cell disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alternative donors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-myeloablative conditioning regimens have been proposed to reduce regimen-related toxicity, but further data are needed to determine the long-term stability of engraftment in the absence of chronic immunosuppression. Preliminary results in a small series of adults with SCD were encouraging, but this approach remains experimental. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonmyeloablative conditioning regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/1\">",
"      Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984; 311:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/2\">",
"      Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 2011; 118:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/3\">",
"      Kang EM, Areman EM, David-Ocampo V, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/4\">",
"      Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol 1994; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/5\">",
"      Bernaudin F, Souillet G, Vannier JP, et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. Bone Marrow Transplant 1993; 12 Suppl 1:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/6\">",
"      Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/7\">",
"      Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/8\">",
"      Vermylen C, Cornu G. Hematopoietic stem cell transplantation for sickle cell anemia. Curr Opin Hematol 1997; 4:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/9\">",
"      Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/10\">",
"      Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/11\">",
"      Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/12\">",
"      Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/13\">",
"      McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011; 46:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/14\">",
"      Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000; 26:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/15\">",
"      Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/16\">",
"      Locatelli F, Stefano PD. New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br J Haematol 2004; 125:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/17\">",
"      Eggleston B, Patience M, Edwards S, et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 2007; 136:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/18\">",
"      Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant 2007; 40:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/19\">",
"      Kelly P, Kurtzberg J, Vichinsky E, Lubin B. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr 1997; 130:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/20\">",
"      Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/21\">",
"      Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007; 11:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/22\">",
"      Bola&ntilde;os-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/23\">",
"      Kuentz M, Robin M, Dhedin N, et al. Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease? Blood 2011; 118:4491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/24\">",
"      Amado RG, Schiller GJ. Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies. Semin Oncol 2000; 27:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/25\">",
"      G&oacute;mez-Almaguer D, Ruiz-Arg&uuml;elles GJ, Ruiz-Arg&uuml;elles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant 2000; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/26\">",
"      Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/27\">",
"      Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/28\">",
"      Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/29\">",
"      Abboud MR. Hematopoietic stem-cell transplantation for adults with sickle cell disease. N Engl J Med 2009; 361:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30775/abstract/30\">",
"      Baron F, Dresse MF, Beguin Y. Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion 2000; 40:1071.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5929 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30775=[""].join("\n");
var outline_f30_3_30775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4643849\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS AND BARRIERS TO HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Siblings as donors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL EXPERIENCE WITH TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31285832\">",
"      Survival and engraftment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31285824\">",
"      Other outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21142822\">",
"      Indications for HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4643940\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alternative donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22619530\">",
"      Experience in young adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonmyeloablative conditioning regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Donor lymphocyte infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4643849\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5929|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/27/39355\" title=\"table 1\">",
"      Lansky performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=related_link\">",
"      Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=related_link\">",
"      Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30776="Causes and clinical manifestations of acromegaly";
var content_f30_3_30776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and clinical manifestations of acromegaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Shlomo Melmed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30776/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/3/30776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly is the clinical syndrome that results from excessive secretion of growth hormone (GH) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/1\">",
"     1",
"    </a>",
"    ]. Its annual incidence is six per million people [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/2\">",
"     2",
"    </a>",
"    ]. The mean age at diagnosis is 40 to 45 years.",
"   </p>",
"   <p>",
"    The causes and clinical features of acromegaly will be reviewed here. The laboratory diagnosis and treatment of acromegaly are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link\">",
"     \"Diagnosis of acromegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of acromegaly is a somatotroph (growth hormone-secreting) adenoma of the anterior pituitary. These adenomas account for about one-third of all hormone-secreting pituitary adenomas (",
"    <a class=\"graphic graphic_table graphicRef73104 \" href=\"UTD.htm?36/54/37739\">",
"     table 1",
"    </a>",
"    ). Growth hormone excess that occurs before fusion of the epiphyseal growth plates in a child or adolescent is called pituitary gigantism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13464?source=see_link\">",
"     \"Pituitary gigantism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division in and excessive growth hormone secretion by these adenomas.",
"   </p>",
"   <p>",
"    The pituitary tumor transforming gene is also overexpressed in most human somatotroph adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/6\">",
"     6",
"    </a>",
"    ]. It also appears to play a role in tumor invasiveness, since expression is increased in tumors that invade the sphenoid bone.",
"   </p>",
"   <p>",
"    The other causes of acromegaly, all very rare, are excess secretion of growth hormone-releasing hormone (GHRH) by hypothalamic tumors, ectopic GHRH secretion by neuroendocrine tumors such as carcinoid tumors or small-cell lung cancers, and ectopic secretion of GH by neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10530955\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical features of acromegaly are attributable to high serum concentrations of both GH and insulin-like growth factor-I (IGF-I), which is GH-dependent. Excess GH and IGF-I have both somatic and metabolic effects. The somatic effects include stimulation of growth of many tissues, such as skin, connective tissue, cartilage, bone, viscera, and many epithelial tissues.",
"     </li>",
"     <li>",
"      The metabolic effects include nitrogen retention, insulin antagonism, and lipolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the somatotroph adenoma itself may cause symptoms due to its size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Insidious onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of acromegaly is insidious, and its progression is usually very slow. The average interval from the onset of symptoms until diagnosis is about 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/10\">",
"     10",
"    </a>",
"    ], but determining the onset, which is usually done from old photographs, is very difficult. At diagnosis, about 75 percent of patients have macroadenomas (tumor diameter 10 mm or greater), and some of the adenomas extend to the parasellar or suprasellar regions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall, approximately 60 percent of patients eventually have headaches and 10 percent have visual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Direct effects of tumor",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Headache/vision loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acromegaly and large tumors have symptoms due to direct compressive effects of the tumor mass, such as headache, visual field defects (classically bitemporal hemianopsia), and cranial nerve palsies. In a series of 310 patients with acromegaly, headache and visual defects were reported as the presenting features in 8 and 3 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/11\">",
"     11",
"    </a>",
"    ]. However, approximately 60 percent of patients eventually develop headaches and 10 percent develop visual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Headache, however, may be the direct result of the elevated serum growth hormone concentration, as well as of the mass effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H18#H18\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pituitary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A somatotroph macroadenoma, due to its size, can cause decreased secretion of other pituitary hormones, most commonly gonadotropins [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/12\">",
"     12",
"    </a>",
"    ]. Many women with acromegaly have menstrual dysfunction, with or without galactorrhea, and some have hot flashes and vaginal atrophy as a result of estrogen deficiency. In a study of 47 women of reproductive age who had acromegaly, 29 (62 percent) had amenorrhea and seven (15 percent) had oligomenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/13\">",
"     13",
"    </a>",
"    ]. Men may have erectile dysfunction, loss of libido, decreased facial hair growth and a decrease in testicular volume.",
"   </p>",
"   <p>",
"    Hyperprolactinemia occurs in about 30 percent of patients. In some patients it is due to cosecretion of prolactin and GH by a somatomammotroph adenoma, in which case the serum prolactin concentration may be over 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    In other patients, the cause is likely interference with hypothalamic-pituitary blood flow, in which case the serum prolactin concentration will likely be less than 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    In a pilot study from a multicenter acromegaly registry (363 patients) hypogonadism was present in 53 percent of patients (49 percent of men and 57 percent of women) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/14\">",
"     14",
"    </a>",
"    ]. Prevalence of hypogonadism was similar in those with macroadenomas and microadenomas (54 and 38 percent, respectively). In macroadenoma patients, hypogonadism was more common in those with coexisting hyperprolactinemia. The cause of the hypogonadism in patients with microadenomas and normal serum prolactin concentrations is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TSH and ACTH deficiency occur less commonly than other pituitary hormonal deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effects of GH/IGF1 excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term growth hormone excess results in overgrowth of many tissues, including connective tissue, cartilage, bone, skin, and visceral organs. Other systemic complications include cardiovascular disease, sleep apnea, metabolic disorders, and colon neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Soft tissue and skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients with acromegaly have acral and soft tissue overgrowth and skin thickening. The characteristic findings are an enlarged jaw (macrognathia) and enlarged, swollen hands and feet, which result in increasing shoe and glove size and the need to enlarge rings.",
"   </p>",
"   <p>",
"    The facial features become coarse, with enlargement of the nose and frontal bones as well as the jaw, and the teeth become spread apart (",
"    <a class=\"graphic graphic_picture graphicRef68059 graphicRef64652 \" href=\"UTD.htm?19/60/20424\">",
"     picture 1A-B",
"    </a>",
"    ). Despite the prominence of these findings at the time of diagnosis, the rate of change is so slow that few patients seek care because their appearance had changed or for other symptoms related to acral enlargement (eg, only 13 percent of 256 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/11\">",
"     11",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Manifestations of soft tissue overgrowth include macroglossia, deepening of the voice, and paresthesias of the hands (eg, carpal tunnel syndrome in around 20 percent). MRI studies suggest that the pathology of median neuropathy in acromegaly is increased edema of the median nerve, which resolves rapidly with reduction of serum growth hormone and IGF-I concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/16\">",
"     16",
"    </a>",
"    ]. Other patients have a symmetric sensorimotor peripheral (rarely hypertrophic) neuropathy unrelated to entrapment.",
"   </p>",
"   <p>",
"    Macroglossia and enlargement of the soft tissues of the pharynx and larynx lead to obstructive sleep apnea in about 50 percent of patients. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Sleep apnea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The skin thickens, making it hard to puncture, and skin tags may appear. Hyperhidrosis is common (present in around 50 percent of patients), often making the patient malodorous. Hair growth increases and some women have hirsutism (56 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bone and joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;When excess GH secretion occurs in children, eg, before the epiphyses of the long bones are fused, linear growth does increase; the result is pituitary giantism. In contrast, adults with acromegaly do",
"    <strong>",
"     not",
"    </strong>",
"    become taller. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13464?source=see_link\">",
"     \"Pituitary gigantism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synovial tissue and cartilage enlarge, causing hypertrophic arthropathy of the knees, ankles, hips, spine, and other joints [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/17\">",
"     17",
"    </a>",
"    ]. Joint symptoms are a common presenting feature of the disease, and back pain (and kyphosis) is common (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64058 graphicRef82074 \" href=\"UTD.htm?14/16/14596\">",
"     image 1A-B",
"    </a>",
"    ). Back pain may also be due to osteoporosis caused by concurrent gonadal insufficiency due to the enlarging pituitary tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7015?source=see_link\">",
"     \"Rheumatic and bone disorders associated with acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone density may be increased in both the spine and hip in acromegaly, at least in women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/18\">",
"     18",
"    </a>",
"    ], but not if the women are estrogen-deficient. A detailed discussion concerning bone disorders associated with acromegaly is located elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7015?source=see_link\">",
"     \"Rheumatic and bone disorders associated with acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Visceral enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many visceral organs are enlarged in acromegaly, including the thyroid, heart, liver, lungs, and kidneys. Reversible prostatic enlargement is also common, even in men with hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13801386\">",
"    <span class=\"h4\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thyroid enlargement may be diffuse or multinodular. In one study of 37 patients with acromegaly, 34 (92 percent) had an enlarged thyroid gland when assessed by ultrasonography; the mean thyroid size was more than five times normal [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/20\">",
"     20",
"    </a>",
"    ]. In another report, 39 of 45 patients (87 percent) had palpable diffuse or multinodular goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/21\">",
"     21",
"    </a>",
"    ]. Thyroid function is usually normal, but some patients with goiter have subclinical hyperthyroidism. A few patients have central hypothyroidism caused by their pituitary tumor. Thyroid function is usually normal in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular abnormalities include hypertension, left ventricular hypertrophy, and cardiomyopathy.",
"   </p>",
"   <p>",
"    The cardiomyopathy is characterized by diastolic dysfunction and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/22\">",
"     22",
"    </a>",
"    ]. The abnormalities are due both to hypertension (present in 43 percent of patients with active disease in one report) and to the acromegaly itself [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/23\">",
"     23",
"    </a>",
"    ]. Reducing GH secretion improves some of the abnormalities of cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. A high plasma fibrinogen concentration occurs in acromegaly and is reduced when serum GH concentrations are lowered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heart failure occurs in 3 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Compared to those without heart failure, these patients had an increase in left ventricular mass index that was largely due to chamber dilation, a reduction in left ventricular ejection fraction (42 versus 66 percent), and a significant elevation in cardiac index (4.3 versus 3.5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2 versus 3.1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2 in controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased prevalence of valvular heart disease has also been reported. In a series of 40 patients with acromegaly, echocardiography demonstrated significant aortic regurgitation in 30 percent and mitral regurgitation in 5 percent; the comparable values in a control group matched for age, sex, hypertension and left ventricular systolic function were 7 and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/30\">",
"     30",
"    </a>",
"    ]. The risk increased with the duration of GH excess, including inadequate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea may represent an additional risk factor for cardiovascular complications and excess mortality in patients with acromegaly. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cardiovascular disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The overall frequency of sleep apnea in patients with acromegaly is approximately 40 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. In most cases, craniofacial deformities, macroglossia, and enlargement of the soft tissues of the pharynx and larynx result in obstructive sleep apnea. Less commonly, patients develop central sleep apnea, which is thought to be due to altered respiratory control [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predictive factors for the development of sleep apnea include the severity of GH excess, duration of disease, obesity, older age, and male sex [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep apnea symptoms gradually improve in some, but not all patients after correction of the underlying GH excess with transsphenoidal surgery or medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Thus, specific therapies for sleep apnea are necessary in many patients, although some require only transient therapy as the anatomic abnormalities induced by GH excess recede. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Metabolic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to high serum GH and IGF-I concentrations, uncontrolled acromegaly is also associated with hyperinsulinism, insulin resistance, overt diabetes in 10 to 15 percent of cases, and impaired glucose tolerance in a further 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Some patients have hypertriglyceridemia or hypercalciuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Colonic effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638590795\">",
"    <span class=\"h4\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting evidence suggests that acromegaly is associated with an increased risk of colonic neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. However, colon cancer mortality does appear to be increased with uncontrolled GH or IGF1 levels. Mechanisms thought to be involved in the apparent excess risk include a trophic IGF-1 effect on the proliferation of epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/47\">",
"     47",
"    </a>",
"    ], and reduced expression of the peroxisome proliferator-activated receptor (PPAR) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link&amp;anchor=H20#H20\">",
"     \"Molecular genetics of colorectal cancer\", section on 'Modifier genes'",
"    </a>",
"    .) Many of these studies are confounded by the observed bowel loop complexity and increased length and megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    A number of individual studies have reported an increased risk of adenomatous colonic polyps in patients with acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/41-43,51\">",
"     41-43,51",
"    </a>",
"    ]. As an example, a prospective colonoscopy study evaluated 103 patients with acromegaly and 138 nonacromegalic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/41\">",
"     41",
"    </a>",
"    ]. Adenomatous polyps were found in 22 percent of patients compared to 8 percent of controls. Patients with acromegaly who are over age 50 years, male, have three or more skin tags, or have a family history of colon cancer are more likely to develop polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An excess risk of colon cancer has also been observed, but the magnitude of risk compared with controls has been highly variable, ranging from two- to 14-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/41-44,51,52\">",
"     41-44,51,52",
"    </a>",
"    ]. The best estimate of risk in patients with acromegaly comes from a meta-analysis of nine studies that compared colon adenoma and cancer rates in 701 acromegalic patients and 1573 control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/45\">",
"     45",
"    </a>",
"    ]. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the eight studies with colon adenoma data, the frequency of adenomas was 2.5-fold higher in acromegaly patients than controls (23 versus 12 percent, pooled odds ratio [OR] 2.5, 95% CI 1.9-3.2).",
"     </li>",
"     <li>",
"      In the three studies with colon cancer data, the frequency of cancer was increased more than fourfold in acromegaly patients (5 versus 1 percent, pooled OR 4.4, 95% CI 1.5-12.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, we suggest that colonoscopy be performed at baseline and then every three to four years thereafter in patients over age 50, especially when GH levels are not strictly controlled. This recommendation is consistent with the 2009 guidelines from the Acromegaly Consensus Group [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638590802\">",
"    <span class=\"h4\">",
"     Diverticula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly also appears to be associated with an increased prevalence of colonic diverticula, as illustrated by a case-control study comparing 107 patients with cured or biochemically controlled acromegaly and 214 age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/54\">",
"     54",
"    </a>",
"    ]. Diverticula were present on colonoscopy in 39 and 19 percent of patients with acromegaly and controls, respectively. Patients with the longest duration of active disease (&gt;11 years), after adjustment for pretreatment concentrations of GH and IGF-1 (standard deviation scores), were the most likely to develop diverticula (OR 4.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to an excess risk of colon polyps and cancer, acromegaly may be associated with other tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. In men, an excess number of malignant tumors including adenocarcinomas of the colon, stomach, esophagus, and melanoma were observed in a cohort of 1041 men with acromegaly (",
"    <a class=\"graphic graphic_table graphicRef52927 \" href=\"UTD.htm?18/53/19291\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/55\">",
"     55",
"    </a>",
"    ]. An increased frequency of thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/58\">",
"     58",
"    </a>",
"    ] and uterine leiomyomata have been reported in women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue and weakness can be prominent symptoms. They may result from sleep apnea, cardiovascular dysfunction, neuropathy, hypogonadism, hyperglycemia, or some combination of these factors. In addition, salivary gland enlargement has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperphosphatemia occurs in approximately 70 percent of patients with acromegaly and is presumably due to direct stimulation of renal tubular phosphate reabsorption by IGF-I [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/61\">",
"     61",
"    </a>",
"    ]. The serum phosphate concentration usually does not exceed 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate of patients with acromegaly appears to be increased. Death is primarily from cardiovascular disease, a risk that may be reduced by strict biochemical control of the disease (",
"    <a class=\"graphic graphic_table graphicRef67986 \" href=\"UTD.htm?2/13/2267\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/1,2,22,62-67\">",
"     1,2,22,62-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best estimate of all-cause mortality risk in patients with acromegaly and the effect of treatment comes from a meta-analysis of 16 studies published between 1970 and 2005 that compared mortality rates in acromegalic patients to those in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/63\">",
"     63",
"    </a>",
"    ]. The mortality risk was reduced by therapy and may have been eliminated by cure as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall weighted mean standard mortality ratio (SMR) was 1.72, which represents a 72 percent increase in mortality in acromegalic patients compared with the general population. Some studies have reported an average reduction in survival of as much as 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When only studies in which over 80 percent of patients underwent transsphenoidal surgery as primary therapy were included, there was a smaller increase in weighted mean SMR (1.32). However, transsphenoidal surgery is not synonymous with cure, as the cure rate is only 80 to 90 percent when performed by the most experienced surgeons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of acromegaly\", section on 'Transsphenoidal surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There were four studies with postoperative biochemical data that could assess for surgical cure (serum GH and IGF-1). When only patients considered to be cured were analyzed, there was no significant increase in mortality (weighted SMR 1.09, 95% CI 0.81-1.46).",
"     </li>",
"     <li>",
"      Independent yet significant determinants of mortality in acromegaly include age, hypertension, GH levels, IGF1 levels, history of prior irradiation, and coexisting ACTH deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?30/3/30776/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"       \"Patient information: Acromegaly (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=see_link\">",
"       \"Patient information: Acromegaly (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174159176\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acromegaly is the clinical syndrome that results from excessive secretion of growth hormone (GH). Its annual incidence is three to six per million people. The mean age at diagnosis is 40 to 45 years.",
"     </li>",
"     <li>",
"      The most common cause of acromegaly is a somatotroph (growth hormone-secreting) adenoma of the anterior pituitary. These adenomas account for about one-third of all hormone-secreting pituitary adenomas. An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division and excessive growth hormone secretion by these adenomas. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of acromegaly are attributable to high serum concentrations of both pituitary-derived GH and liver-derived insulin-like growth factor-I (IGF-I), which is GH-dependent. Excess GH and IGF-I have both somatic and metabolic effects. In addition, the somatotroph adenoma itself may cause local symptoms. (See",
"      <a class=\"local\" href=\"#H10530955\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of acromegaly is insidious, and its progression is usually very slow. The interval from the onset of symptoms until diagnosis is about 12 years. At diagnosis, about 75 percent of patients have macroadenomas (tumor diameter 10 mm or greater) and some of the adenomas extend to the parasellar or suprasellar regions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Insidious onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with acromegaly and large tumors have symptoms due to compressive effects of the tumor, such as headache, visual field defects (classically bitemporal hemianopsia), and cranial nerve palsies. Overall, approximately 60 percent of patients eventually have headaches and 10 percent have visual symptoms. Macroadenomas can also cause decreased secretion of other pituitary hormones, most commonly gonadotropins. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Direct effects of tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all patients with acromegaly have acral and soft tissue overgrowth, and skin thickening. The characteristic findings are an enlarged jaw (macrognathia) and enlarged, swollen hands and feet, which result in increasing shoe and glove size and the need to enlarge rings. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Soft tissue and skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular abnormalities include hypertension, left ventricular hypertrophy, and cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to high serum GH and IGF-I concentrations, uncontrolled acromegaly is also associated with hyperinsulinism, insulin resistance, overt diabetes in 10 to 15 percent of cases, and impaired glucose tolerance in a further 50 percent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Metabolic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acromegaly appear to be at increased risk for colon polyps, colon cancer, and other tumors. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Colonic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality rate of patients with acromegaly appears to be increased, especially if strict biochemical control is not achieved. Death is primarily from cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/1\">",
"      Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/2\">",
"      Bengtsson BA, Ed&eacute;n S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988; 223:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/3\">",
"      Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/4\">",
"      Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/5\">",
"      Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:R31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/6\">",
"      Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/7\">",
"      Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985; 312:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/8\">",
"      Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. N Engl J Med 2000; 342:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/9\">",
"      Altstadt TJ, Azzarelli B, Bevering C, et al. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor: case report. Neurosurgery 2002; 50:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/10\">",
"      Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/11\">",
"      Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/12\">",
"      Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 2000; 85:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/13\">",
"      Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/14\">",
"      Katznelson L, Kleinberg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001; 54:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/15\">",
"      Brue T, Castinetti F, Lundgren F, et al. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol 2009; 161 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/16\">",
"      Jenkins PJ, Sohaib SA, Akker S, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med 2000; 133:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/17\">",
"      Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/18\">",
"      Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 1997; 12:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/19\">",
"      Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/20\">",
"      Cheung NW, Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 1997; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/21\">",
"      Kasagi K, Shimatsu A, Miyamoto S, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid 1999; 9:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/22\">",
"      Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/23\">",
"      L&oacute;pez-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997; 82:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/24\">",
"      Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/25\">",
"      Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/26\">",
"      Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 2001; 55:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/27\">",
"      Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA. Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 1997; 46:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/28\">",
"      Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002; 112:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/29\">",
"      Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004; 89:5308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/30\">",
"      Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/31\">",
"      Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/32\">",
"      Weiss V, Sonka K, Pretl M, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 2000; 23:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/33\">",
"      Davi' MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008; 159:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/34\">",
"      Rosenow F, Reuter S, Deuss U, et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol (Oxf) 1996; 45:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/35\">",
"      Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007; 156:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/36\">",
"      Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/37\">",
"      Wass JA, Cudworth AG, Bottazzo GF, et al. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/38\">",
"      Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/39\">",
"      Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85:3779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/40\">",
"      Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004; 151:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/41\">",
"      Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/42\">",
"      Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 2005; 90:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/43\">",
"      Bogazzi F, Cosci C, Sardella C, et al. Identification of acromegalic patients at risk of developing colonic adenomas. J Clin Endocrinol Metab 2006; 91:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/44\">",
"      Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/45\">",
"      Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 2008; 14:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/46\">",
"      Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85:3218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/47\">",
"      Cats A, Dullaart RP, Kleibeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996; 56:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/48\">",
"      Bogazzi F, Ultimieri F, Raggi F, et al. Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 2003; 88:3938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/49\">",
"      Resmini E, Tagliafico A, Bacigalupo L, et al. Computed tomography colonography in acromegaly. J Clin Endocrinol Metab 2009; 94:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/50\">",
"      Renehan AG, Painter JE, Bell GD, et al. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf) 2005; 62:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/51\">",
"      Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 2002; 87:1909; author reply 1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/52\">",
"      Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001; 86:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/53\">",
"      Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/54\">",
"      Wassenaar MJ, Cazemier M, Biermasz NR, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 2010; 95:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/55\">",
"      Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer 1991; 68:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/56\">",
"      Cohen O, Schindel B, Homburg R. Uterine leiomyomata--a feature of acromegaly. Hum Reprod 1998; 13:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/57\">",
"      Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol (Oxf) 1997; 47:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/58\">",
"      Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010; 13:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/59\">",
"      Manetti L, Bogazzi F, Brogioni S, et al. Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 2002; 57:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/60\">",
"      Thomson JA, McCrossan J, Mason DK. Salivary gland enlargement in acromegaly. Clin Endocrinol (Oxf) 1974; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/61\">",
"      Quigley R, Baum M. Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 1991; 88:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/62\">",
"      Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/63\">",
"      Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/64\">",
"      Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/65\">",
"      Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/66\">",
"      Kauppinen-M&auml;kelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005; 90:4081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/67\">",
"      Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30776/abstract/68\">",
"      Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94:4216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6633 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30776=[""].join("\n");
var outline_f30_3_30776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H174159176\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10530955\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Insidious onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Direct effects of tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Headache/vision loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pituitary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effects of GH/IGF1 excess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Soft tissue and skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bone and joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Visceral enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13801386\">",
"      Thyroid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Metabolic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Colonic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H638590795\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H638590802\">",
"      Diverticula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174159176\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6633|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/42/27311\" title=\"diagnostic image 1A\">",
"      Early acromegalic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/31/15856\" title=\"diagnostic image 1B\">",
"      Late acromegalic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6633|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/27/38325\" title=\"picture 1A\">",
"      Facial features of a patient with acromegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/39/26224\" title=\"picture 1B\">",
"      Hands in acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6633|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/54/37739\" title=\"table 1\">",
"      Causes of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/53/19291\" title=\"table 2\">",
"      Cancers in acromegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2267\" title=\"table 3\">",
"      Mortality in acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=related_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13464?source=related_link\">",
"      Pituitary gigantism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7015?source=related_link\">",
"      Rheumatic and bone disorders associated with acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=related_link\">",
"      Treatment of acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30777="Definition and classification of the cardiomyopathies";
var content_f30_3_30777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and classification of the cardiomyopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30777/contributors\">",
"     Leslie T Cooper, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30777/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/3/30777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/3/30777/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/3/30777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathies are diseases of heart muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardiomyopathies include a variety of myocardial disorders that manifest with various structural and functional phenotypes and are frequently genetic. Although some have defined cardiomyopathy to include myocardial disease caused by known cardiovascular causes (such as hypertension, ischemic heart disease, or valvular disease), current major society definitions of cardiomyopathy exclude heart disease secondary to such cardiovascular disorders.",
"   </p>",
"   <p>",
"    Definitions and classification systems for cardiomyopathies are described here. The individual disorders and the evaluation of the patient with heart failure or cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1978197\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1980, the World Health Organization (WHO) defined cardiomyopathies as \"heart muscle diseases of unknown cause,\" to distinguish cardiomyopathy from cardiac dysfunction due to known cardiovascular entities such as hypertension, ischemic heart disease, or valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/2\">",
"     2",
"    </a>",
"    ]. In clinical practice, however, the term \"cardiomyopathy\" has also been applied to diseases of known cardiovascular cause (eg, &ldquo;ischemic cardiomyopathy&rdquo; and &ldquo;hypertensive cardiomyopathy&rdquo;).",
"   </p>",
"   <p>",
"    As a result, the 1995",
"    <span class=\"nowrap\">",
"     WHO/International",
"    </span>",
"    Society and Federation of Cardiology (ISFC) Task Force on the Definition and Classification of the Cardiomyopathies expanded the classification to include all diseases affecting heart muscle and to take into consideration etiology as well as the dominant pathophysiology [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/3\">",
"     3",
"    </a>",
"    ]. In this 1995 classification, the cardiomyopathies were defined as \"diseases of the myocardium associated with cardiac dysfunction.\" They were classified according to anatomy and physiology into the following types, each of which has multiple different causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilated cardiomyopathy (DCM)",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy (HCM)",
"     </li>",
"     <li>",
"      Restrictive cardiomyopathy (RCM)",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular",
"      <span class=\"nowrap\">",
"       cardiomyopathy/dysplasia",
"      </span>",
"      <span class=\"nowrap\">",
"       (ARVC/D)",
"      </span>",
"     </li>",
"     <li>",
"      Unclassified cardiomyopathies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiomyopathies that are associated with specific cardiac or systemic disorders generally fall into one or more of the above morphologic types. These categories are included in subsequent AHA and ESC classification systems. Etiologies include a host of genetic, inflammatory, metabolic, toxic, and other diseases (",
"    <a class=\"graphic graphic_table graphicRef78298 graphicRef52168 \" href=\"UTD.htm?15/10/15520\">",
"     table 1A-B",
"    </a>",
"    ). The 1995",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    classification system included ischemic, valvular, and hypertensive disease among the causes of cardiomyopathy.",
"   </p>",
"   <p>",
"    A 2006 American Heart Association (AHA) scientific statement proposed a contemporary definition and classification of the cardiomyopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/4\">",
"     4",
"    </a>",
"    ]. The expert consensus panel proposed the following definition: \"Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic. Cardiomyopathies either are confined to the heart or are a part of generalized systemic disorders, often leading to cardiovascular death or progressive heart failure-related disability.\" Cardiomyopathies are categorized into two groups: primary cardiomyopathies (predominantly involving the heart) and secondary cardiomyopathies (accompanied by other organ system involvement). The primary cardiomyopathies are subdivided into those which are genetic, mixed (predominantly nongenetic; less commonly genetic), or acquired. The genetic cardiomyopathies include HCM,",
"    <span class=\"nowrap\">",
"     ARVC/D,",
"    </span>",
"    left ventricular noncompaction, PRKAG2 and Danon glycogen storage diseases, conduction defects, mitochondrial myopathies, and ion channel disorders. The mixed cardiomyopathies include DCM and RCM. The acquired cardiomyopathies include myocarditis, stress-induced (takotsubo), peripartum, tachycardia-induced, and infants of insulin-dependent diabetic mothers.",
"   </p>",
"   <p>",
"    The AHA definition and classification are not intended to provide methodologies for clinical diagnosis, but are rather a scientific scheme that aims to aid in the understanding of this complex group of disorders. The main departure of the proposed AHA Scientific Statement definition from previous classifications is the inclusion of the ion channelopathies as primary cardiomyopathies, despite the absence of gross structural abnormalities.",
"   </p>",
"   <p>",
"    In 2008, the European Society of Cardiology's working group on myocardial and pericardial diseases presented an update to the",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    classification in which cardiomyopathy was defined as: \"A myocardial disorder in which the heart muscle is structurally and functionally abnormal in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to explain the observed myocardial abnormality\" (",
"    <a class=\"graphic graphic_table graphicRef64479 graphicRef74268 \" href=\"UTD.htm?6/62/7150\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/5\">",
"     5",
"    </a>",
"    ]. The ESC classification is meant to be particularly useful in everyday clinical practice.",
"   </p>",
"   <p>",
"    The AHA and ESC classification systems differ from the earlier",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    classification in emphasizing the distinction between",
"    <span class=\"nowrap\">",
"     familial/genetic",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     nonfamilial/non-genetic",
"    </span>",
"    causes of cardiomyopathy and excluding heart disease secondary to CAD, valvular, or congenital heart disorders (",
"    <a class=\"graphic graphic_table graphicRef64479 graphicRef74268 \" href=\"UTD.htm?6/62/7150\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/5\">",
"     5",
"    </a>",
"    ]. The ESC classification differs from the AHA classification in also excluding channelopathies.",
"   </p>",
"   <p>",
"    Clinically, the term &ldquo;ischemic cardiomyopathy&rdquo; continues to be used by some including the 2009 update of the 2005 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology heart failure guidelines, the 2006 Heart Failure Society of America guidelines, and the 2008 Canadian Cardiovascular Society guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, cardiomyopathies were originally defined as disorders that were idiopathic. Nevertheless, in clinical practice the terms ischemic, valvular, and hypertensive cardiomyopathy have been used commonly, particularly in North America. The 1995",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    Task Force used the term 'specific cardiomyopathy' to reflect this reality and the fact that the genetic basis of the cardiomyopathies was being elucidated. The 2008 ESC proposal starts with the patient who presents with symptoms, a family history of cardiomyopathy or ECG and echo abnormalities, which are otherwise unexplained. Like the 2006 AHA proposal, it focuses on the established morphological types described by the 1995",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    Task Force (hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy). Both AHA and ESC classification systems then go on to define the familial and, if possible, genetic basis of disease. The use of the term cardiomyopathy to describe valvular, ischemic or hypertensive heart disease unnecessarily broadens a term best suited to predominantly reflect genetically determined diseases with recognizable phenotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of various cardiomyopathy phenotypes relies primarily upon echocardiographic evaluation. Two-dimensional and Doppler echocardiography can, in most cases, define the anatomic and functional characteristics of the heart that are diagnostic of dilated, hypertrophic, arrhythmogenic right ventricular, or restrictive cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In select cases, cardiac MRI or CT may be useful to identify and localize fatty infiltration, inflammation,",
"    <span class=\"nowrap\">",
"     scar/fibrosis,",
"    </span>",
"    focal hypertrophy, left ventricular apical aneurysm, and right ventricular structure and function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic dysfunction is characterized by a decrease in myocardial contractility. When myocardial contractility is decreased globally (ie, throughout the left ventricle), a reduction in the left ventricular ejection fraction (LVEF) results. While a variety of approaches are available for the quantitative measurement of left ventricular systolic function, the LVEF is often assessed qualitatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When systolic dysfunction occurs, cardiac output is initially maintained in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left ventricular enlargement, which results in a higher stroke volume",
"     </li>",
"     <li>",
"      The Frank-Starling relationship (an increase in contractility in response to increasing stretch)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these compensatory mechanisms are eventually exceeded and cardiac output decreases, resulting in the physiologic manifestations of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systolic dysfunction is characteristic of dilated cardiomyopathy. It is also seen in some patients with hypertrophic cardiomyopathy who develop progressive left ventricular dilatation and a decrease in LVEF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic dysfunction refers to cardiac dysfunction in which left ventricular relaxation and filling is abnormal and is accompanied by elevated filling pressures. Diastolic dysfunction may occur with or without associated systolic dysfunction. In patients presenting with heart failure but without systolic dysfunction, diastolic dysfunction is the presumed cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diastolic phase of cardiac function includes two components. Left ventricular relaxation is a dynamic process that takes place during isovolumic relaxation (the period between aortic valve closure and mitral valve opening) and then during early rapid filling of the ventricle. Later in diastole, after relaxation is complete, further left ventricular filling is a passive process that is dependent on the compliance, or distensibility of the myocardium. Either active relaxation or passive compliance or both may be impaired in a patient with diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diastolic dysfunction is more difficult to identify and quantitate echocardiographically than systolic dysfunction, and may be missed or underestimated in many cases. Echocardiographic evaluation of left ventricular diastolic dysfunction includes Doppler assessment of transmitral flow and pulmonary venous flow as well as tissue Doppler imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diastolic dysfunction is characteristic of both hypertrophic and restrictive cardiomyopathy. However, some component of diastolic dysfunction is also common in patients with dilated cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANATOMIC AND PHYSIOLOGIC CLASSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of one or both ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/9\">",
"     9",
"    </a>",
"    ]. The dilatation often becomes severe and is invariably accompanied by an increase in total cardiac mass (hypertrophy) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59773 \" href=\"UTD.htm?37/29/38357\">",
"     image 1",
"    </a>",
"    ). Affected patients have impaired systolic function and may or may not develop overt heart failure. The presenting manifestations can include atrial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular arrhythmias, and sudden death can occur at any stage of the disease.",
"   </p>",
"   <p>",
"    The incidence of dilated cardiomyopathy has been estimated to be five to eight cases per 100,000 population, with a prevalence of 36 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/9\">",
"     9",
"    </a>",
"    ]. These figures may underestimate the frequency of the disorder because so many patients with dilated cardiomyopathy have incomplete disease expression which goes unrecognized. It has been suggested that up to 14 percent of the middle-aged and elderly population have asymptomatic left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complete list of causes of dilated cardiomyopathy is extensive [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/11\">",
"     11",
"    </a>",
"    ]. The common causes include viruses and gene mutations, which are now recognized to be relatively common among patients with idiopathic dilated cardiomyopathy. In addition, the later stages of hypertrophic heart disease may resemble dilated cardiomyopathy (such as genetic hypertrophic cardiomyopathy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'End-stage HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The echocardiogram in dilated cardiomyopathy shows left ventricular cavitary dilatation (with a tendency for the shape of the cavity to become less ovoid and more spherical), normal or decreased wall thickness, poor wall thickening,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced inward endocardial systolic motion (",
"    <a class=\"graphic graphic_movie graphicRef78668 \" href=\"UTD.htm?40/35/41521\">",
"     movie 1",
"    </a>",
"    ). In addition to these changes in the left ventricle, other findings include left atrial enlargement and, less often, right ventricular enlargement and dysfunction. In such patients, all four chambers may be dilated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link&amp;anchor=H2#H2\">",
"     \"Echocardiographic recognition of cardiomyopathies\", section on 'Dilated cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary artery disease and valve disease are other causes of ventricular dilatation with systolic dysfunction (commonly called &ldquo;ischemic cardiomyopathy&rdquo; or &ldquo;valvular cardiomyopathy&rdquo; although these are not defined as cardiomyopathies under current AHA and ESC classification systems). These causes of heart disease should be distinguished from DCM for appropriate genetic counseling and clinical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous disorder caused by a variety of mutations associated with hypertrophy of the left ventricle, and occasionally of the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/12\">",
"     12",
"    </a>",
"    ]. The term &ldquo;hypertrophic cardiomyopathy&rdquo; is also used in a broader sense in the 2006 AHA and 2008 ESC classification system to include a variety of conditions with increased ventricular wall thickness or mass not caused by pathologic loading conditions (eg, hypertension or valve disease) (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 2A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"     table 2B",
"    </a>",
"    ). The prevalence of hypertrophic cardiomyopathy in the absence of aortic valve disease or systemic hypertension is at least 1:500 of the adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/13\">",
"     13",
"    </a>",
"    ]. The interventricular septum is typically more prominently involved than the left ventricular free wall, but concentric and apical hypertrophy can occur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78856 \" href=\"UTD.htm?18/7/18559\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef54527 \" href=\"UTD.htm?40/20/41295\">",
"     movie 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The left ventricular volume is normal or reduced in HCM, and diastolic dysfunction is usually present. Systolic pressure gradients across an area of obstruction caused by the hypertrophied myocardium are found in about one-quarter of patients. Characteristic histologic changes include myocyte hypertrophy and disarray, which usually corresponds to the areas of greatest hypertrophy (",
"    <a class=\"graphic graphic_picture graphicRef55914 \" href=\"UTD.htm?11/5/11352\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately 60 to 70 percent of patients, HCM is caused by mutations in sarcomeric contractile protein genes and is transmitted as an autosomal dominant trait with incomplete penetrance. The most common mutations are in the beta myosin heavy chain and the cardiac myosin-binding protein C genes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and natural history of HCM are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1613344\">",
"    <span class=\"h3\">",
"     Athlete's heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;In response to intensive endurance training, there can be physiologic increases in left ventricular wall thickness, cavity size and mass, often referred to as \"athlete's heart.\" Intensive athletic training has also been associated with a number of arrhythmias, also usually benign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, athletes with underlying cardiomyopathy may be at risk of lethal arrhythmias during physical exertion. It is important to exclude such disorders before assuming that electrocardiographic or echocardiographic abnormalities are a consequence of athletic training. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)United States and European Cardiovascular Societies differ in their recommendations for preparticipation screening of competitive athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction of physiological left ventricular hypertrophy in an athlete from hypertrophic cardiomyopathy has been emphasized. In individuals with athlete's heart, LVH is generally symmetric and wall thickness is &le;12 mm, however, in some athletes, LVH reaches 14 to 16 mm. Ethnic differences also affect the degree of LVH and EKG abnormalities. Black women athletes have a greater degree of LVH and repolarization abnormalities than white women athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/19\">",
"     19",
"    </a>",
"    ]. Reliance on left ventricular wall thickness alone may be problematic and diagnostic evaluations of athletes with suspected cardiovascular disease should include a family history, 12-lead ECG, and echocardiographic assessment of the distinguishing features of athlete's heart versus HCM.",
"   </p>",
"   <p>",
"    Criteria for distinguishing athlete's heart from HCM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H2599226#H2599226\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Athlete's heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1613186\">",
"    <span class=\"h3\">",
"     Other causes of hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic causes of cardiac hypertrophy include other genetically determined syndromes (eg, Noonan), metabolic disease (eg, Friedreich's ataxia, Pompe's, AMP-kinase), mitochondrial disease, and Fabry disease, an X-linked recessive glycolipid storage disease. Although classic multisystem Fabry disease is rare, isolated cardiac involvement may be relatively common in patients with otherwise unexplained concentric left ventricular hypertrophy (LVH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1613456\">",
"    <span class=\"h3\">",
"     Not HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, cardiac hypertrophy with resulting ventricular dysfunction can also be caused by cardiovascular disease. The most common causes of LVH are hypertension and aortic stenosis. Cardiomyopathy as defined by the 2006 AHA and 2008 ESC classification systems does not include hypertrophy secondary to cardiovascular disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Restrictive cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive cardiomyopathy is characterized by nondilated ventricles with impaired ventricular filling [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/20\">",
"     20",
"    </a>",
"    ]. Hypertrophy is typically absent, although infiltrative disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an increase in left ventricular wall thickness. Systolic function usually remains normal, at least early in the disease.",
"   </p>",
"   <p>",
"    On two-dimensional echocardiography, RCM is characterized by nondilated, nonhypertrophied (nonthickened) ventricles with moderate to marked biatrial enlargement, which is secondary to the elevated atrial pressures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69180 \" href=\"UTD.htm?43/11/44209\">",
"     image 3",
"    </a>",
"    ). However, the physiologic abnormality in restrictive cardiomyopathy (impaired ventricular filling) is difficult to discern from two-dimensional imaging. Doppler assessment of diastolic transmitral flow velocity is more sensitive for the detection of filling abnormalities (",
"    <a class=\"graphic graphic_waveform graphicRef68541 \" href=\"UTD.htm?8/7/8304\">",
"     waveform 1",
"    </a>",
"    ); tissue Doppler echocardiography is also an effective diagnostic tool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link&amp;anchor=H15#H15\">",
"     \"Echocardiographic recognition of cardiomyopathies\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathy is much less common than either dilated or hypertrophic cardiomyopathy outside the tropics, but is a frequent cause of death in Africa, India, South and Central America, and Asia, primarily because of the high incidence of endomyocardial fibrosis in those regions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"     \"Endomyocardial fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of restrictive cardiomyopathy can be classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfiltrative disorders include idiopathic restrictive cardiomyopathy, familial cardiomyopathy, hypertrophic cardiomyopathy, scleroderma, pseudoxanthoma elasticum, and diabetic cardiomyopathy. Familial disease (unrelated to amyloidosis) may overlap with familial hypertrophic cardiomyopathy and may be caused by some of the same gene mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"       \"Idiopathic restrictive cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"       \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H4#H4\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Relation to restrictive cardiomyopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Myocardial disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link\">",
"       \"Heart failure in diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"       \"Natural history of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, secondary restrictive physiology can develop during the advanced stages of dilated, hypertensive, or ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltrative disorders include amyloidosis, sarcoidosis, Gaucher disease, Hurler syndrome, fatty infiltration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"       \"Cardiac sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\", section on 'Hurler syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Storage diseases include hemochromatosis, Fabry disease, and glycogen storage disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"       \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other disorders include endomyocardial fibrosis, radiation, chemotherapy, hypereosinophilic syndrome, carcinoid heart disease, metastatic cancers, and drugs causing fibrous endocarditis (serotonin, methysergide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , mercurial agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"       \"Endomyocardial fibrosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Cardiac disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endomyocardial diseases (eg, endomyocardial fibrosis, hypereosinophilic syndrome) are characterized by endomyocardial scarring that usually affects one or both ventricles and restricts filling. Involvement of the atrioventricular valves is common but the outflow tracts are spared. &nbsp;",
"      <br/>",
"      <br/>",
"      Radiation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drug (eg, anthracycline) toxicity can cause an RCM or DCM. Endomyocardial fibrosis has been identified in some cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H16#H16\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Cardiomyopathy and diastolic dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathy must be distinguished from constrictive pericarditis, which causes a similar impairment in ventricular filling. While details of the clinical history may sometimes be diagnostic, this distinction can require careful echocardiographic and hemodynamic assessment, pericardial imaging, and even endomyocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The details of this diagnostic evaluation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1978642\">",
"    <span class=\"h3\">",
"     Endocardial fibroelastosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocardial fibroelastosis (EFE) should be distinguished from endomyocardial fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"     \"Endomyocardial fibrosis\"",
"    </a>",
"    .) Endocardial fibroelastosis (EFE) is characterized by diffuse thickening of the left ventricular endocardium secondary to proliferation of fibrous and elastic tissue. Two forms have been described: a dilated form (DCM phenotype), in which the left ventricle is enlarged, and a contracted form (RCM phenotype), in which the left ventricular cavity is small [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EFE, which occurs primarily in infants during the first year of life, is often seen in conjunction with congenital heart disease, particularly left ventricular outflow obstructive lesions and hypoplastic left ventricle. It appears to represent a nonspecific response to various kinds of cardiac injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/26\">",
"     26",
"    </a>",
"    ]. Anoxia, endocarditis, viral infection, genetic factors have all been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/25\">",
"     25",
"    </a>",
"    ]. Familial EFE has been reported in association with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, an association with maternal autoantibody-mediated congenital heart block (neonatal lupus) has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of metabolic myopathies\", section on 'Systemic carnitine deficiency with cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On echocardiography, LV cavity size may be normal, small or dilated and systolic function may be preserved or depressed. Diastolic dysfunction may be detected. Dense echoes along the endocardial surface of the left ventricle (and right ventricle) may be seen on echocardiography, but endomyocardial biopsy is necessary for definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/29\">",
"     29",
"    </a>",
"    ]. Case reports suggest that endocardial hyperenhancement detected on gadolinium contrast cardiac magnetic resonance (CMR) imaging can help identify EFE [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival in one series of 52 patients at six months, one year, and four years was 93, 83, and 77 percent, respectively; however, only about one-third of these patients had histologic confirmation of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast, in another report of 13 infants with neonatal lupus, congenital heart block, and EFE, 11 either died or required cardiac transplantation because of EFE [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/28\">",
"     28",
"    </a>",
"    ]. A report identified EFE as a cause of diastolic heart failure in teenagers who had undergone successful balloon aortic valvuloplasty in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arrhythmogenic right ventricular cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy is a genetically determined heart muscle disease characterized by ventricular arrhythmias and a specific myocardial pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/33\">",
"     33",
"    </a>",
"    ]. The myocardium of the right ventricular free wall (and frequently the left ventricle as well) is replaced by fibrous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibro-fatty tissue, with scattered residual myocardial cells (",
"    <a class=\"graphic graphic_picture graphicRef78104 \" href=\"UTD.htm?18/9/18580\">",
"     picture 2",
"    </a>",
"    ). Right ventricular function is abnormal, with regional akinesis or dyskinesis and, in severe cases, global right ventricular dilation and dysfunction. Mutations in cell adhesion genes cause disease in 40 to 60 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Unclassified cardiomyopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"unclassified cardiomyopathy\" was included in the 2008 ESC classification system to describe disorders that do not readily fit into any of the above phenotypic categories [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/3\">",
"     3",
"    </a>",
"    ]. Examples cited include left ventricular noncompaction and stress-induced (takotsubo) cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Left ventricular noncompaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular noncompaction, also called isolated ventricular noncompaction, is a rare unclassified cardiomyopathy with an altered myocardial wall due to intrauterine arrest of compaction of the loose interwoven meshwork. There is continuity between the left ventricular cavity and deep intratrabecular recesses that are filled with blood from the ventricular cavity without evidence of communication to the epicardial arterial system (",
"    <a class=\"graphic graphic_picture graphicRef57125 \" href=\"UTD.htm?39/31/40435\">",
"     picture 3",
"    </a>",
"    ). Left ventricular noncompaction has been associated with a high incidence of heart failure, thromboembolism, and ventricular arrhythmias in adults, but may be more benign when it presents in childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1613473\">",
"    <span class=\"h3\">",
"     Stress-induced cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress-induced cardiomyopathy, also called apical ballooning syndrome, broken heart syndrome, and, takotsubo cardiomyopathy, is an increasingly reported syndrome generally characterized by transient systolic dysfunction of the apical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mid segments of the left ventricle that is often provoked by stress. This condition is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29123596\">",
"    <span class=\"h3\">",
"     Cirrhotic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While alcoholic cardiomyopathy is one cause of heart disease in patients with cirrhosis, experimental and observational studies have found that cirrhosis is associated with myocardial dysfunction independent of alcohol exposure. The causes and manifestations of cirrhotic cardiomyopathy are not well established. The condition has been defined as an otherwise unexplained chronic cardiac dysfunction in patients with cirrhosis with impaired contractile responsiveness to stress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Electrical abnormalities include QT interval prolongation, electrical and mechanical dyssynchrony, and chronotropic incompetence [",
"    <a class=\"abstract\" href=\"UTD.htm?30/3/30777/abstract/36\">",
"     36",
"    </a>",
"    ]. The left atrium may be dilated but the left ventricular cavity size is generally normal, although dilatation may develop in some cases.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23159760\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomyopathies include a variety of myocardial disorders that manifest with various structural and functional phenotypes and are frequently genetic. Myocardial disease caused by known cardiovascular causes (such as hypertension, ischemic heart disease, or valvular disease) should be distinguished from cardiomyopathies for classification and management purposes. (See",
"      <a class=\"local\" href=\"#H1978197\">",
"       'Major Society Criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification of various cardiomyopathy phenotypes relies primarily upon echocardiographic evaluation. In select cases, cardiac MRI or CT may be useful to identify and localize fatty infiltration, inflammation,",
"      <span class=\"nowrap\">",
"       scar/fibrosis,",
"      </span>",
"      focal hypertrophy and better visualize the left ventricular apex and right ventricle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Echocardiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main cardiomyopathy phenotypes are dilated, hypertrophic, restrictive, arrhythmogenic right ventricular, and unclassified cardiomyopathies. Each cardiomyopathy phenotype is caused by a variety of familial and nonfamilial disorders (",
"      <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"       table 2A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"       table 2B",
"      </a>",
"      ) . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anatomic and physiologic classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/1\">",
"      Abelmann WH. Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis 1984; 27:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/2\">",
"      Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/3\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/4\">",
"      Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/5\">",
"      Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/6\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/7\">",
"      . Evaluation of patients for ventricular dysfunction and heart failure. J Card Fail 2006; 12:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/8\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/9\">",
"      Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/10\">",
"      Devereux RB, Roman MJ, Paranicas M, et al. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 2001; 141:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/11\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/12\">",
"      Braunwald E, Seidman CE, Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 2002; 106:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/13\">",
"      Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/14\">",
"      St John Sutton MG, Lie JT, Anderson KR, et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980; 44:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/15\">",
"      Maron BJ, Wolfson JK, Roberts WC. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am J Cardiol 1992; 70:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/16\">",
"      Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/17\">",
"      Corrado D, Pelliccia A, Bj&oslash;rnstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/18\">",
"      Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007; 115:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/19\">",
"      Rawlins J, Carre F, Kervio G, et al. Ethnic differences in physiological cardiac adaptation to intense physical exercise in highly trained female athletes. Circulation 2010; 121:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/20\">",
"      Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/21\">",
"      Benotti JR, Grossman W, Cohn PF. Clinical profile of restrictive cardiomyopathy. Circulation 1980; 61:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/22\">",
"      Ammash NM, Seward JB, Bailey KR, et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/23\">",
"      Hatle LK, Appleton CP, Popp RL. Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 1989; 79:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/24\">",
"      Palka P, Lange A, Donnelly JE, Nihoyannopoulos P. Differentiation between restrictive cardiomyopathy and constrictive pericarditis by early diastolic doppler myocardial velocity gradient at the posterior wall. Circulation 2000; 102:655.",
"     </a>",
"    </li>",
"    <li>",
"     Denfield, SW, Gajarski, RJ, Towbin, JA. Cardiomyopathies. In: Science and Practice of Pediatric Cardiology, 2nd Ed, Garson, A Jr, Bricker, JT, Fisher, DJ, Neish, SR (Eds), Williams and Wilkins, Baltimore 1998. p.1851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/26\">",
"      Lurie PR. Endocardial fibroelastosis is not a disease. Am J Cardiol 1988; 62:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/27\">",
"      Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1981; 305:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/28\">",
"      Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/29\">",
"      Mahle WT, Weinberg PM, Rychik J. Can echocardiography predict the presence or absence of endocardial fibroelastosis in infants &lt;1 year of age with left ventricular outflow obstruction? Am J Cardiol 1998; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/30\">",
"      Tworetzky W, del Nido PJ, Powell AJ, et al. Usefulness of magnetic resonance imaging of left ventricular endocardial fibroelastosis in infants after fetal intervention for aortic valve stenosis. Am J Cardiol 2005; 96:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/31\">",
"      Robinson JD, Del Nido PJ, Geggel RL, et al. Left ventricular diastolic heart failure in teenagers who underwent balloon aortic valvuloplasty in early infancy. Am J Cardiol 2010; 106:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/32\">",
"      Ino T, Benson LN, Freedom RM, Rowe RD. Natural history and prognostic risk factors in endocardial fibroelastosis. Am J Cardiol 1988; 62:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/33\">",
"      Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009; 373:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/34\">",
"      Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis 2007; 39:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/35\">",
"      M&oslash;ller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/36\">",
"      Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/3/30777/abstract/37\">",
"      Timoh T, Protano MA, Wagman G, et al. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011; 43:1649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4943 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30777=[""].join("\n");
var outline_f30_3_30777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23159760\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1978197\">",
"      MAJOR SOCIETY CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOCARDIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANATOMIC AND PHYSIOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1613344\">",
"      - Athlete's heart",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1613186\">",
"      - Other causes of hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1613456\">",
"      - Not HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1978642\">",
"      - Endocardial fibroelastosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Unclassified cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1613473\">",
"      - Stress-induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29123596\">",
"      - Cirrhotic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23159760\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4943|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/29/38357\" title=\"diagnostic image 1\">",
"      Dilated cardiomyopathy CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/7/18559\" title=\"diagnostic image 2\">",
"      Subcostal view HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/11/44209\" title=\"diagnostic image 3\">",
"      Echo restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4943|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/5/11352\" title=\"picture 1\">",
"      HCM myocyte disarray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/9/18580\" title=\"picture 2\">",
"      Morphologic features ARVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/31/40435\" title=\"picture 3\">",
"      LV noncompaction autopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4943|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/35/41521\" title=\"movie 1\">",
"      Dilated cardiomyopathy four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/20/41295\" title=\"movie 2\">",
"      Short axis echo 2 HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/53/27486\" title=\"table 1A\">",
"      Causes of cardiomyopathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/4/21582\" title=\"table 1B\">",
"      Causes of cardiomyopathy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/63/18429\" title=\"table 2A\">",
"      ESC 2008 CM familial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/42/8876\" title=\"table 2B\">",
"      ESC 2008 CM nonfamilial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4943|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/7/8304\" title=\"waveform 1\">",
"      Doppler restrictive CM I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=related_link\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_3_30778="Cutaneous changes of Stevens Johnson Syndrome";
var content_f30_3_30778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F59418%7EDERM%2F68682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F59418%7EDERM%2F68682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous changes of Stevens-Johnson Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized eruption of lesions that initially had a target-like appearance but then became confluent, brightly erythematous, and bullous. The patient had extensive mucous membrane involvement and tracheobronchitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCnbgfdB4HcjvU4jyMDNRRoAD83I74q1EjOoZvvetcCR9JoJtx1wCPTrTRtIJ57cmp2QsMDgDigwrtA5465NUSxqKCR+WamUAjGeRTVPoBg1YWLgc9sVLRN0IudgGRk+tMlQKh+7UrAr0xUUpAUZJ55JqGioq5QY7idpPFN2An09MVMUZnG0de9I64JDDBApGziVpoyMLjBPbHWsvU7JJfLCls53MyjG32zW9nZCzMu446HtWY8zzuiCNMMcdKiTS0NadJt8y6GPNZxoQMfJ/OoRYxyjMbBHHVa6JrVpAEkXHt/hVWaylQfIuD0HHNaImUYvRnPy2jIDlCcHqByKiWV4zhZGBH8LVuH7XCCDuTPGUPNV7hJLtw9xIJSOAoUA/nVJ2OWdLXQoLfgZMqFT045FRTXcZBO/n+7Ut1Z7ubdXU/3WH9az5LeQZ3IePUVWhhJSQiTZDNkYNWIH3EADHvVJ4FKk5wRxgVd0V7SK5U6mJngHaPr+NOyMnLua2n2s11MsdtEzv6KM12uneDr6SNTIvlsR35rU8MeI/DUUKR2bwQnHIk+VvxzXYwarZvHuhlR93TaQaiQvatnM6d4Zn02Mqly25jliAMmtCPTrvfxLLj1JxWwkqOd7uPpnpVjepZSWBHtUqN+pk5GR9kuY8f6Q59sZrn9XsLs3SyXG54icLt6Z967u6kVLdzGBuxxWKWkeFsvwBkiiOkknqQ27Mp2kXkxcgbz1p+DnnpTCxAPekJZgMHivZStocNyn4kulsdDvJ2ONsZxWX4As2s/ClqXGHuWMz/jzVD4hzNNa2OnITm7nSM/TPNdcIhbpFAnCxRhQKl6ysaRdotk6njNABOaiViRxShj61ZmS7Oak5xjHFVwzZIzxS7jnHNAXJXBz3FC57ioSzHrmjcccHmgCx05xShh3HNU2ds9TTldvWgEWs9gKYWLE9ag81sdaZJMykAH86Qy1HuEirtzzWD42+a8jGMHHStSO4kEq7W5B4rH8VlpblHc/MayrfACOOn2rdAO20mr8cDMoKkEVR1CBXlViGwD1xViGMhB5b18pjKb9o2j0KPwkxDqelIZSDzmkE0qZ3AH60C4iP30xXHyyRrZEizD2NSh1b0qriF2BV8E0ssMkSllO8e1IVicwh8Ypjw44NRRXJXG7g+9XEmDAZoYioYvTik+denNXjtYUwx+n4UXAjhuinDfrVqKZH4DbWqAw5GDzUJgK8rkH2pqViXEsRp8u0MGI656UjsyoBuyByTmkQt95yFQdqULkbyD+XSvqD1ESx8Dc2T/ACpw5Zipx65pCFVecEe54zTT9xRnAPoe9MlomjGXU4xmpVGDu6VAsuAcn6HFPjmQ4yCT9Klgo3JsAtknkc4FQXBOPmIPp7Us9wgHQ5boPaoBdopPmZ+qjt61nJ2OinTfQnSNXHyhWwO3apDCnlZIXJpLZ4+ApGD0x0NTP5Sj5sqewz1pA42ZQubF2RdrjOQcdzVO3sZBL5ki8KcjFakpEjDbkY75pTuxlVJHTAqXFXuaRnKMbFK+BcjYe3GDzUaEE9w1Xyu4ncoA9SvSle0hchjkEdAKozZlssfzcnb7+tVry23gqMKpO7OOSa0Lm2UN8r7c9c1DiWNipGQPWmS1bUxmjbO2QcdOvIqA2chzueNsdO5rflgVwxI5x19Ky5rQEkjOB3/rR6E6Pcx5IE8/bJHuxyQO9LqVlbMENkjqQBvVh3rWhh2JtUAg8gkdKYIGGQV5NNMxnBM5l7Nlc5SiGS4tXDW9xLGR0KsRXRCEkfcBPvVe4gjHbLeoFUmYOkiG28Ta1A3y3bSKOzjNa1t471FP9bAj89AxFYb2qnoQM1G1m/AUgg96GkxexO2g+IZOPNt5Rn0OQKr3fxBbeyx27mP3OM1yn2UjI2tntgcUfZSUBKHmiCUHzIzlQurHTx/EIDAa1kqynxBh24e0k/LFccbLPRalge6tDmJgQP4XUOv5GutYl9UcssI+ht6Trkfirx/aFUMdvYKZGz644rb1Pxzb22oXMSwM+1iM+tczpet2djcPJcaHal5Bh5bUmF2/pUrf8Iletua51iykJ5VkWUZ9jVRqxbvczlTklaxtR+PoMc2z4q3H44gP/Lu9c8ll4VibLaxqkg6/LaKP61YXUPCltwtvrNz7l0T9MVp7WK6mXspPZG4njGAkf6M9S/8ACYQk/wDHtJ+VYsF94YvCEiu77TZTwDdRiSP8WXkUmrxT6OkU1zGJ7KU/uru2Ikhf2z2PsaaqRa3F7OW1jcPi6Aj/AFEn5UDxbbr1hkGa5Jdcsy2DkfVasjV9PdcNIo+op+0j0Yckux0i+LbVv+WT5+lSL4ptB1jkH4Vi2l9pbL/roifeta2/s24ICvGfypqSfUl3XQkHiiyzlg4H0pus67Fb2EdxbKJ/MOFFW5dJtDbF4/LYgdMVmadpdrdpdWki5iDblA7fSqadtBJmh4b1ZdWtmkVCjo2xl96PEQ/exenvU2k6fBpStBbLtVjuz3NM8QqTLCRWc0+TUrqXPC+jR6npOpREDzsbo/wrlLi2MTEbcEZBHoa3vC2qnT/E+nRFsRzExuOxzUvjKx+yeIruNRhH+cV5OMpRnT5lujenJpnKYOcGmbAOSMgdqsyKQ45/GoWBBOa8ezizqUrk1rHpsyFLhnjm6Bh0roNP8NW02n3MseoGR9uIhnHPvXHOdkpz3rdtN0UMCJkFgScGiFNuVwc0lYykilMk1uyb2TPzelLFtWMb2Ib0FXbO3djdSoSiKME5qvZXX2K4E3lh8nBDCitSSV0XGSe4kcgLbQ/51MHbkg5xxwa0xrtlK2LrT4/qopyXmgSPmS3kiz6Vxu63RpyJ7MzkkPqM04yjJDVqwR6DcFhFcyoe2ahewtbq5aKK8QIo+8e9KOr2JcCg2ZWVlC49CPSmwszpwwcHvUibjGTgZK4C05CQMAgZ7AV9ady0IXjZsMQT2470iLxxnPbHOKmIL85+Xpn0p8SEgnnFKwyG3t3Y/vWzn0NWY4CScfSpYz8pyOB39akHbstSxxuVbqFycZ6d8VTdXlVIQoBRT84Xlue9bDhWJAOW6kVW2jeVVT1456VnKPMdNKpykNjbuhxICVHIUHgU+9c8jYSF+92Aqx5bqAsZyX/i9BT5oyCqH7oHIByCfr3pWFKp72pnxKy5aQ7EPReuPeozdlT8hwK0pIzswcA+lUHtI3JY/Ju6EU7ApIkS7LbRGy4HXtVjzVP3slux9KzxZPiTmMso4YinWZdIWZ1LFfXmiwmky26RuoOCzjrmoJlDINx+p70PGChk37ewBPNV33Ou5WLEc89aEhWsDlEYK/AzVeZVlYhEOB0NSrAxGTz7Z7U9FXaVAYKR2NMzkrsoqhyeADnGKSZQpJbGPer91hI8bcnHY9qzHdZJAuMD370JC5Lla8ZmcBfu+3eoERmX7vy+uK0hbMGBdwyk/dFTva/LkMBjnbTJsYLwsXAC845NTwQkfewQegrTSF0AMgGD3z1qQQ5YOR8o9utK42tDOVzkhcbR69/pSBVZgBgn8se+a1JrZXyQAuBjOOtVZIwv313A9cUXJcUxNiRRKFCyTdBgfKv+NVZbaRsMSqknJyOaldcruUkDP4UgJIw7OAfQZq0znlTtsUbqywpYnk9sVnzWmFLEfgK6JUJ4ErY9OOlRPb7Vx5gBPZlFOxlbuc2UK8Nx9aPLYZO7Na09uckvsdaoyQBcmMke3YVL0E4ldCM4fn0re8Oa5No4mtwEudNuOLiynG6KQevs3uKwwWGT1NAcj71CkQ430Oyk8L6VrAEvhfUoI3b71hfSBJEPornhhVSXwB4kjO3+yZZCejRMrg/iDXOo644q/FeyqgCTSgdtrkfyp3i90FpLZl6PwL4jY7RoN8T0/wBXUyeBfEkbcaRcxMOmXVf61nNe3Of+Py6I95m/xqtJdSmQFpJT7lyaV0ilGT6mte6f4k0WPN3FfW0R/ikGUP49KfoviG606aR7iHz0k6leCKXQPE+p6U5axvJQDw8T/vIm+qNwa2Zb7w1rzH7dA2g37nme1UyWrH1aPqn4VSqNfCyJUU/iX3Gvp2r2eqbfs0oEo58tuGFHiR/9Sc4IrkNb8PXejtHOzRy2rH9zfWr7on/4EOh9jUsOuS3Yht9RILocLMB9761v9YuuWe5yzoWXNDVFhnKapZTAnKTKc13XxNKJqNlcZz5sAH4159qbGGSFs9HBr0Lx/H9p0PQ7g5OUxn8K5ajb9ovQiK0RxEv+rU9ahb5lz1pkL4Yo3QVMoGfbsa8acrs6EjPmXLqa6C3JeTI4EcdUdP0y41LVbextF3zTvtT271qT2Nzo+p3FndKTLH8rEDrWtFNrm6EyfQidXttNDmRStxklR/WsNypK56Vp3S7YHXO3HY1jhg2AT7ZrOoyokxIOPWoSfmIPerFzbm0m8tpFkOA2VPFQgbm+lZNWdmaJkkGBIi52qSMkda25LONDJ9nyUxxnrWPpy+bepFjO5q6QtFFDdSkf6tSoHvW9OKknczlJozFZvm+bPHLelSKGxklT7D0qsoIAGTjqe9TROTtbjGe3SvbPYJkGVyABzSgkHABBBAPoaYZFJAUfgT2qVZWJI6jr05J9KGgQKC3zBsjPTGKuopKhuCMZyarQyfN1+XuDVhpjwAoCgcc96mxZDIhfd1wOOuKRFHmDjBx27VI0oHzMoDevpTY2xE7/AHWPTucVLLiLK6gBEJeTPpj86mjQIF2DtwDVKU3A2+SVDd8/ypTOpWIyNkPhcr2Poazclexo6UmromlQrliQQO9QAeZjjZngH1qX5QzBySByeeBUCXaEMyfNtORxkZ/wqieUmiQjcMqMdRnpQXjCso2sw/i/+tUUPmO7ZfBPUbasx2AVWYsHB68U7g0Zsq+cWBGB603aVjIjXp39K1HRRtKIQF9unvVd4HG2QKMEdB3qdwGqoEKkELnrmqczFG2bWwTk1PLCc4JbgdQCetOji3SRg4wOme9ArJK5mTuyK5cEBuBkZFVIlYNmYcr0U8V0ctgASz4OOgz1qjJp0kmJefKYYA71SFcRI/Ptxs4dTyR3qxDahCQX3OeTTraPycKAwbv2q6Ylj+YqSx4Y55pPci/QoxQHzNpwxPY9h6U6S2IUhcZz+GKuFwqgKEU9T61UmmjjiYhwyk9BSFZtlKRDuweF6VXfYI2+YZ+6Dnp9KklvYXRgDub6Vm3EwMX3cDqccZptFqHcZcE7f9acA8kr1/CqksnzqTMeP4RUrRtIv3QfQkmlNjKxJfEaj+FaERLlK5kjUhhI2T13dPwqIzoC21uo6Hmr0dkrYDbmPrmpltkHHlgc+lUjCVuxjmdsH5ie2NlQNNIF6Bh6EYzW/wCUjKQE4GaqS26E5XHFDsZ6sxWnI/1kLKPajz4ThWbH1rSktiF+bmqstojAjbSsjOUWyFkHVGFNDMjdaabNhxESuOgppimBwTnnuKLIizRMJjnkn8qbK4dSCcemKhdJF4IXn2qIlwvKZHfmpaC7HI8kL8MTWna3YIKnGT3rELHOct+POKfHJIvIUk+o6VNi/aHZaJrV1o8jtabJrWT/AI+LOXmKde4I7H0I5FP8RWFpGltqWks0mkXwLQhvvwuD80Te6/qK57Tor65i3xQAg5Ch3ClyOoXPU11Xhm2kntL7R9RUWsN2wmt3lIUJdLwBnsGHB/CtopyXKzKcop8yMmK7a6jWKZslBw3qK9i1Afafh5pMowdmASa8U8ryL14S/lXERKvBNwwPcA9DXqelasJfhw0bYJhk6elZKLcpp9V+Rz1Uo6o4m7ba7MvDbqkifIzn8qo3su4vg9TVOO8ED7CeDXlOm2Xc6jSrma11S3ntZWinjbKuvUVo6nezzJPdTzNLcyOQznrWBot4jX9u7YKqwPzdD9a6DUJkjd5lSNt8ocJjKkelaUlKMHfuZytcztZWP7HBcQSCTeMPjsawghJB5rofEV3/AGrLJPFBDapkboY+BkCsaSJo0DHoR1rGtZy93Y0htqRlckc9KcVMYz1B71GCQc1PAwZSrd6xb1LsbPgSwXU/FlnasrOGDHC9eBmrOrxk2uoiRtktvMYwnToe9N8DC4tvGOkvatiVptgJ6YIwa1/El5Hpo8S6Ld2SSXs935y3PcKcHj/Peu2lyug793+X+ZlL4kc1AhC7hnbnB9KmQEoMsNo9KWOWPZ5QGM96cpGduRtJwOnNeyetcWEMqAlOWORmrHlAnP6/0poVckNkHHHPNTjOOOefWhjTI4YDyQOvTipZIFKgDdkHOc9DVu2UZGcKRzTNwEhOOTzjvj2qbFqRD9nUhGkPyDqoNRXCgwoE4Vm6rzViR/3TRxqckckjGM09okiiVmzhSCBUlp9TL1FSrJCiuNy7mJ71RUbpEJRxEDnAODx3rS1E+YBIysucgL7e9UDJuXPQg4wRyBjrXJU+I9bD2cEjShRZYkDksrAgnpmpEhiRfkjA2jBGag0qYYZZI98f3uPX0pzzrJITzzzjPAreGqucNaPLJomgAaUfIMc8CrQVjlUGT0AJwKpwxSfaMNsTC4wDnitKFAvReOvBptGUiq8DHCtuwB+RqrdI0actvOOma0r1jnKkqcYrOnRsZYk54ppCUioZmBwU+XtzjNTwRn5mkAC9vep4LUllaQBgOKsSW+5QgG49OOwoYnLsVC/mPuKgBfQZPFJ9oUwuJRyeQpFWY7ZYQxYnJHc8YqrcbI5NwXJA5A/lTsK6eg7jcHYL06DrS3MiJEXDb3HTnp+FVI4ZppXkCBUHB5yfzqUW6hccoQck9SaLA0jMvLhsqzbhxxtI5qrM2UAWIMW6ljWvLaRyAsT8vZQOtIsKoi7kUMeRjoaWxXNYyY4pGJLAqR6DFTCziUZY8H0NaQtjMwbI+gHFMYLEGDpnFO5k7yKsCRKSVXPHDGorpVZCFU+5I61ZEnI2YX9MUrldu0g7vTsRUj5bGag4BC4HTFTDlsrnI6CnumwAHBKjjFCIMBxwO49KVwcUyBlKrznnoKqNFtbdyR19K1+pBC/LjrVeaBXyTwc/hRcSpmK6u0mW6E54pDbA5B4/GtR4Agyfm9h3oS3xt4GOpzzQPkKAtcJkEbarzWqd+/TnNbJQfdA+XtxnFVZLchvnyEHTjrQQ6ZiTWmAdpJx71nzYtiCxTafU10dxB5aFsZzzXN3FsJ9UkMqthUBVWHy59RRchws9EV5nk8xzbxI0TKDk/wALe/tVyGPdECTtf+6BwfxqDcYpBjkH0/rWhE5li+RQG6AZ60uYn2Nio0zAgS4+XgDPSrDXLyQGMzMyHsWzUUlszHDxjeOvrTRatuDJxzg4OBQpMl0kxkkbSuZGLO+eWJya0LLWtSstPms4ZFNvL95XXPNMSEYO78vWiTamQFH1q49zKVFPRkD3tyzFmVT2wKhmknkYEptPrmpWkVQMrzSqSxztWsnSg3exLoofZ38luyF0bC9QDXQL4ggmaAFyqDg7h0rnHgVh1yT74qNrcdeufQ0citYzeHvqdPcahDI7mKRSM9jUdzqebZQT8q8e1cxJDGOhAPrUbPsTHmNtPbtXPLDx1F7KSOjS+Rv4hU0d2m/IPFcrGSwyucCpY5GHRua55YTsFpdj1X4dl77xdpkUDqkqy+ZuY9AvJqfxvei/8V6tduAoL+UoHQheM/pXm+ga7PpGpRXS5LLkAetWb7xBJeXLyvlQ3IUdq2jS5KTj1uZyUubY6WIBowM89RnqKmifkhx8y9Kht1KMOp7c1KwYnr8+ORXq7HqLUtRhvMBPtjNXIQcEHJIHeseOd0cZ7Dr7VeguAS2Sfp60rjtY1Y+Iy/f2quXP3WYFv5U0s7QhgMjPOewqWBUCs3B44NIaFhi2tvYsSep9KWd/N7nA4IzT1LNkEkdxxzTgm+YBQMY69qVjRMqPGRFvPUHpnkg9h+lUJbcMrO/PUH1rY8lZITG4LFfQ459qpWbPcQuVWRmwSRtyfauWrF8x6GHqcsbjdIjbypsqSQw2kcf56U+Mbnb5goJweMnNXLKNVgEfRgDu7c/ShYhHM7KN2/naB+tb01ZHPXqKU20MhjXerrnjgHqTVwJt/h69u+KjiAR9owB6HtT42Zn3FQcdCaqxg5XIL1suo25JyQQfShF3gMwBJOcCrE21jlVGex+tDDcwwAD69KdrCuV5Mwknd8zHpUh2woVQkkDgU9wsrBFxx3p6Q5XLFcAY2nrU2HfQozOY4P3pHfPpiqMZ88/KixrngnvWq0LGQMNrDIHz8VE0a/aAwTCqMg9jTLSIvKMcanzCHHGf8B2qIwjdnJJ/vNnJq1KFfcHTIPKnoaB15wFK4+lDJsyi6NjMmAucDPpSMrBcZBXtx0q5NCXVHYIxHFV5cxnIBAIwT6UrAVvNIWNV+4Oo6c0XAZyN3Tvjt/8AXoYrjcFJYdO9MKMcklTjkc96lqxcY3InhGBtzg85B4NBjGzAX5/zp/mcbVXOKkSQlQMjA6gUhtNFYRMAVC5700Ae49RV0hghKZHr3qmyBpMvj/gNAooMICWB2kDAqMKXAzljnsO9S/ZyWCjlewNTQYG5ZSYz2K0jS2hAlv5cmZBye46ipHQEHcpIzjgYqykaOmWPCnqD/nmmSTrGrBADnjjkmgzZQmCjKD5SOAc4qCYKq/Me3BNW51Dg84/2mHWqc0JVM7iRjg0Ba5nXVyjbhGw3Y9azHRwxYvuJGAO1X7uBlP7kZY9T3qKJCj5kAY1m2acmhnNEQ+duT3ApsoKDIIBPXA5rTb58fL85ORjn86ikiLbcqGOeeOlF0S6dxbeb/R1E8eQRw3TFTTpatDlTIkg7jGDUM6sHJHQHke1KUYhfLADE555yKtMwlR6kDR8Z3fmKpzROF3KQSD0IrTkiIBwOQP4qrxkSOQMdOpp81hexb1KEVvvbJkDE+g4qxFasmSuAPfrTNP8A9HklW45UHIPc/wD1q6AQAxlhgn1qb3K9jZamIEJfkjgZ9qSUcZ5P+e1adxD5cLMFyenArPNu7oSylVPcUzKcUtik9s0wOGIHtUX2RFcjcW9RV7yJImIy208j2oeI7OuD64pXM+QqxlI2G9flB5x3FaCS6cIz50GGPQj0rNmQBQzt8oPHvVaRGuMDov3aVyJ0brexNM0Urk20ZKDjk0m04yF2kcYq3BbeXEAwJx0zxTvJdgdvyg9+tOwuSy1O2iJAySRxVqTaHbJyhxg4qhkM3JxVhfmAyTntzxius08yUZaU5UbWHJ96nCDcT90HgVXjJABJ+Xpz1z3qcMcYPQnvSKRpQn90yN6Y+lRhnAVTgjGcds1DbOVkLFgQT0NK4Jl+8ME9B2pGmxcRty4U496u6Y2JfJc4ilODjqD2P1rOhXk8ghcZWpbd3jZpF5KuCPb2pikrk20F5GU8KepHX6VVdjbzh5Hc2sgGMdEb/CtVhDKJJ7YbAoyYTztHqDVWdPtNpPEir8wyoaomuxpSkpLllt1Mg6qqzhY083nl+7VtI/mhCwKYG4r0P0qhb2FvDIGVMhgDnGTVwFssqBsVEL9TesqdkqaC3ZFaRzjaoz7mpYQ2C5OFzlV9KanlvE/AVsAGpUU7QoJBYYBxWpy3ERlbd9734pHIXrjH9KfCm52DBht65PWpzFGXXI6D1p7DvqVthkVSm3IPNV59SghuANzOQPvKMge1W74iGzk8s9ePl681ggCNclHRyOvXFc1Wo07I7KFJNXkbAZJmEpw64yCBwKewV4lCksW6D0Gaw49R+yGRPKZgxGPQVrRXsDQJKx2qPlyx6exohUUtxzoSWttCSI4Ugr+J9KhkAMHDB2z24ANV49QtZC0YlAGSAMHnHarQJ2lUQDcOo6dK05k9jN0pRexRIYOFcH5hkkH/ADxSTIspBXmNeMdAasJC0iMAOMDPFKVYxknhRwPUe+KaYOGlygwCZ2j5u4xUBjO3IwN3t2q80JbAUYA659TSiAoxJ+YZ+Uf1psSVigkDKpAAYAZGe5pU+5hgASQWIHIq75O8lm79B7dqWKDYzOcgDpz1qUrFPuyorsS6ncSPXjioZYleNfL6HoR1q75bxPuaRWJB98UsUfmFgdxPBz/jSHa2xVjQgMo7DP0o8sj75BYH8qtooDuFYKGbnjv/AFptyhjzxlumQOCKVg6lKaQn90CGU8lhUZKjLHgtxkjirH2dHxswo+vFPMHlnBZX/i4Pf2pBZFOaHjKZYqOoHeo5bZnXLdexz0rSlyxVEG2MDJ9zUH+rQRsoK+lAloZFwgjALAEk4DVR8phnbhdw5OTzmtm9QeaGP3So+X09qpuGk3AdG6ADms3Y0imZrwYRmWQAfdyKoXEEgBNvK6SbdvJ3Lj6evvWu8aiTLqSD1AHNNkjUu/lxrhhgleMUtEXyXVjno5L2K42kR3Hlj7secnPb0q+s12X2pbAlgDjkBfr7Vfs7ERXLuRmRyM4PTFXpkU7tx4PSri0YulK9rmbHFKsf74KZRzheRj2qjMUAEsBBkPGzGCa6CGPkEn5emcUJYIsbsmOWJBYdPYUpalqCRzul2iam7lnIkjOcDjH1roUQQgKx5A5OOtTW8CDJjQBj97bxVO7lLv5Q5UHG6iKsRU0GSHqSQBUErttA3Z9QetSyxFGGRyf0qILmR8ZYgZJ9Kps51TuQYBONo+tMmZQQF2huufarn2dWUbAT+NVLiJcEKAXb9BUtjVMyr1TM6gj5R0yOlNt4mjbodvtWgIBglj8w6DFRxANcqqbuTUozkrjJXcusYRicdPStaxgZ4wXTY2Mc9xTrdIlkBIBZjxnjNauQke44JHpW0EjKasNBK4T73oQMVPFy2Gx61XzlQQAQewqaFiynGSBx9K6BJXLO4bgAOD2HNLvB4HY5FQvwu4Nk/lSqMpnoT+lIvYt24LFCOg+96mrAYpJyBx0FVLdmCgH9DVt5MDPUkYPpSYE6vllY/L65qWBTIz4woySfeq+/eQSPwJ6inQPlPlLEHOB0oK6Fq3k8mVHHLjgg/wAQPUflVtIvLcSRqzRODtyensT61mlyFHI3Dt6VcinlEJi58tiGIHTPrQxWd7mbZXh2Ot2GD7yDtHQ//WrRt5BKJC33+gI7g+lZuuIYZlmQjay9CcYbP61Jo0qsJk35AAce2etc0W1Ox6dSEZUudIsEspCYbJbjFaNuhERYHOe+aqpEZnUCVBzxu/lV2JdsOBuU5ww/Gus8pvUkUKAynr6471KsZQZOOOrH1qusvzBSCT14PSrWMqA2M4z60PYqO5hTTq926M2Y43G7HUHFV7gRFgI+gz35pGtrmO8vCsTlSxbO3jHqPWqzkSBFMu5Rnjpz715073eh7FOEVazIGkj8ttwzxnmqm/ByEfaeeOhNP2lnCgEnOSB0x6UpSUSqhLAOOfTbUpWOxJJFiC3wgGwnjDc9c1owXBhi8pSuUO3JyPwqsOmF4Y8A9BT41J3ELySQM9yOtTFuL0OSfvbkxlkaRizFAegX/PNEdxNG+5isgAA+bt71E4V12szLkHle3Hf3pEJ3KshPI4Ock1XPK97hyJovyXUOHO4nHZBktVaK5Yr/AKRG4T+Er1+lNVA+FXLYycetWUQ7ARlgpz0zg4qnWkxezhYkijjlhJiZGCjk7un1qKOFlYhy2Mdu9TaYii8jwgAkGGLHljVue3xI2FO0dyetdVOXMrnPVjyuyMzZljvwq98dqase1sKSAfQYJq8iHeBgjLZHHDCnmOTnaSGJ/EfjV2uZOVig0mHDMBtA5JHNVrt2ZeCBgcHoce4q/dxMrNktg+nc1nrECfnJJznaR296GrDi76kFuMEFnyPX3q1cviUbV3H+LA5qR0ABCqxXHtz/AIVFIrRruyMEcOx5H4VnY0dtxVlUoMZwBncR1NVXzIx3ZDNx7j8KsElUAGBxuA65qsWVpziMl+vPUflSehKRBJH+7AYAd/m7moZF2R7h2GMDrU7Ryyc5fZnBJHFCQSMwWQMR6r+lRY2iZj+Y2xOdzn7vTI96fDASrMMHsBVu7ttjRj5jgkcjv9aUBkAK4LHODjpU2NVtoV1gEZLFt3tR9m2YYAkEcg9KtiI+hZupx3NE8eUICgeo9T6VS2FbUhWINFyvTk5FPjQ7dqr97p9acykxEBiueoz+lRzzm2tjOXBfGFA6eg49aBP3Vco6jci0BijxvI5IFZ8DeZgoRjk5NLskdpHlOWYZJPeoY2m4jZUUHjHcChysZcnNqy0FwjNuyf72c0IfKUOc/Mcf59qaqfuDyFj3YGPQVXvrtVjALrjIFQ5D5C+7ps35568VmSxlfn9ePc1Si1ADODkMfTmr0R3MBuO4dDihO5jNdhk0UpiKo+HIqew090hVn2l+eR3p5dIwWOCB1J6Vbhn8zAQ7zj5QBgYq0kYSQR2DZDOpZuhOOPpmpriEJKkKCQMg+dZBja3t7VsZWXTIbcXUUDoxLo+cNnocjuOlRX3+kPGscnnGKMI0pGN5z15/KtbJIw3ZiwsNuASFHPzHpVmN8tkD2qrG+Pl4+YcipI+OVPHTFbmaZeKnJyw2t2py5ChcA/7VQxNnayEnjoamiYYwwOfWgrckiBJ46mp/NAyOT7VGg4BwMjoaecL8zAk5NBRYWVfK9PUU/K+XkKeD1qorA9eccD2pRKF+UZwOvvSsVctptYAsCeM8+tWUfCKR164qmJORs6Ht2FAYkAjkA9KQyTUYftcKKWw6NuTPrVbTvOaYK0PlbVO44+82f1FXEf8AeDdnkenSpxIUUfTGc1Dppu5vHEONPkFJJVd3ykcc1bkueS/A3HBFVIsKuG+buKemGfOCCRwTWyOOWrL0JVnBYcgdRVhn2SDOeuB9KpQZU4J3AfnT3lLksuTt+UnFD1KgSyTFpVTZlF7E4LVm6tZiaJ54kEZQEkqPvexq/bqXYMAQV6evSpmYbXXAKkYJ7Gs5RurHTSnySujlbS2kmuUQEZPzFu4HtVm8tTp8mVDSxSfdOPuEnnNbkdvFArmLGWHzEnNOjkKxjJJ5xgjP6ViqC5bPc7JYtuWmxzsCJKRsO1uclj1OeMelPXZjywysd2Ap/pW+VRsr5SAEDacDipEsbae2ZnihPljLAcce1Q8O+jJeJinqtDBmVYJRDJEzszbVC89ehq9HYRqhEyr5jr8xHue3artrbLBJuiRQTyWbrT9iZxu3MCT9PStIUbbiniOkTFuBLaTsGQmNQFVvXjvUsDqxTyzgKBkY/XFaZLSLliSB1HvT47KGYkSRqJsYD9MZ9+9RLD9h/WFbUowzGG6jliVNyj+IZBzWyrQ3NvHKgLqeB7HvkVkzae9u3mRFpFycFucY74q5pAkLMoC+URxlcc96VLmhLlYVeWUeaLJ1jijBeV8fxH0H+fSovKty6LnI6ja2SaxNQnWS6lETOELkYY9x1zSafCzXFuljI8dyxKs+cKqnqKv2+tkhfVfd5mzQvYy0xKqcDggc4+lVzAUm3BVjx1yM/rW49oYZMkjzCxVR6mo5tPfzFRgQgG4kt0z/AFrc5eaxhyRhm2qELHrz/nrTXgJjBcAlevHU9hVuOMLIwUZbJCt1xjrUNyGJdR8obqzHkAUuUpSuZUiSM7Dpg8n/APVSyooRQoYn0H9RWhHCyqNnGeSAOg+tPaBUTKNlmGee2azkbJ23M9PmiG5vu9dnP59hUsLRygRcbiNwHTipVjEMuFO0HgxgfKaT7GqgFX4J5I9PQVFgbKlxbuFbLMSeOF/Wo/s7lsgnygOCe9a0OxpmCoxXpvIJFQ3UM0BA8vAz1J6/h2pOJcKl9Co6b1GFYYGev9KhlzwQB0wQeOa0o0Owjy8DsM5yff0qG6TdAQ6gMp4Yjr+NI0T1MmbaqFuACe45rBu5hPN8o+6eB/WrWpXBY7BgM/AGMYFV7BMtnbnH8RNMcld2LUUa7QrcnqeOBUZtwHJJ5J49604ohsG85J/WmyqpmBRSFxycdKiSuEVYx3VkV93r19fpWNq+mySKfLbg4O1v5109zBmTk7h04qle2+5RwxVjjjuPSocQlJI46KzmilCSydBjgY/XvWvalz96TCjgD1qxcwrGcuqYC5OTmqsauzllUNkcA9hQtDmaRbaUNhCAU/LJ/rWnpUaklmznsPSqVnbmWQ9iDgt/QVu2UAi2MR8qno3cVpC7ZlJdDY0/7QdPgNnLDCdzCTeVDNzwee1JdpO7obqQPJjjbjAHvjvQbuFWJawtc8AYUnA/OnzSws/yRpDxyFHB9zW5lGDTvY4/Pzcngd6ljfbwD+faklj+Y8jFNI2c+o/Gtzi2Lgxn26VYjdN2GIJ9qpxOCMKBmpFOXRienGPWg0i7mgVHykng9Ke33dqgfSoV5YjPBpSSRhj+NBZJCuFfpzzzTt2UIxgrzSGTLHC5X1xTXxjG0n6UgbFD4OcZPc+1WI5FKg4Bx61UViFYHpjrUq7SODhhwKATLy/MQTjB4yTUsK5bYCcZ4qrbscncRyduBV5AIFbccEHg0A30FlK+fIC2Fx6UCZo5FXkqFyfWoi3mXDA8qQCfrVlrYxsQG6LgUXKtbcsQKDtYjbkk8HnNM3kJgH+LIxxTrZiNzZ+ZRwMdKrB9k5dSOuCKLhGJft9okAkyBjr/AFpG3gtkZB4HoKgaXYG3DORwMc9aUckMGwgzQaRJgQpUSMMgdMcD3qON0UN8xIyckUmAYyDjA5J68UqFVUsqrtJPSgtMmyNwOTxyO1EjusXloCFcAkdzz/Ko2BJ+Qg7eSW9KljuMqWfnI6EUhojLyllwoHfDGpZAN5kyORyM9MVUmO5j5ecJkZ7A5pwcyHnGTnrTQnoTWoUE9ckZ+tT728s7R+XYY5IqtHKuxQfvE4J9qtRovJB+UcDntQ0S9i5byssa4IBYEMAMACpGk8i2klcLvVc7j6+1RkgsSSBt7fhVPV7oIse5wiIVPK5z7flzWc5KMWy6UG2kYd5shtgYxIzbiTcZ5POdpHcUxN+xHKspC7gB2Bqa8IjEkCgyRoc9M5yRz7HpSpFHHKYUkCg5O6Tgn14rgtqevF2iB80qpd2B4KnPSnf2zdRHZJiVQOQ33vY0ki5RWLtu5Bz09sVVeNnWVyAcgDcewz1FUpNbC5IzXvI27K5tZ33QyqrYyUkyOfTPepZkiIzuj2k7txIOMdTXORRMHmaPmJf4lHBHSnRORIDLueNRtRe3+e9bKu+pg8JG7aZvyvZLGubyIsAWXBPBHr6n0FOnWKSLfEiu+fmYcnP09cVz5X7p+8TnIPpVuBpYJsxrtyM4PGRjvUqtrqhPDLo9TTe2XaSDnA5XGSvuTUN4PKj+Z1x6IMbv/rVWnvZzAoDIMjDOowQB2NUbqZ5BGzyuwHPJ6GnKqugoYVt+8zchuoZHKBHRONgU9Tjt+NXLiwZVZZIz8qhmVjghT6/41z9qzlly4IPYdjWxYvJITKz7kCFCZDn8B61pCfNoY1aHs3eJnyfIilE5QkY3cE9j/wDXrB1TUGNvl1x2ZP7xrb1BNrsVbDpgAA5BGOprmLzbLIfLA8mM9R0GaVi1JIynUkb5d25m3H0A9K0ba3SNFfGAOuaZBGd2cHnnDdMVcGzG0yBcHj3xSNUiWJAwchiWGBgngUy5Plx5ibluQPU09jIFJDbj3wtJKu8KQoPGCc8LSKRQXeELYCuOp9KosJnkK5AB5wK2QFMIUjg8AVA8CiQ7flJ4yamxjOV2Yc9pu6Z3dSPQUkVvICyxKAO7GtcRbn3Y6cYPapVVVY5ydpzx601AxcrkVtF5WBtyCPxrUghbHzD7vUVWtwXJfgY55NWYpCctvwCMnPWqQrX1JdpEgQfePA2g8t9anEOFKNFIsynDbzwT349Ks2E0YtY2HmB7cOyoFyNzdGJ7YqO8mBSOONiSkYRpWGCTnPA/GtEjNya0scso3AjPBqAKxyDgjrU6kFeeVPbpUcMSp93tx9K3OBkMatz6mpwx2YUKGPf0pJEKkEfdPWo1wjKSfl6Z9aYloXImwAWBPbNWFACZGAPrVJX2HBHB96lJVvu5OfT0pGidycFmC7TyTzzTw2Cc5IH61VV8DKnAHORTxKGPXnvSB+RYjO5+Ccd/enqdrs3Q+vtUAf5dwPPf3pmS/ToOvbimCLvmrHCAoJb1rQt2Elryy5JxnuPesmIZ46g859KtxLtUsx6nFSy4ovyN5cqOq8EcfX3qZJC78ZDADNVElLRLt/hHfpVhG+Yg4zj1oQ3oWYm2fXPUVG6qJ5CBgk555BpkZw5Gd2T1z/Ko9zZYNkgcAimESQhw+wtnJ4wamkkChRzgjGB603f8iMEPyjGBzmnyATKPL4wOfakaLWw3DEYC5J5PtzUuGVAzMGbGM57f41FbuAwAYCTqc1LcgqBKVzHnABoTKsNSTfvXoP60oXKA4LHvz0xUlmI5mLBQDjBGaYd0LsN43dTjoPagd7aCOVUjcCoI+YdutRfeYc4GSC3qKlbZNGSwYA9cd6cqI2MsSCScj0poTYkARC2RnPf6VdXcI1cYHHQ+tVpY2Uo7DA9Paq9zeHaAchWGCBwSKipPliXSpuUtBYNaUnZKUJY4GBjGeM/hVO3ZneZbrdKHU7S2SAcdRVcJCMyLgHG4ipi8k8UUQYMg3OoJwK4OeUtz1eSMfhRJGoMn7p2VmQDg9RnmmnBnzs3gbvmJwWxwPy/WlPyysuDI2NoyORxnAqtZ3AVp3dDJkbcEdCe4+lK5py3VyxI4+ZsFyI8Z7D8P61CAcjaWAZcGkMgDrwcDgKe9JMfMThjgjCkd/UUrjUbEhkigtT87NI3YcbQPX1zTeWRBCWO4Evjnn1FNghCwGV48qn4gnsDWnaQpiKJlVGceYhVskZHB/nxTIlJQI4SkZiePJ2ff3889OPatK1gIKKyxt5iE9ct+Hv8A41XWOGJsZKnCyJk7m3Z4GP8AOK0rU/ZpvtEzF9u/5hyox95vYZPanGNzkqz00M65tJwZLZeFTafLQEh3P+1646/Sq9lZi4umtiduCVZ2HAbsM9BXSWttPd6d+5ijKEALcbSXJz0VT/On3FulnplrYy+XdROQytGQADnkMR3P6ZNW6Zj9acVydf61/wCActdxR2YJWQNMhKuFOQRjnDVt6FfQXFkqSMWuYl2lOORzg/41F4slVNO063ntEikj3KZI+jr7cc4/pXLW9ldJcw6hEzJFHnyw3Dufp2HvVwvGVka+7Woc03Z62+X+ZNrEhNwRCSZP4j2x/wDWrKhkEUpPVMEEY4ar1wwIlj3lpTwffPWqcEJU4YBsHPHtWr8jGOu4+yjVgWycEYwRgin/AGbLD5wvI28VJHCZA4LbM9MdqvBPLQgL0PPOS3tU2N+ZR2KeVCuH4dOmerVFJAducnJOeeBU8gBd2b7qnJI5IqGVWPztwexPRR7U7BzakIQscKSO3FRzqI87+QemO341OgEQIJIIHp09hUUzNI2zjnI5PSjl6mUnqVM7mAJ/4Fn+VLt37UTIyeuaR1URM2eOi57U61Qlwdo2g9c0MSiXvJ2xJ/d7gd/rTvJBO/GWPOTUjDaVAXdjvnv6n6UmDkHkAHqe/pSQtVqauliNrZY/OjQqsnmRs23cx6E+vp7VT1M+a1v+88xoUCu69Gbnv3x0zVuAuunwslmk0hYhyY95U54B+vXNXZYEFpIHt4oCsSuWReVbP3fy7VpZmLaUrs4CMxSoCM+46Yp/l7Pusc02PbuLKOO9PYdCeFA4Pet7HBuQuWbucn070xlcEggdM4qcZADZ+gpkpJYY4JoERkNgbsZ6VLDgDcrFT3FRnLH370qfIxyOCaTGmT5+U4IDHkj/AOvQhAUAjBI4FIw6dM/ypeRjc2B1oKuCt83PTtjqanXdg569x6VCVyyk8svQVYQ7sevQ80WJcieBCzDBANWY+H5+7nnNVI9wPX8amQkksTjGTg96GXFluHGxsH5Tz06VOW3kYOWA7dqqxruIMbckZIPSp4MgjtJ3A4pGmjJ0CjgkdM56YpjdOpx2GKedrZPG70NJwqFTnrx7CgFoSKfLG4BMkYI9qmiGI92QvJ4xzVYICN3QdMZqWJ8IDkZIwMUilK+hWlcmbPlsBwMgVetpGePlcnPfpUSozJtI2EgY2nr9KzX1EQvMiLuWMjknrxmolJR3OiEHVdkasbBpC0uCOgUHp+FSkpy4wB0wfUd6z47qG6RZF2hh2VgcVYyZF+XafXFCkmtAlTaepYBXYN5CH+FQP1p1tcRiFlCn15FV5fLjbc52nknceMe1QwlJ32xSKTnHJ6/SjnRapXXMWbqcsuJD+7B5x/Ksy6lLSM5GGY+n6CrGqsVVEQEHHzGshd0i4yflXk9zXJWk27HZhKStzMsRb2yQBtbgkcZp0pEcORjKg/xd+1MHyRIoHAwSfX6Uy8kMSiNRuZj07+/41kdi1YvntCrbkILHIctyP/11JDMzQDhSevTn0qtdTB5RHvAxg8d+KliiYRZUjOM5J5NMtpWuSSISFYkbs9e1BCgk7uOnHf3pHIYHcRyedvX3py4WZ8NnCEcHGARx+HtUk3ZZj3SsqD5lVgSM9auwxsCzIEjJBxt6NyMqKq2pUSgKgdVHzbuN+e+K07ePaUbIw3Q4J/DFUjmqMVN0VytxHtIjb+E9V/qfapUl8y5eC2dXQhQSXOxhnLAD8O1R3UpREjEisoDEbTgLzz/+qq0Dg3XlExk7m2Opxjjr/wDWq1oZcvMrs6c3bJFGLNHK25/49lyQ0R4zn0+lPS9tdKtLu1kjVb6SFXjiUiZdwz7YX3rn4723CYW4AOV4LkAnJBI9Bn9KguLm6vZhFcvbxRRZZbq3TGFU/fA7+nvWnPbY5Hhbu0tvx7/PX5i3uoy6/JaWl4scsFkgdpYpMgsScLjpz3HtSX11DFay3MzbE3CPPULx0FSx62NS04LNJbQGMGHbCmCAPX0+v1rC1WaG7igECu1sjbckYDN3P0x0rTmUI36jjSdSap8tkhEMbASRyqxYbiAec9s0yEFX3kYbpxVTyRC4cDoRjHTNbgWDEchcvHgnK0U5cxtWp+z22K9uCzsCvCjdkcD6VaflECsen0psSBmyMqmM/l1zT1Kr8ucyfeHsPf0rXlMG7lcxLtxjG/GQBnApsxViu1Tx0B9avbcZboOvy+3pUEkYUnoB6luM0uUXMZrLgsxfPuR0qoqlmIb5cnkDuK0ZlBcKPvA5Iqs5+VlyAx6nH8qOUOYq3CgsoAwD90VajRFQYGemQKbGg3BtrZHHPep0Vip8sEYHzH0FQ0UmBQqw2k5J9O3vTF3q+VGcEHn1zVgZLY+YKep70/yVLFFGAevPTFOKHJmpp8UTrE8sEjzSq77lcqBt6DjvUWoopaGSBGRJVDMu7J9Mc1NZqkcETPLOGZjIqx4CjHAJz3ouWS4uV2tJhfvbwMkj0x2q3sYRXvXPN9zRTFGJ2mraM23/AGT0zUVwAZgeeKmQ8BS3TpWp5+wb25z+FRsxAGACRT5AR0Hy1GEy+Mjdj86BXE3hl78elTABo8gc+9RspZcoCDnDY7U9SAowCHY4/CgL2Hx4aLJzkc57kUv3gWxj05qORWhbg/KcHHrmnKw3OoOPQUkVcc/qM5/lSqRzg9/TFMDAEqw696XOH65GOTTIZagb5GAJx6mpYDljkZzVeM4XGN3oafDycgncKRSZdjmKEg5x0I61ejPmIM9VHB9az4n2uC3U8e9WEdgrAZI9BSNkWRkHjAJzjHehsnggZz1A5FRnOFxjjFSFs9wTwN1IolDYGMdO/wDWlQDlMkHsfeowzb/m+6RUwZUwc5HrTFcSBnG1CFJ7etUdThRmeVolDj76jgN71fEmW68nocZxSGRXPKgg84P9KznFSVmbUqrg+ZHLJIdrGALgDJB6gVsaCS2nq4O35zu5/lmpLmwjdiJVw3Z14PXpmrVhDbW8ITYyKGJPzZ3e9YwpOLPQqYqFSFralLUBHdXDsjM7KAjDt+VZbuRITFI0bK305z1rR1OErI01sxKMdzAHv6461lurAHewL5GSegrGaakduGknHRmxJeNdhVcjK8Fumaq7CDkkbTwMVnW86ISN+4+g6GrrN5kaPjOOgB6D1NQ3fVlcnI7LYmZiyZZec461GWfeJAwLAHC9arR3G2Mhskn7xNNEiJKD1BOaRskNO7eWKcjliemM960LOZirssYUgkcdG9OvSs933uS5B7LVuB8RKuQee/pTHPValqF0dugUD7xxx/8Arp01tJsModCegUnqP8ahjZQWYkqBz1qZRvLNk4xwD2HapMXdPQmglKowVPm+8c8cDvWpBPG0SS5I7/ewFPf6Vio2xV8vaWccqDk//Wq2mJNhkYPu+9kfewKpGc4KWrJ5ZMOjOoDlQWCtnGT2PY1Xe7ENyrxPGFJJYSJuApQ7DakK7lcAIhPII96rPdKkYRpgG3lWUKCQf7xz/KmVGF1YZLdwRwPEziBSNxMi498j29qyNYvpFgjt5UYEqcJuyFJ6tgdKS9eFlikdzKq5wHBGev6Z7VQltzFCA+Q+5WBQAfIR0+v40HTCmtGJYBtzlpCIu465Pv61tLGFZ037ChwQzdDWcqIyK/ylPu+URtI+p7mpYEkmlCg/Jn05oLkru5oANjLFSwOAcZP1rQ0voUkBx94E+nvWdE4R1SQtlfl29cVbV3tyjlSI/QrgjPQ1cJWdzjrQ5otGiYyWIAPzHIGcZp0Me1skgZPy57EmpZ0AVXHOPmOO3r/+qo0JZyDkqcnGMY9K7rdjxXKw+UYZk3YJGC3YVTJ685wee4wOlTuoVgC2F+7gn7vvUYXBYFcADP19qLE82liE4Eh6dOBVUgl/VRk8+tXChIOSM4zyKjaNcYUZzjj3oFfUhCmViFOzjGc/zpqI6EcgLnGT3qdVUhztz3P1qWBC6BDgN69s1NjaMrDbdz5u6TJfBGcfrVyH5iMqpPX60wRlZDnjBOPY4qW3HlsgkO5QQRk9aWw21LY0bbzBZx+RPHCysxdHYAtk8E0l6z+YC7ox29VOfw4FNa5hwWexiHTuTmnnZKwKxrGq8YXufWmZJWd2jzRvmYHPIqykQOdo/OoGUqxPXmraKwXJGQOgFXc5XDUUAMgjYAE1AyFic9R3q0RnBYdOuKYwBIJ/iFVcy5SsctkA/MO9IspcFX7e3NSeXhyRwelQyRkgkDB/nSYmiQMCgRjkY4PrSD7ucYZePqKYgAzzyetO/i9R60WsA/AJ9V9acqqCSPrUaEKTzgr19xSNJtA7c9B1oTBq5KhO9gMkdQKcrbW3AH35qMMTggH04p4ZhIxYDHTimTsXUYMQSRz271YilbgFgcdqzhlRkflVmKYFgenbmkWmaUbLhvmwc9c/pSq+cj+E9TVUdgKkDlT659+KRqncn5I3KT171Y3IF5PJwOnSqkb/AD5UErT422yMoQYPIBpF2JmyxAxgj070gwzMpB+ophyFAc9SeQPypY23cHg9aBpWJQ5wB2B6GpGMbjDLtP1pmVCfMpPfjigDcjbSQO1JgmNfymTB+YZzn0qpctDJDGzW6S4b74JDDjp71ZMTCNkVtueAc1DPFhQ3LAAZ9zQop7hKUrrkdimNFW6jM0BjWINucqcnHt6Yps9hNbMfszebbnkjPzL68d62o9Ne106S7imb5yNyj7pUnqfesxmJckHkHse9Zzox2R04bH1Zx993KH30YMQW29CMHH+e1NSNQDsUAgA5PPWr1xbfaZPOhlRbhvvKRw3v7VmSNNBIYbiMox6+h9MVySg4s9ajWVRabhLG3msVUeVk8+9KZWAXbjP07U2Sfgjbj5jjJ6j/ABpEmDErGCcNnP8AhUHQm+pZtnLsZG+U85x0q5ISuMsQOg9BVGKVpdqsCBnGelTpycltyA889OO1BL3JxjaWCjOedvQCg3w2sOS3B3eoHYe9QclAVLFCenp7VDuZNsZCkycfL19fwoHGKkX3maSNUH9443fe5/8A1VSYlyfJKCZiQGz9/wDpmoZTM9s0gUMiEbsDacZxn8O5qvc3BV1D8ANsztOPx/nTRpGK2RNieOMid49qrl1XGGBPT07fn71m3MvmyyqF3KSGCn0HT5utTLcW84kcLtchvMUDoSR9ztjjpUaBpXKqACAcBuy5zyadzVK25NBbHJSSMB4/lYFuvfpV3e0Su6oTnhc8EVVhfY5Lglgcn647VeiCSbFQOSSrEN6ii5En3JIJiJY/MjCl/nG31xjg1aB89H46YGWbsKrbRGp2qUK8g9wfT9auwQvdrlSWiHBYg4AFNa7GE2lqXIWleGISN87LuOe1COUmJXuOMeuKncBphKgwrcDA6+49qjO0YQgbzzXoQ2PCrWbuRuxJ3OM59eaIsjLbsjjdk9BRcAgYCnOe/wDWm2qvMQgAye4HSqZjsORgSVxwDwMYprqMrgkY6kVKsJ87cSAQcHnOafdoVAwR05qUguVUCyMysBnGAaWPIO0nLJgcd6kSH5F3DBPOc9aaRtPPDY4I5pPQ0T6F1Buydo6ZOalAjWNd3r90fxDvUQOE5PUcmpWy6JnBUZ6fSgEWYtlxbiSCwZow3eXGfXGaiuI2tmCCHZuGSu/cRz1zUkEirDDuDAIWjIAyCCOfxpLogOkab8xptJcYY++KbQotp2OBmRZkDIPmT7w9alUkAYPPfimRkqDjqO9SsN6gj7w64pdTK91dgBgkZPvTiB5YwM7e/rUQySTT45FXIYnaeuOuasyaGTKCRg8nmqxBDAdOeKtFgWx3H3ajnHG30pENWK0isZA659CB/Ol3FmJJIOeaV2+XjOcc1CW6MVJFMlqxIeSG4yOvpQcMQpANGAY2CkA9c+tNg+ZRvx7YqWUKZAm3HT0NTIQxBHOe1Ruu4BgMrnr3FNZdu1lB46U7isWQM7sk49c0sbgAhuAOuRUSP8pDcZ9KdIQEwxyPpQKxcikYYw2cdM1aR+chME8565rNhcghmOQfftVyN/lB7Dpig0TLyMNx7frUrIpVmIGOxqpG+RyQMjnNWIWYrx908c81JomL96MAZGO9SAgA7SD6kCo9mAw3fIOvHNNjPfJJ+nagvctQuGGdx3dqcp25DNketQqSOVBJ65NPCnqMZBzmhCcSZFUqCDg9MY7+tNZSjN8wZcdMUobjHX3zxShlyMDJ6EUyNiSKZRoUttkmR5gVQg8L1yKx5h85wK0UPyHdjPQ1UnjOWaPkg9/1ptDjaL0IIAFYnq1WbmEzBQwDL1YP60yIAH5lz7VacoUwAc9fcj0rKSOiM+qMXU9HBcy2jcsRiMnCqPY1SOnXSuGVoiwOdu719PWt+cf3eBjgHioY0d2K43ZrP2MWdkcbUirbmZaLKZ2h+zurhRkseKZI7wh4Jo1V0OevFbTyhcKyjB7mrUcaPEMqGGOOBxUOiaxxvVo523mkK4aIgducZzRdkALJtLbc/dUmtjU7aS6t9sJXzYyHVTxnHUZqpDaTSTLJdM8SIdwRTgn6ms3Sd7I2hiotc2xU0eRp74zsHWGOPYpJwHJ4IA71v2iRzQT74wyspAyAcn1qk6ecWKZAXOR2FW7HKjYTgHk4PArojBRVjirVnUfMtDiEgaMOrDrk4K4zg/yq7Zw7T83zh+hStnXtHaacXNlEhDgmSPdjPuB7+lZ0U0VtEIponikzwCp4H1rmlFxZ7EcQqsE4jbqLcQQ4255C9eO9W4HRVUncFPPHQ/jVTY0jlYBuYtgqOTWvp+lN5caXsjYPJRT90+maIwctiKlSMUuZlaKKW5u7dfmPnMVyOyjqTW/dIAVROIkGVA4FXLW0so5G+zqiEjbnOc/jSvBIkmxwDjnHrXTGlyo8ytifaNW2RBJc7oIg4YiBcLt4wCagypwZACxxjAq0IwvmLt+RhhlznB9RmqkH+tkRgoKnP1reJxTsRsBlhkkkYP8AhU1uUjdnA2/NjPrSOq7gynB64I60HCqecBsgY6UzJu5YTEbFuGz1wKhuCXZsJz0FSp/q/cdvX3qNmOw5U5x1PekG2ojDbblWIbnpioVyCMkYAHDdqlHU5wMnmoiEDgSIdmcA0rFRdyxFtw7plue/QUp5G9cnrhfemRYRCrSEY7ijzVDKQWDJhlK0M0iX4mjngii8zyXjzkspIbPfjvTbuVCIwhLFF2b3Ugtz/KrWnZhskle6mTcxYAID35NNvohKglW5aZwm8bxjK57fQ0ybq558WGQBjHfNIrshyp4qAPj5XUqw7EUNwScZ7U2jFSTLGdyEcjPeol3BSHwCPQ1XvXeKyWRSTiToPpUizb0V1wVboKSld2CcHy862JQ+QMdSeKkYhnAIH9Kp7jGTvbGTUyvmLnr1xTZncJEXac4z/SoyoEA9QeKcpbOev4Ukh25YdMdRTJkRqcMMqMdD3pVYlSB2PFGWBVjja1EjBXOO/OBSGkO35wSDzUgxnBP0zUKSKWBcbc8Zqy3zRhtoHOAPSp2KtcFXCkYzQEIBx35xUkGXwOn+NSomVK5w46U2yeUgKYQHHFSRSYOc9aciNyGGMU1ohjjNMTuiwmDhf51cifaVHGCME1mbjgY6jirMTbl5zkUilI0Gb5iRznr7+1JGw3EAYHr61BG5BA6gmpUYeZ1yAO9I0iy0rKOMYyenpT22o3OcjuKgZo2UFQxHrSxFicfrmkUTCNtm7Ocnr1pFyAGAU89aHkwCuz5sZ9KbuzHk8g9hVEsc6tkE7TnjimuAoyThvSlyoUZBKkdqN+VKnn8KLklaRCQSGP4ipIydgXjd3PrU6A9No6cVGFAY7VwR1oKTsRzJ8+c5HPB/pUILo+V44wCauLlgSxAJ6EVXmUAnPOeaRakRyOG5kA7cinxzSsgRMhcYx0o2jy+QTjnipEA+UOPvcDnBFJmiaHRhhHlhkdeTUcgkkbaMcjoadceZHuA5B4xilL4hX5QpUfjU2K5rEKK0eRHwSfWrMIVScEAnseabC2ZRuA3D1NSqiLIW5IA656U7EudySKU9cLtHU9xTpUhKEuqt0ADDNMZohjYSDnnB4p6xFoTtOf8APahruVGdtUVlAgAWJAuR0UYFELyFssclT0PAIqKZz90HPpTBPgnIBx0HrTsP2jZZfhTwQ2eAKsR3MkYXbMykdu1VNrGMbMAuM470+M5ieMEkDGcCmkJz6F1b/wAzAYLlBtA29Pb3qpNkTbhhFY5zVGFGEpAPyqM8nFX5gCoU4yvI9KZEmSoM/KQDnGGIodtoICgj2GBQiNtVl+91JzS7SuUznIz1pszGxbsDJYgEcMccVNJwm3Pv64qIljKVDAA8Yx0pRjAxkAetIGwdV+bPI9qgkA2leQR93B61OFJXJY89R0NRMoQKwbPNJjiyRTmMbufcdajxvPyDaSQQe1CnKEc5HQ4/zmnhSrbeN3XIo6Fx0epo2zhLdTdGJY2J8veCSPXGO1Szbw7AmPbIgCmMdEHZfQVVs7mLyFju4mOwfKQ2CPY5qS6YlojjYhX92Ac8Z7n1zTJe+ozWNKivYSGhCuBxIByM9K8+vraexuPLnQqw6E9CK9UjK+WBlSe3+BqtqWlQ6lA8MygSAHy2963lC+qPJp1nF2Z5kkwZHSRQ0b9Qf5io40SILFEflPIz1zT7yB7WZ4pQVljOCh7VXEg8wg8YGc+lZW6napu1ug6fl42fkjg4HNO3EjGQpHT3qGaVt5P8JFCPjPBwOhJoJuXIDvBySGxSEE989sGoInG7liT1zUqyDJOentTAkK/ueAcj19KiY4kQng46VPG67FGcE+tRTABgwy3rUlojbliCC30FWgCsa7TgY60z5c5HU9KkUMCAw+bqKRSJowQBlgG68VPE4LDftB9femRbVGWUNuGPofWgEqQpGe/Sm7CW5K2C2C2C3T0pzIyjngio1O07X4xxnFWUPykKT06ntU3Kkig8ROcHaR1FEbEOATjtirJgJZs53Hr703blvm5ZaZHKSRPkDqSOnrUkcp6Oo5PeoiCoBGM9RxUi5IVsnjqKCk7E6tgDAqdCAu05+vSq6tvQ5Uk+1OVz8q54Hrz+dIdy2zbiNzKT64pBjHyDofXiod/JOOR6cinhwBlR8xHSmIe2RgYAx3qMHYRgFgTTpHDADJOe9NRsRlsdPU9KBkyDgjpnpml3L5hJOARzmoRJ8oIHXpjsKmAwM4JOKBpDHOXOAOO9RSlpDjqccGn7S0mVOfUelOIUMM/jQNkdsXAbeAFPTNEQXczdR9envSlc/dI4pRjaoxk9KQ0xR8ilmy2R+dMlZJYw6FQccgVK3KBFIzjg1CY92eNvHzYFItbDACSPnHJ9KmKMG4YY71F5pUFR17FByKlt43l+Vsk9RkU9SWPtly5LZA7kDirq3LKAkcYKjsKVrcbcrnaOopsMm1sNkD1x1pXJT0KcqruEj4yaiKYJdNrLkZBqSfY8wVCSpzwaPLAYDcNh4IPaqsUmMwPNDjYEHvSySKBlDx156VHsHzZG4D1/nTlwqHHAP8qB3Q63J8xsYBP4/hVglGQhsg/SqiM2CTnBGRxUqKcksxUeg70CHxuc4yRjjrU2WA6Z478VAy+xPHU0qndtUEYz60yGx0TFmbjt0H+NLtCAbjz/ACprSfOxUAD34FEh9+MZyKQiQkPnjj8iaRxsUNtJBPBJ5qGOXaVKnI7k1NK6kDHQngChivqIAPmVlO7r16U63CtdL125/Gmoxbj+ADA4709Y3MiBBl3wB25oS0L5jSQ2Y+Um4YMMAYX1pt1LFI0aRZ2RrtBP1qFkhjkUNe8qcYVCRn696LgeVt3CN9w3K68BhRYSZsC3Ku/AKtxtPapBGY13bicevUfSkFyGyxxTWkEi4IyM8813JWPFOM8e2sbRxajAh3lts39Ca4ssOBjv+VeqarZfarO4tmx+8UqT79q8lkDwzyRS8MhKsfpWFWNnc7KE/d5RzDYc56ninKwJIPQj8qYHwCPvDsaDwTjoRzkVma3J0OBt4I7VIhIB74qvGc5WnEsowO/rTQF5XUqBzxzmkB3AqevJGD1qFCCmB1PWpCTGu4DkdKTRaHB8kAIc9/apS2UAB+nNNPyNvH8QB/GnYLqvHGeaRdizGxxhTwKenDbSTuPNMRSqjjI4yadHvEnOKQIlwGIbcR3we9WrYgAlgMVCysCoCjFPOB1ycDgCpZaJoyDK2zJ7c9qiMXzOc9SB61Kgyox1xkH/ABoCgkbictyaA3IwAi4OME0oQDo3B680/YrEAAcjFOZEGEIx7UxcpEm8H5TjHcdqmDFctxvOPxqNcg7dvCmnsAWwPyBoE9BFyCxXPPrTmdgBk8ZwDUQYg7QSMHjNPZh6gt34oES8E5IyfcUKQGIwOe9QKxYkduvJ/lSBuQHB9setIpF2AAqQp5zgVI8IOcNgjt61WGCykFlOOR608lscnigZJDwdzBcHjNIZlbIAzt9O9MRlIIJGBweKHAjyVGGx0FMdxjPt3dBn3p6fNgkEgjqagBxtL5wcj3FToxPCj9e9Ia1HqhOWDkf56YpqvsLD5SM9R3oJdBkrjjn296YGBUnaSD79aQxjJ85lx04q7asoGDuA6YzkGoI4yqBscZyR7VJvbYTGNoPBp7iZaEmCVYluMAZ5qJ33IC4wRx/n3qBHIkBIAJ/nTJZHLnBwDTsK45kY/MgDEDhT1pzFGUFiwboaImwnJHTjHWmsylfY+vamNFXzFDYJw3vUpYCMMJMEc9M0BEkQ45x6inFF3LwMgc470Mm4CTJAbBPY9P0qcSNk5GR+tVjhJBuVue45zT227Rh+h79qBNkkZ2g7zknqAO9NgZZAyD5jn6c0xvmY4JGPTvTATE2VYcdSe1BNyUkLlSTj68CntLu+bHJFQMHK5GCT1NMEhKlT1oH0JYmxuDccnNTfLuXnCjBqmGAx/ePr/SrG47c9s9xxTJ2JVYDLYyeDntSGVy42cup+XB5FRyMzKd+BnrQJQrKclWJyCO1CHzGluVzvaxy/UkblBP0qKaWSR0Z4yqhdqoFwAKspPqUxV0WdW24JDYDH1xVK4lnd2Fw5MoGAH+8KGKLOql09/nMIyMZ24/kazTPiba6+Ww67jXZgBxgJkg9/51R1HToLvqg3/wB4dfpXbc8ZM5d5RIzeWykjp6Vz+seEbfV7s3UVz9nmbHmbeQfwrs59O8kcRbwOhXjNRSW8ajiIjj60NJlqTWqOITwNaREGS8uJAOp4APtV+LwdpY2nFzj3k5P4V0LJGSCA/A444FW7FoY/3tydoHHzDr7VHKh88u5zjeDNLWI7Y5V3fxFySK52/wDCM8JL2E6XCg/df5Wr1B9RRwTEsR9MVQa5Zm+4uAeo7CpaWxUakkeQTwyWUxWaNopPRqI3zARkEHqK9dntrO7TE8UMij+8uaoz+F9Lmhb/AEdVH96E4qfZvobxxC6nny4ZARzhQKSGTJKg4Oe1dZf+EZI4NthcB++yXg/nXNXdhd6bKftVu8Z+nB/GsnFx3OqFWM9mTQKV5zuz1OaVQN5K9ulVY5wocDkGrUcqg5x165pWNEXIjiNWzn1pCMsd2MdsVDFJ2U5OehqaNlDMQPpRYZNbsGYqxA4yOae0ZMbEgfL0NVgAGOWxz1q1GHPclemPWs2rMtRK+doPQN61PCiPGx3AkjNIVyc55z6U+MDaFIBVu47VQDXCngdj1oZMsT3A4+lMm4dlB/SrEa7k3tk7eBjvSHa5XCY5GMnkCmvGfv4x7VcVVY42Yx69qbLGCTs57Z7UyGigvLkE4H9aft2DPcH1qZl6ZGSeR9KaQUJDL1pXFYccsm7g9zk04429skZBFRJnzPlxsPfFPb5VGSSe2KB2Y4EovOG9f/rVJjeN3GfWombdgAEdsntTR8hxuJGevpQURykliD2/Wljk5wAcH36UycNk8qqjjPeowwyMHGf1oHcteYxGTkg8e9Pj/ebdwGO9RxqB1fnPSlZ16KTnnJoESvOQNgB2Ac7f501s+WNp6D8fypiPglgOCPwpHbByh5PJ700iWyVNu0FgST+hodiyjceQcfSoFY446dxTnO4ZGQaoklD7kC87j3FRyIwwA2RninxgbdpKEk9e9MmO1lVyAx/QetIoaNy4IJBx+FAkYYLrkelNbAbOSM9x0pWOQwYYOM57UCdyR9pbI3E9cZ6Uwy/MSV79QOaPMKKBnJIwOKYjnIbIOOo70CHk4bAJBxxuqJiTyvXPO09KkDeYRk8Co3VRnoCOC4osTdDmfYflIyBnHWhZQQWIz/SkJVoto5qEERM3PJ4GaAJ1fqcjPoaljf5euMjjBqqmd2Dkk1LJnapHUHPvTQMnDhsgnP8AKl80LPHIyB/LYNgHHAqvHjJJ5YVNbqDdJ5wBhLLu9xnmgll+ZYbiRnN6PmO8B1bcPy61JcyLOYhuZ/LQLvYY3YP8qbcSk3L29+Q0WfkaPB8sdiCO3tS3m1PsyOyOVhxlGyG5NUQmdol844IHsV/nSmYNu2yEPnqO34dz/KmRxKGzGqhgMlR/UVIY1EZ8wANnIwePr61ueZYUs5BzkqOhJ6fjVdrfeTsyuD+YqWKTyzudt6eo7VZjkWaPcgVwOmapMDGuIXViHzt7MOlKqNtJ3H0wea1yuWBkVWI5yKga2OS0Y5B5XtimmgKH2dUYkRjkdqjkt8g8fJ6AYrQRhk5G3J+7jrUixrjPUelDsO5nQ2wypRiPYjvUximhXMa8scew9TUzQ5YlAV5609GlhX96u4eo5pAJIhkJV9rfofxqOa0hMeyQtIrjlZAGyKuoscqDa3B6gUr2q+YZAcYHU+lAXaON1PwhZzSM1mZLWVudoG5PyrDu/DWp2mWVEuY+5iPP5GvSJEkU7ckLn+EfieKhMe9ysJ+YHHTAP41LgmbwxEonkj74ZNswKOOzDmpBPgAd+x9a9KvLaKZSl5BHLFjOWXJ/Ouev/CtvIxfTZxGR/wAsnOQD9azdNrY6oYmL3MFNrKN/3u/ep0YCLIOCp4z3FV7rS9RsSTPbSY67k5BqK3uQFw3fgg9RWTTOqMk9i+iNkkDtk4oLjy+CeuenNRJKOnCns1TR/IoLkEHowqS9BS4YKVHH61Ejsy5ByR2zUnChhgHIzxVcSbGyOG96Botgsy7lzu9PWmvK5G0jbg85qESAMCc7Txx2qQTKccjI4oAkHzA9yB2ocN5ahgCvrTUdQ7MvA68Ur3B4U5PPJIpCsMUL5h2HB+tG0kuCPTg1HLKGYAcEdzSlyxyVBOKSTFawNuYbW49PpSqjgewpNjFS/r39KJAxCs74B4NDCxDKjSMCeDUqRoF4JDd+O1S5jUAKBgdBTCzE/KNoB575qOZj3GbdxDKwNMdCSwyDg9jUj5Y7kGPXIqF5C564Yf3eKpNjsKobn95kDqKEx3GM85pgZw3PK578VI4YNuRflPUVSZEoiOSTwcc8YpzFhwp4xzTZF3LujOKcInEe4ED15p3FyjlkO4HAz34qS4kR4ugJP6VWYljhQN3Un1pG3bcnC888UrjSJ7Vip2kjZnoaVmySGUY9QarRkbdxbkHAGMVJKF2DchyO4OKBjixUbRzzke1A6ZBA4xk1HAAHbk47YqZ1XDBUyCcZobsTYbnIBAyT07U1idwXYQh6mhWVchl/AcU5yoyVOR6D0pqWgOA0gYGzaeM4IximSIHG7A3YyRSSPtQZU4z1oYsBuI3Y569qCWrEayeWPmXHP5VZBLjemSMc1VkBcHOeetOgJRcMWHbINFw5Swu5eeoB/KpEmXLKRkemOc1BKyqCAcg4xS2N0sdxG8nIVxkEZ4qiGjTjhyNjzxRyg8jBJHsSKrXAaGQwuNrjvwQR61bQ7J7dndlePoqoW3c5ypHBzUGpSqDEuVDoCGXj5ckkL+AOKaIV2zvBMyLuXAI4BqXeTkNgjAznvRRW55g5ok6AYBXdgcYqoZWilUIcZHJoopDNGznZwpYKSR6VbABZeMZ64ooqhMrXCqZMEDoTVZztyR1A4zRRVICWPEiqWAyTgmlAzIVJJGRRRQBHOiqCVG0j0pbWd2LKTwDRRQD2LUg+fH93JFRmFMOmCVGOM+vNFFAkVI3JkKnG3YGxjoScVDc2sOchdueOOPeiigpEMUjfKM8HPFNn02zuSyz20bgjOcYP50UUSNU7bGFr2hWlombcyrz03ZH61zDuw3LnI96KK5JnfRba1LCklAehA7VBINzKT1PWiikjpROADEpIzTGUHeMcDNFFIZYRR5ZOOi8VXlmcAAYoooENkOGb8KfaMWOTRRQJ7FvGIs+9Rsd0ZyB82c0UVnIcSOKMbjyTx3NR5O08nkGiihDH27MYwCx60+RApOBjNFFAytCdxbPbpUrcsqnlSelFFBMhjZXgE4HrSuoUZA5xRRTZQ8MWjBOM5xwKJ41VQQMEkiiiqEV4/v47dalLsB1zn1oopAQPIY8hccCi2nZsZx8x5oopkD5nIfHHXvRMxU7l4OM8UUUi+hCZGx9DigHcWJ5IIxRRTJYlwNpOM0uTsKnkD1oopgSW5LQnPOTiopVCSoo6HnFFFCM2SwTzRYjSWQIwJIDHFRbsscgdaKKok//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stevens-Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions and crusts are present on the lips of this patient with Stevens-Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30778=[""].join("\n");
var outline_f30_3_30778=null;
var title_f30_3_30779="Anatomic causes pancreatitis";
var content_f30_3_30779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anatomic abnormalities associated with pancreatitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Biliary anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biliary cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anomalous pancreaticobiliary junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatic anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreas divisum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Annular pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystic dilatation of the pancreatic duct (pancreatocele)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Duodenal anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Duodenal or gastric duplication cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Duodenal diverticulum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic infestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sphincter of Oddi dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired Immunodeficiency Syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30779=[""].join("\n");
var outline_f30_3_30779=null;
var title_f30_3_30780="Bacteriology normal human flora";
var content_f30_3_30780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bacteriology of the normal human flora",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anatomic site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total bacteria (per mL or g)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anaerobe/aerobe ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Upper airways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nasal washings",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         3",
"        </sup>",
"        to 10",
"        <sup>",
"         4",
"        </sup>",
"       </td>",
"       <td>",
"        3-5:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saliva",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         8",
"        </sup>",
"        to 10",
"        <sup>",
"         9",
"        </sup>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tooth surface",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         10",
"        </sup>",
"        to 10",
"        <sup>",
"         11",
"        </sup>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gingival crevice",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         11",
"        </sup>",
"        to 10",
"        <sup>",
"         12",
"        </sup>",
"       </td>",
"       <td>",
"        1000:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Gastrointestinal tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stomach",
"       </td>",
"       <td>",
"        0 to 10",
"        <sup>",
"         5",
"        </sup>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small bowel",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         2",
"        </sup>",
"        to 10",
"        <sup>",
"         4",
"        </sup>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ileum",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         4",
"        </sup>",
"        to 10",
"        <sup>",
"         7",
"        </sup>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colon",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         11",
"        </sup>",
"        to 10",
"        <sup>",
"         12",
"        </sup>",
"       </td>",
"       <td>",
"        1000:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Female genital tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocervix",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         7",
"        </sup>",
"        to 10",
"        <sup>",
"         9",
"        </sup>",
"       </td>",
"       <td>",
"        1-5:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vagina",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         7",
"        </sup>",
"        to 10",
"        <sup>",
"         9",
"        </sup>",
"       </td>",
"       <td>",
"        1-5:1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30780=[""].join("\n");
var outline_f30_3_30780=null;
var title_f30_3_30781="Clues viral CNS infections children";
var content_f30_3_30781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical clues to viral infections of the central nervous system in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Frequency of meningitis versus encephalitis*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Potential clinical clues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Meningitis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Enteroviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Coxsackie A and B viruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Herpangina, hand-foot-mouth disease, conjunctivitis, pharyngitis, pleurodynia, myopericarditis, rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Echoviruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Polioviruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Flaccid paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Arthropod-borne viruses (arboviruses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        West Nile virus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rash; mosquito exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        St. Louis encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Mosquito exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        La Crosse (California) encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Mosquito exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Eastern equine encephalitis virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Mosquito exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Western equine encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Mosquito exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Powassan virus",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Tick exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Herpesviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Herpes simplex type 1",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Oral lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Herpes simplex type 2",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Genital lesions, sacral radiculopathy (urinary retention, constipation, paresthesia, weakness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Varicella zoster virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Vesicular rash; shingles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Epstein-Barr virus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Other viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Intravenous drug use, risky sexual behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rabies virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Animal exposure; prodrome of nonspecific symptoms (fever, headache, malaise, myalgia, cough, sore throat, nausea, vomiting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lymphocytic choriomeningitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Rodent pets or contact with rodent droppings or urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Influenza virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Classic influenza symptoms: fever, cough, vomiting, headache, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mumps virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Painful parotitis; occurs in unvaccinated or incompletely vaccinated individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Measles virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Conjunctivitis, coryza, cough; occurs in unvaccinated or incompletely vaccinated individuals",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The terms common, infrequent, and rare refer to the propensity of a viral CNS infection to result in either meningitis or encephalitis and not to how commonly a specific virus causes CNS infection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30781=[""].join("\n");
var outline_f30_3_30781=null;
var title_f30_3_30782="Heel to toe walk video";
var content_f30_3_30782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/68978/Heel_to_toe_walk_video.mp4?title=Heel+to+toe+walk+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance exercise video: Heel to toe walk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Having good balance is important for many everyday activities, such as going up and down stairs.",
"    <br>",
"     <ol>",
"      <li>",
"       Position the heel of one foot just in front of the toes of the other foot. Your heel and toes should touch or almost touch.",
"      </li>",
"      <li>",
"       Choose a spot ahead of you and focus on it to keep you steady as you walk.",
"      </li>",
"      <li>",
"       Take a step. Put your heel just in front of the toe of your other foot.",
"      </li>",
"      <li>",
"       Repeat for 20 steps.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30782=[""].join("\n");
var outline_f30_3_30782=null;
var title_f30_3_30783="Necrotizing funisitis";
var content_f30_3_30783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrotizing funisitis - \"barber pole\" umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_3_30783=[""].join("\n");
var outline_f30_3_30783=null;
